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 2 
1. General Introduction  
 
 
 
1.1 Protein Affinity Chromatography 
 
 
 
1.1.1 Principles and Development 
In the last decade considerable attention has been focused on the role played by drug 
transporters in a drug’s therapeutic and toxic profiles. Because of their importance in 
pharmacokinetics and bioavailability, the screening of a lead drug candidate for 
interactions with drug transporters has been incorporated into the drug development 
process. Transporters also play a role in the development of multiple drug resistance 
and are targets for new drug discovery.  
One superfamily of protein transporters is the ATP-binding cassette (ABC) class of 
proteins. They are the largest class of transporters, appear in every cell , and are 
arguably the most important family of membrane transport proteins. First identified 
over thirty years ago in prokaryotes, these proteins hydrolyze ATP in order to power the 
transportation of mostly hydrophobic compounds. An example of an ABC transporter 
can be seen in Figure 1. 
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Figure 1. A typical ABC protein containing two transmembrane domains (TMs). Each 
GRPDLQ FRQVLVWLQJ RI Į-helices which 'criss cross' the phospholipid bilayer, forming 
between between six to eleven (usually six), membrane-spanning regions. All ABC 
proteins also contain either two ATP-binding domain(s), which are also called 
nucleotide-binding folds (NBFs) and are located on the cytoplasm side of the 
phospholipid bilayer. 
 
ABCs are mostly unidirectional, meaning they only function in one direction. In 
bacteria, they mainly pump essential compounds such as sugars, vitamins, metal ions, 
etc. into the bacteria. These transporters are called importers. In eukaryotes, ABCs 
mainly move compounds from within the cytoplasm to the outside of the cell or into a 
membrane bound organelle (endoplasmic reticulum, mitochondria, peroxisomes, etc.). 
These transporters are called exporters. ABC transporters are largely dispersed 
 4 
throughout the genome and have an extremely wide variety of uses. For example lipid 
flippases work by flipping a lipid from the inner phospholipid membrane to the other 
phospholipid membrane. 
P-glycoprotein (Pgp) is one of the most important and best characterized member of the 
ABC transporter family and has a high expression in various tissues. In addition, Pgp is 
also a pharmacological target because of its anatomical localization in relation to the 
sequence of drug movement, i.e. cellular uptake, intracellular distribution, metabolism 
and excretion. 
Various approaches have been used for the study of Pgp function. However, it is 
difficult to classify test compounds as Pgp substrates and/or inhibitors by a single assay, 
as different experimental systems and test conditions produce different classifications. 
Also this process is very laborious and time consuming. The topic of the research 
programme therefore involves a new approach to the classification of drug candidates as 
Pgp substrates and/or inhibitors, as well as the investigation of the functionality of this 
membrane transporter. 
The approach utilized in this work is based upon affinity chromatography. The 
mechanism of affinity separations is most often described by a “lock and key” analogy. 
Retention depends on complementarity of a ligand molecule (the “key”) and a specific 
binding site (the “lock”) with high affinity for the ligand. Typically the molecule 
containing the binding site is a protein, although some nucleic acid interactions may 
also be useful. The ligand can be a small molecule, a carbohydrate, another protein, a 
prosthetic group, a specific amino acid sequence in a protein, or a specific nucleotide 
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sequence. There are virtually an unlimited number of affinity separations that can be 
used, the only requirement being a strong and specific binding interaction that is in 
some way reversible. 
In some cases the ligand is covalently bound to the stationary media. The affinity 
adsorbent thus constructed can be used to specifically scavenge proteins or other 
macromolecules containing a binding site from a sample which may be a complex 
mixture containing many other non-binding molecules. This strategy has been used to 
isolate proteins with binding sites for specific cofactors, enzyme inhibitors, cell-surface 
carbohydrates, and nucleic acid sequences, among other possibilities. 
In other cases a protein with affinity for a specific ligand or sequence is covalently 
bound to the media and used to scavenge the ligand, or a molecule to which the ligand 
is covalently attached, from solution. This approach has much in common with the 
fundamental processes of drug action, absorption, distribution, excretion and receptor 
activation which are dynamic in nature and have similarities with the basic mechanisms 
involved in chromatographic distribution. Indeed, the same basic intermolecular 
interactions (hydrophobic, electrostatic, hydrogen bonding) determine the behaviour of 
chemical compounds in both biological and chromatographic environments. (Kaliszan 
& Wainer, 1997) 
The relationships between pharmacological and chromatographic processes have been 
emphasized by the inclusion of a wide variety of proteins as active components of 
chromatographic systems, in the creation of protein-based stationary phases. The 
extreme complexity of biological systems limits rational design of an individual 
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chromatographic system that would directly mimic a total biological system. However, 
construction of the right protein-based stationary phase can readily yield a great amount 
of diversified, precise and reproducible data about key aspects of that system. The 
possibilities are only limited by the ability to create and use unique phases. In addition, 
the ability of enzymes and carrier proteins to act as chiral selectands has been 
extensively used in drug development, as well as adapted for use in the 
chromatographic sciences.  
An example of the utility of the latter approach is the creation of chiral stationary 
phases (CSPs) through the immobilization of biopolymers on chromatographic 
backbones. These CSPs have been based upon enzymes and carrier proteins and used 
primarily in liquid chromatographic systems. The use of biopolymeric based CSPs has 
been particularly valuable in the quantification and separation of small chiral 
compounds on an analytical scale (Lough & Wainer 2002; Wainer 1993) 
In general, two approaches have been used in the construction of biopolymer-based 
CSPs – covalent immobilization and entrapment/adsorption. The enzymes Į- 
chymotrypsin (ACHT), trypsin (TRYP) and cellobiohydrolase I have been covalently 
attached to silica supports (Marle et al., 1992, 1991; Jadaud et al., 1989, Thelohan et al. 
1989), ACHT and TRYP have been entrapped in the interstitial spaces of an 
immobilized artificial membrane stationary phase (IAM) (Chui & Wainer 1992, Kolbah 
& Wainer 1993), while ACHT has been adsorbed on LiChrospher phases (Marle et al. 
1992).  The carrier protein phases have been synthesized using entrapment followed by 
cross-linking as in the case of Į1 acid glycoprotein (AGP) (Wainer 1989) or through 
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covalent immobilization used when immobilizing serum albumin (Hage & Austin 2000, 
Domenici et al., 1990). 
Biopoylmeric based CSP’s have also found a use in pharmacological applications. The 
immobilization of proteins has also been widely studied and a variety of covalent and 
non-covalent immobilization techniques have been developed. In addition, the 
experimental approaches to the isolation and purification of receptors from biological 
matrices have been extensively studied and discussed.  
It has been demonstrated in recent work that these techniques can be used to immobilize 
transporter proteins such as the P-glycoprotein transporter (Pgp) (Zhang et al. 2000), 
carrier proteins such as human serum albumin (HSA) (Noctor et al. 1993) and receptor 
proteins such as nicotinic acetylcholine receptors (Moaddel et al. 2002). The nicotinic 
receptor and Pgp were immobilized via hydrophobic insertion into the interstitial spaces 
of an immobilized artificial membrane (IAM) stationary phase (Figure 2). The IAM is 
comprised of silica particles (12 ȝm id with 300 Å pores) to which phospholipid 
analogues, with functional head groups, have been covalently coupled in a monolayer.  
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Figure 2. The chemical structure of the monolayer that is covalently bound to the silica 
on the IAM-PC particles (12 micron, 300 Å pores).  
 
The specific feature of IAM beads is its resemblance to a hydrophobic environment that 
allows immobilization of membrane proteins and receptors.  The IAM stationary phase 
used in these studies was commercially available from Regis Technologies (Morton 
Grove, IL, U.S.A.) as the IAM-phosphatidyl choline (IAM-PC) stationary phase.  
The stationary phases were characterized using zonal and frontal chromatographic 
experiments. Binding affinities (expressed as dissociation constants, Kd,'s) were 
determined using the stationary phases and in some cases a mixtures of ligands were 
resolved according to their relative affinities. The immobilized proteins retained their 
ability to bind and/or transport ligands and were suitable for determining the 
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pharmacological activities of the tested ligands. Thus, it is conceivable to envision the 
creation of a wide variety of immobilized-receptor phases. 
The protein based stationary phases can be employed for quantitative affinity 
chromatography, a theoretical approach to the use of protein-based stationary phases as 
probes of ligand-protein and protein-protein interactions. The two predominant methods 
for the analysis are zonal affinity chromatography and frontal affinity chromatography. 
In the case of zonal affinity chromatography a small sample volume is injected into the 
mobile phase and the analyte (or analytes) move through the column in concentration 
zones. The shape of the chromatographic peak produced by this process represents an 
equilibrium process defined by the association and dissociation rate constant while the 
retention volume represents the total of specific and non-specific interactions of the 
solute with the stationary phase. Refer to Figure 3. 
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Figure 3. Schematic of a zonal chromatogram depicting the movement of the analyte 
through the chromatographic bed in concentration zones. The process represents an 
equilibrium process defined by the association and dissociation rate constant. The 
retention time k’, can me measured as the time at which the counts per minute (e.g. if 
radioactivity detection was being used) are at the peak (maximum). 
 
 This technique can also be used to study the binding of drugs and other solutes on 
immobilized protein columns, to determine drug-drug protein binding interactions and 
in the development of quantitative structure-retention relationships that describe these 
binding processes. Information on the kinetics of solute-protein interactions can also be 
obtained if appropriate data are collected on the width and retention of solute peaks 
under various flow rate conditions.  
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In frontal affinity chromatography a larger sample volume is required than zonal 
elution. A marker ligand is placed in the mobile phase and passed through the column. 
The frontal regions are composed of the relatively flat initial portion of the 
chromatographic traces, which represent the nonspecific and specific binding of the 
marker to the cellular membranes and the target (Figure 4). The saturation of the target 
by the marker produces a steep rise in the chromatographic trace, which ends, or 
plateaus, when the target is saturated. 
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Figure 4. Schematic of a frontal chromatogram showing a saturation binding curve of 
the marker ligand when placed in the mobile phase and passed through the 
chromatographic column. The plot looks like the familiar sigmoidal dose-response 
curve or is described as a rectangular hyperbola or a binding isotherm curve.  
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Frontal affinity chromatography can be used to calculate the dissociation constant Kd 
and the number of active binding sites Bmax. 
 
The Kd value is used to describe how tightly a ligand (such as a drug) binds to a protein. 
Such binding is usually non-covalent, i.e., no chemical bonds are made or broken. Since 
the binding is usually described by a two-state process 
  
 
the corresponding dissociation constant is defined 
 
where [P], [L] and [C] represent the concentrations of the protein, ligand and bound 
complex, respectively. The Kd has the units of concentration (M), and corresponds to 
the concentration of ligand [L] at which the binding site on the protein is half occupied, 
i.e., when the concentration of protein with ligand bound [C] equals the concentration of 
protein with no ligand bound [P]. The smaller the dissociation constant, the more tightly 
bound the ligand is; for example, a ligand with a nanomolar (nM) dissociation constant 
binds more tightly than a ligDQGZLWKDPLFURPRODUȝ0GLVVRFLDWLRQFRQVWDQW 
 
Kd and Bmax values can be obtained from frontal chromatographic data using one of two 
models, a) linear regression model or b) non-linear regression model. (Gottschalk et al., 
2002) 
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For the linear regression model, the association constants of the competitive ligands 
(CL), KCL, as well as the number of the active and available binding sites of 
immobilized receptors, Bmax, were calculated using the following equations [(1) and    
(2)] 
 
(VmaxíV)í=(1+[M]KM)(Vmin[Bmax]KM)í+(1+[M]KM)2(Vmin[Bmax]KMKCL)í[drug]í  (1) 
 
(VíVmin)í=(Vmin[Bmax]KCL)í+(Vmin[Bmax])í[M]        (2) 
 
 
 where, V is the retention volume of the marker ligand (M); Vmax the retention volume of 
M at the lowest concentration and in the absence of drugs; Vmin the retention volume of 
M when the specific interaction is completely suppressed. The value of Vmin is 
determined by running M in a series of concentration of drugs and plotting 1/(VmaxíV) 
versus 1/[CL] extrapolating to infinite [CL]. From the above plot and a plot of 
1/(VíVmin) versus [M], dissociation constant values, Kd, for M and CL can be obtained 
as can the number of active binding sites on the immobilized protein [Bmax].  
 
In the non-linear regression model the relationship between displacer concentration and 
retention volume can be established using Equation 3 and can be used to determine the 
Kd value of the displacer and the number of active binding sites, Bmax.   
                 [X] (V - Vmin) = Bmax [X] (Kdx + [X])-1                (3)          
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where: V is retention volume of drug (displacer); Vmin, the retention volume of drug 
(displacer) when the specific interaction is completely suppressed (this value can be 
determined by running the drug with a high concentration of displacer).  
 
An example of a non-linear regression model is shown in Figure 5, where [X] (V - Vmin) 
is plotted vs [X]. The plateau represents the Bmax where all the sites are saturated and 
50% of the Bmax represents the Kd. 
 
 
 
 
 
 
 
 
Figure 5. A representative non-linear regression plot of [concentration] M vs. [conc](V-
Vmin)  that results from the data obtained from frontal chromatography which is used to 
derive the dissociation constant Kd and the number of active binding sites Bmax. 
0 25 50 75 100
0
255
510
[Concentration]
[C
o
n
c] 
(V
-
V m
in
)
100
50
-----
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Kd
----------------------------------------------
Bmax
[C
o
n
c] 
(V
-
V m
in
)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
 15 
In affinity chromatography various isotherm equations may arise according to the 
chemical system considered. For the intereaction of the solute and the immobilized 
ligand, non equilibrium conditions must be taken into account. The association 
constants measured between the solute and the immobilized ligand are hardly 
comparable to the solvated conditions. Thus the trend is then to produce immobilized 
ligands with affinity properties as close as possible to those of the free ones, to decrease 
the nonspecific interactions of the support itself. Frontal affinity chromatography 
decreases the nonspecific interactions between the solute and the immobilized ligand as 
it saturates the column. Thus for measuring the equilibrium constants of complicated 
systems frontal elution is a powerful tool, since the amount of interacting 
biopolymers/compounds at equilibrium is easily related to the chromatographic data.   
 
1.1.2 The application of quantitative affinity chromatography to protein binding 
studies 
 
The interaction of small solutes with proteins is important in many biological processes. 
Examples include the action of enzymes upon substrates and the binding of hormones 
with their receptors. The binding of drugs and other compounds with serum proteins is 
yet another example of such a process.  Protein binding in blood is important in 
determining the eventual activity and fate of drugs once they have entered the 
circulation. These interactions, in turn, help control the distribution, rate of excretion, 
and toxicity of drugs in the body. In addition, the presence of direct or indirect 
competition between two drugs or a drug and endogenous compound (e.g. fatty acid) 
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for the same binding proteins can be an important source of drug–drug interactions or 
drug displacement effects. For all of these reasons, it is important to have a good 
understanding of how pharmaceutical agents bind to serum proteins and of how these 
interactions are affected by other substances.  
 
Zonal chromatographic techniques have been used with the human serum albumin 
chiral stationary phases (HSA-CSP) for the direct determination of the percent of a 
compound bound to HSA (Noctor et al. 1993).  A series of benzodiazepines and a series 
of coumarin derivatives were chromatographed on the HSA-CSP and the retention time 
of each compound (expressed as k’) was compared to the percent of the compound 
bound to HSA determined by ultrafiltration techniques.  The values were correlated by 
plotting k’/(k’ + 1) versus percent bound to HSA to make the plot linear and correlation 
factors of 0.999 were obtained for both series (Figure 6).  
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Figure 6. The relationship between the chromatographic retention, expressed as k’, on a 
chiral stationary phase containing immobilized human serum albumin (HSA-CSP) and 
percent protein binding to free human serum albumin for a series of 18 
benzodiazepines, see Noctor et al., 1993, for experimental conditions and identity of 
compunds.   
 
 
A third series of triazole derivatives was also studied, but no correlation was observed.  
This result reflected the fact that the members of this series did not significantly bind to 
HSA (percent binding for all triazoles was less than 40%) and were not retained on the 
HSA-CSP (all k’s were less than 0.70).  The data indicated that the HSA-CSP could be 
used to determine whether compounds bind or do not bind to the protein. 
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Frontal chromatography on the HSA-CSP has also been used to determine the extent of 
binding to the protein (Loun & Hage, 1992).  In this study, the association constants for 
R-warfarin and L-tryptophan were determined.  The calculated values for R-warfarin 
and L-tryptophan were 2.47 x 105 and 1.10 x 104 M-1, respectively, which did not 
significantly differ from the results obtained by equilibrium dialysis or zonal elution 
techniques. 
 
1.1.3 The application of quantitative affinity chromatography using the nicotinic 
acetylcholine receptor (nAChR). 
 
The nAChR has been immobilized on the IAM liquid chromatographic stationary phase 
and used in frontal affinity chromatography experiments to determine receptor-binding 
affinities (Kd values). The Kd values determined chromatographically were comparable 
to those found using standard membrane affinity binding techniques. Frontal affinity 
chromatography could also be used to detect differences in the binding affinity of a 
compound between nAChR subtypes. (Moaddel et al., 2002, 2003). 
 
Zonal chromatography results demonstrated that the immobilized nAChR stationary 
phases can be used for the on-line screening for ligands to the nAChR. The nAChR 
columns can be used to identify both competitive and non-competitive ligands to this 
receptor. (Moaddel & Wainer, 2003). 
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Thus the possibility of the extensive use of immobilized liquid chromatographic 
stationary phases containing drug targets in on-line high through-put screening (HTS) is 
extremely encouraging. Successful development of stationary phases containing 
immobilized receptors, transporters and enzymes will lead to their use for on-line 
pharmacological studies and as rapid screens for the isolation and identification of lead 
drug candidates from complex biological or chemical mixtures. The usefulness of this 
approach is only limited by the ability to identify potential targets and the construction 
of the appropriate chromatographic system (Baynham et al., 2002). 
 
 
1.2 Aims and Objectives 
 
Membrane bound receptors and trans-membrane transporters and ion channels are 
difficult to characterize and to utilize in drug discovery unless you have a marker 
ligand.  It will be particularly important in characterizing orphan receptors, ion channels 
and transporters.  To put things into focus, G-protein coupled receptors (GPCRs) are the 
target for over 50% of the marketed drugs. The human genome contains about 1,000 
genes which encode for approximately 10,000 GPCRs, however only a few 100 GPCRs 
have been characterized. Clearly there is a growing need to develop methods which 
would help in the process of screening for various drugs and identification of suitable 
lead candidates. Also it is very difficult to classify test compounds as transporters and 
inhibitors by a single assay because different experimental systems and test conditions 
produce different classifications.  A well defined strategy should be used to identify 
potential inhibitors and substrates of these transporters.  
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Recently the use of affinity chromatography, which is based upon target biopolymers in 
a flow system, has been considered as a valuable method in identifying substrates for 
different biopolymers. This method can rapidly determine a compound's affinity for 
biopolymers and whether it is an inhibitor/substrate of the transporter. This is a key 
element in drug discovery and drug development programs. Therefore the method can 
be used as a pre-screen to identify all substrates and inhibitors, which could be 
subsequently moved onto a more expensive and time consuming functional assays to 
determine functional activity. 
 
Accordingly, the aim of this research programme was to develop novel methodology to 
enable the study of the interaction of drugs and related compounds with these 
transporters, in a rapid and facile manner. 
 
The initial studies were designed to develop practical experience in the application of 
affinity chromatogrDSK\ 7KHVH VWXGLHV LQFOXGHG WKH XVH RI DQ LPPRELOL]HG Į1 acid 
glycoprotein (AGP) column to achieve the enantioselective separation of the drug 
ketamine. The second study was designed to explore the use of online affinity 
chromatography in the isolation of ligands to an immobilized nicotinic acetyl choline 
receptor (nAChR). 
 
The final and primary objective of this program was to characterize the Pgp and hOCT1 
transporters and immobilize these cellular membranes on a chromatographic backbone. 
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These stationary phases would then be used in frontal affinity chromatographic studies 
to determine the binding affinities {Kd values} of various Pgp and OCT 
substrates/inhibitors and lead to identification of competitive, allosteric and 
enantioselective interactions in ligand binding to these transporters. This would help to 
ascertain whether competitive binding experiments on the Pgp and hOCT1 columns 
could be a rapid method for the identification of synergistic pairs for specific clinical 
targets.  
 
Also an aim of this programme was to attempt to use these immobilized biopolymeric 
stationary phases in on-line pharmacological studies and as a rapid screen for the 
isolation and identification of lead drug candidates from complex biological mixtures. A 
further objective was to study its application in determining apparent equilibrium 
constants (association constants, dissociation constants, binding constants) using very 
small amounts of biopolymer and ligand.  
 
Also these affinity chromatographic methods could be of particular relevance in 
monitoring interactions between exogenous or endogenous compounds in binding to 
different drug receptors. This might lead to the understanding of their pharmacological 
and/or toxicological activities. A further objective was to screen varied drugs for their 
drug-protein interaction and to develop a pharmacophore (structural feature in a 
molecule that is recognized at a receptor site and is responsible for the molecule’s 
biological activity) which would depict the possible interactions of the active site of 
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these transporters. Also possible enantioselectivity studies would be carried out to 
identify for any enantioselectivity of the transporters active site. 
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2. Application of Protein Affinity Chromatography to Analytical 
Studies  
 
 
2.1 8VHRIDIILQLW\EDVHGFKLUDOVWDWLRQDU\SKDVHĮ1-AGP for the determination of 
ketamine and norketamine in human plasma 
 
2.1.1 Introduction 
 
+XPDQĮ1-acid glycoprotein (AGP) is also known as orosomucoid (ORM). This is a 41-
to 43-kDa glycoprotein with a pI of 2.8 to 3.8 and a high carbohydrate content of 45% 
(Kremer et al., 1988, Fournier et al., 2000). The peptide portion of this protein has 183 
amino acids in a single polypeptide chain with two disulfide bridges. The carbohydrate 
portion has five to six highly sialylated complex-type-N-linked glycans that are attached 
to the peptide chain. AGP has a high solubility in water and polar organic solvents.  
 
AGP is one of the plasma proteins synthesized by the liver and is mainly secreted by the 
hepatocytes, although extrahepatic AGP gene expression has also been reported 
(Kremer et al., 1988). The hepatic production of these proteins, also known as “acute 
phase proteins,” is increased in response to various types of stress, such as physical 
trauma or unspecific inflammatory stimuli.  
 
The biological function of AGP remains unknown. However, a number of possible 
physiological activities have been studied, such as immunomodulating effects. Due to 
its low pI value, AGP is the major plasma protein responsible for the binding of cationic 
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drugs (Chui et al., 1992). As will be seen later, this property has made AGP supports 
the most versatile of all the serum protein-based chiral stationary phases. 
 
2.1.1.1 Preparation of AGP-CSPs 
 
An AGP chiral stationary phase (AGP-CSP) was initially synthesized by coupling this 
protein to epoxide-activated silica (Hermansson et al., 1983). The silica (LiChrospher Si 
300) was activated using 3-glycidoxypropyltrimethylsilane and mixed with a solution of 
AGP dissolved in pH 8.5, 0.1 M borate buffer containing 0.2 M sodium chloride. The 
resulting AGP-CSP contained about 35 mg of AGP per gram silica. 
 
The first commercially available form of AGP-CSP (i.e., EnantioPac) was prepared by 
first ionically binding AGP to diethylaminoethyl silica. This protein was then cross 
linked using a process that involved the oxidation of the terminal alcohol groups to 
aldehydes, Schiff base formation, and reduction to form amine groups (Wainer et al., 
1989). This process yielded an immobilized coating of approximately 180 mg protein 
per gram of silica. The resulting column is a useful CSP but has a short lifetime. A 
second-generation column (i.e., Chiral AGP) was later produced with better 
chromatographic performance and stability. 
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2.1.1.2 Bioanalytical Applications of AGP-CSPs 
 
Because of the broad applicability of AGP-CSPs and their use with aqueous mobile 
phases, columns based on these phases have been used in many bioanalytical studies. 
The AGP-CSP can be used alone or in a multidimensional system. The latter approach 
involves the use of an achiral column (usually as a precolumn) for the separation of 
compounds such as a parent drug and its metabolites based upon structural differences; 
this is followed by an enantioselective separation on the AGP-CSP. However, the 
growing use of liquid chromatography/mass spectrometry (LC-MS) and selective ion 
monitoring has reduced the need for multidimensional systems, with the required chiral 
separations now often being accomplished using just the AGP-CSP. Bioanalytical 
methods based on AGP-CSPs have been developed for disopyramide (Hermansson et 
al., 1984), atenolol (Enquist et al., 1989), verapamil and norverapamil (Chu et al., 
1989), citalopram (Haupt et al., 1996), mepivacaine (Vletter et al., 1996), and 
thiopentone (Jones et al., 1996). 
 
Looking at the success of AGP-CSP in the enantioselective separation of wide variety 
of basic, neutral and acidic chiral compounds and its use in bioanalytical applications, 
the AGP-CSP was used to develop and validate the enantioselective separation of 
ketamine and norketamine from plasma samples. 
 
Ketamine (Ket) is a dissociative anaesthetic agent that has also been shown to induce 
analgesia by non-opioid mechanisms (White et al., 1980; Oye et al., 1992; Klepstad et 
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al., 1990). Ket is a chiral molecule that is commercially available as a racemic mixture, 
i.e. a 50:50 mixture of its enantiomers, (R)-Ket and (S)-Ket. (Figure 7)  
 
 
Figure 7. Chemical structures of cationic drugs ketamine, norketamine and 
bromoketamine (anaesthetic agent shown to induce analgesia by non-opioid 
mechanism). * indicating the chiral centre. 
 
However, (R)- and (S)-Ket have significantly different pharmacodynamic activities  
(White et al., 1982; Reich et al., 1989) as the therapeutic potency of (S)-Ket is 2 to 4 
times greater than the (R)-enantiomer (Marietta et al., 1977; White et al., 1985) and (S)-
Ket  is a more potent analgesic agent than the (R)-Ket. (Oye et al., 1992)   
 
Ket is currently undergoing trials as an analgesic agent for the treatment of neuropathic 
pain.  The clinical protocol utilized in this study involved a continuous infusion of 
racemic-Ket designed to reach plasma concentrations of 60 to 120 ng/ml.  It was 
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assumed that the study would produce Ket and norKet plasma levels at or below the 
previously reported lower limits of detection. Thus, the objective of this study was to 
develop and validate a highly sensitive enantioselective bioanalytical method to analyze 
the plasma samples associated with this clinical study.  
 
The aim therefore is to develop a sensitive enantioselective liquid chromatographic 
assay with mass spectrometric detection (LC-MS) and validate for the simultaneous 
determination of plasma concentrations of (R)- and (S)-ketamine, and (R)- and (S)-
norketamine. The compounds need to be extracted from human plasma using solid 
phase extraction method and then directly injected into the LC-MS for detection and 
quantification.  Enantioselective separations could be achieved on a liquid 
FKURPDWRJUDSKLFFKLUDOVWDWLRQDU\SKDVHEDVHGXSRQLPPRELOL]HGĮ-acid glycoprotein 
(the Chiral AGP column).   
 
2.1.2 Experimental 
 
2.1.2.1 Chemicals and reagents 
 
 (+)-(S)-Ketamine, [(S)-Ket]; (-)-(R)-ketamine, [(R)-Ket]; (+)-(S)-norketamine, [(S)-
norKet]; (-)-(R)-norketamine. [(R)-norKet]; (R,S)-ketamine, [(R,S)-Ket]; (R,S)-
norketamine, [(R,S)- norKet] and (R,S)-Bromoketamine, [(R,S)-BrKet] were a kind gift 
from Dr. Thomas Wolfe from Parke-Davis Pharmaceutical Research (Ann Arbor, MI, 
USA). HPLC grade 2-propanol was purchased from Fisher Scientific (Fair Lawn, NJ, 
USA). HPLC reagent grade ammonium acetate was obtained from J.T.Baker 
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(Phillippsburg, NJ, USA). Ultra-pure water was obtained using a Milli-Q water 
purification system (Millipore, Milford, MA, USA). Pooled drug-free human plasma 
was received from the Apheresis Unit, National Institute on Aging (Balltimore, MD 
USA). The extraction cartridges were Oasis HLB 1ml, 30 mg and Oasis MCX 3 ml, 60 
mg (Waters Corporation, Milford, MA, USA) and Bond Elut-C18, 1 ml, 50 mg (Varian, 
Harbor City, CA USA). 
 
2.1.2.2 Apparatus 
 
 The analytical system consisted of  a Series 1100  Liquid Chromatography/ Mass 
Selective Detector, LC/MSD (Agilent Technologies, Palo Alto, CA, USA) equipped 
with a vacuum de-gasser (G 1322 A), a binary pump (1312 A), an autosampler 
(G1313A), a thermostated column compartment (G1316 A); a mass selective detector, 
MSD (G1946 B) supplied with atmospheric pressure ionization electrospray (API-ES) 
and an on-line  nitrogen generation system (Whatman, Haverhill, MA, USA). The 
chromatographic system was interfaced to a 250 MHz Kayak XA computer (Hewlett-
Pakard, Palo Alto, CA, USA) using ChemStation software (Hewlett-Packard). The 
extractions were performed using a 12-Port Vaccum Manifold, PrepSep TM from 
Fisher Scientific (Fair Lawn, NJ, USA). 
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2.1.2.3 Chromatographic conditions 
 
The enantioselective separations of (R)- and (S)-Ket, (R)- and (S)-norKet and (R)- and 
(S)-BrKet were accomplished using a guard Chiral-AGP column  (10 x 2.0 mm i.d., 5 
ȝ฀m) and an analytical column Chiral-$*3  [  PP LG  ȝ฀m) purchased 
from Advanced Separation Technologies (Whippany, NJ, USA). The mobile phase 
consisted of 2-propanol: ammonium acetate buffer [10 mM, pH 7.6 (adjusted with 
ammonium hydroxide)], 6:94 (v/v). The flow rate was 0.5 ml/min, the injection volume 
ZDVȝODQGWKHFROXPQWHPSHUDWXUHZDVNHSWDWoC. 
 
Mass spectra were recorded using a full scan in positive ion mode, with a  scan range 
from  m/z 100 to 600. Single ion monitoring (SIM) was used to quantitate the target 
compounds.  The chromatograms were monitored at   m/z = 238.1 (Ket), m/z= 224.1 
(norKet) and m/z= 284.0 (BrKet). 
 
2.1.2.4 Optimization of the mass selective detector (MSD) parameters 
 
The sensitivity of the Ket and norKet signals was primarily dependent on the MSD 
experimental parameters.  In order to identify the optimized condition, the following 
MSD parameters were investigated: fragmentation voltage (50 - 80 V), capillary voltage 
(1000 - 3000 V), nebulizer pressure (40 - 55 psig) and  drying gas temperature (200 - 
350 oC). 
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2.1.2.5 Preparation of stock solutions 
 
Concentrated stock solutions of (R,S)-Ket [1.00 mg/ml], (R,S)-norKet [1.00 mg/ml] and 
(R,S)-BrKet [0.40 mg/ml] were prepared in ultra-pure water, placed in capped 
polypropylene tubes, wrapped in aluminum foil and stored at –20 oC. Spiking standard 
solutions for the calibration curve and quality control samples (QCs) were made by 
serial dilutions with ultra-pure water starting with their respective concentrated stock 
solution.  These spiking standards were placed in capped polypropylene tubes, wrapped 
in aluminum foil and stored at 4 oC. 
 
2.1.2.6 Preparation of calibration curve and quality control standards 
 
The determinations of Ket and norKet were based on the internal standard method, 
using BrKet as internal standard.  Calibration and QC standards were prepared daily by 
adding ȝORIWKHFRUUHVSRQGLQJVSLNLQJVWDQGDUGVROXWLRQFRQWDLQLQJ.HWQRU.HWDQG
%U.HW WR  ȝO GUXJ-free plasma. The 7-point calibration curve ranged from 1.0 to 
125.0 ng/ml (1.0, 5.0, 25.0, 50.0, 75.0, 100.0, 125.0 ng/ml) for each ketamine and 
norketamine  enantiomer and   a constant concentration of 100.0 ng/ml  for each 
bromoketamine enantiomer . The QC standards were 5.0 ng/ml {low quality control 
(LQC), 50.0 ng/ml {medium quality control (MQC)}, and 100.0 ng/ml {high quality 
control (HQC)}. The concentrations are given per enantiomer. 
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2.1.2.7 Extraction procedure 
 
Sample extraction was performed using solid phase extraction (SPE).  To 15 ml conical 
SRO\SURS\OHQHFDSSHGWXEHVZHUHDGGHGȝODOLTXRWVRISODVPDVDPSOHVDQGȝO
internal standard.  The resulting solutions were made alkaline by the addition of 0.5 ml 
of ammonium acetate buffer [10 mM, pH 9.5], vortex-mixed for 2 min, and centrifuged 
at 1250 x g (4 oC) for 15 min. The plasma samples were then added to preconditioned 1 
ml solid phase extraction cartridges (Oasis HLB).  The cartridges were conditioned with 
1 ml of methanol followed by 1 ml of water and then 1 ml of ammonium acetate buffer 
[10 mM, pH 9.5].  After addition of the plasma, the conditioned cartridges were washed 
with 1 ml of water and the retained compounds were eluted with 0.5 ml methanol. The 
methanol eluents were transferred to 300-ȝODXWRVDPSOHUYLDOVDQGȝODOLTXRWVZHUH
injected onto the LC-MSD system. 
 
2.1.2.8 Validation 
 
The intra- and inter-day validation studies for precision and accuracy were performed in 
quintuplicate with QC standards at 5.0, 50.0 and 100.0 ng/ml per enantiomer. The 
analyses were carried out over a period of 3 days for the interday validation.  The 
curves were constructed by plotting the peak height ratio (R)-Ket /(R)-BrKet, or (S)-Ket 
/(S)-BrKet, or (R)-norKet /(R)-BrKet or (S)-norKet /(S)-BrKet against its concentration. 
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Extraction efficiencies  (% recovery) of  (R,S)-Ket ,  (R,S)-norKet  and  (R,S)-BrKet 
were determined by comparing peak heights for the QC standards to the peak heights 
resulting from the chromatography of standard solutions  containing the equivalent  
final  concentrations. 
 
Accuracy was determined by comparing the observed concentrations of the QC 
standards calculated from the calibration curve to their nominal concentrations. 
 
The specificity of the method for each analyte was examined by individually screening 
Ket, norKet and BrKet after spiking in pooled human plasma. 
 
2.1.2.9 Application of the analytical method 
 
The validated method was applied to the analysis of plasma samples obtained from a 
clinical study on Ket in pain management (Protocol A00-M91-00), conducted in the 
Anesthesia Research Unit, McGill University Medical Center (Montreal, Quebec, CA).  
After signing consent form, the patients received infusion of Ket (Ketalar®, Park-
Davis) delivered using a computer-controlled pump (Stanpump, Harvard 22 Basic 
Syringe Pump®, Harvard Apparatus, South Natick, MA, USA). The target plasma 
concentrations set on the pump for the Ket infusions were 0 ng/ml (baseline), 60 ng/ml 
(dose 1) and 120 ng/ml (dose 2), during three testing periods of 15 min each. Blood 
samples were collected at the end of the baseline period and at the beginning and the 
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end of dose 1 and dose 2 periods. Plasma was obtained by centrifugation and the 
samples were frozen at -80 oC until analysis. 
 
 
 
2.1.3 Results and Discussion 
 
2.1.3.1 Optimization of the chromatographic separation 
 
(QDQWLRVHOHFWLYH VHSDUDWLRQVRQDQ LPPRELOL]HGĮ-acid glycoprotein chiral stationary 
phase (AGP-CSP) are affected by the buffer concentration, the type and concentration 
of organic modifiers and the pH of the mobile phase (Yanagihara et al., 2000).  Each of 
these parameters was systematically studied in the development of the enantioselective 
separation.  Temperature also plays a role in separations on a CSP.  However, in this 
study, the temperature was maintained at 25 oC and this parameter was not adjusted. 
 
2.1.3.1.1 Selection of the buffer in the mobile phase for an LC-MS application 
 
The buffer selected for this study was ammonium acetate because of its compatibility in 
LC-MS applications. Buffer concentrations of 10 and 20 mM were investigated and 
there was no significant influence of buffer concentration on the enantioselective 
separation.  Therefore, a 10 mM concentration of ammonium acetate was chosen for the 
study. 
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2.1.3.1.2 Selection of the organic modifier in the mobile phase 
 
The mobile phase concentration of 2-propanol was varied between 3 and 10% and it 
was found that the enantioselective separations of Ket, norKet and BrKet were highly 
dependent on the 2-propanol content.  The optimum enantioselective separations of the 
three compounds were achieved with a 2-propanol : buffer ratio of 3:97 (v/v).  Under 
WKHVH FRQGLWLRQV WKH REVHUYHG HDQWLRVHOHFWLYLWLHV Į¶V ZHUH  .HW  QRU.HW
and 1.34 (BrKet).  However, the analysis took 35 min.  When the mobile phase 
concentration of 2-propanol was raised to 10%, the analysis took only 13 min. 
However, while the observed Į’s were acceptable for norKet and BrKet, 1.27 and 1.13, 
UHVSHFWLYHO\ WKH HQDQWLRVHSDUDWLRQ RI .HW ZDV HVVHQWLDOO\ ORVW Į    7KH EHVW
balance between enantioselectivity and analysis time was found with a mobile phase 
composed of 2-propanol : buffer, (6:94, YY8QGHUWKHVHFRQGLWLRQVWKHREVHUYHGĮ¶V
were 1.09 (Ket), 1.46 (norKet) and 1.22 (BrKet) and the analysis time was 18 min.  This 
mobile phase composition was used in the remaining optimization studies. 
 
The addition of acetonitrile to the mobile phase has been shown to often improve the 
enantioselectivity (Wainer et al., 1993).  In this study, the addition of acetonitrile (0.5 to 
1.0 %, v/v) to the mobile phase had no significant effect on the chromatography, 
although there was a slight decrease in retention time (0.25 to 0.5 min difference).  The 
mobile phase selected for the validation and clinical studies did not contain acetonitrile.  
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2.1.3.1.3 Optimization of buffer pH  
 
The effect of pH on the enantioselective separation of Ket and norKet was studied using 
the previously determined mobile phase composition of 2-propanol : ammonium acetate 
buffer [10 mM], (6:94, v/v).  The pH of the buffer was varied over the range 4.0 to 7.0, 
in intervals of 0.5 units and from pH 7.0 to pH 8.5 in 0.1 intervals.  At all pH values, an 
enantioslective separation was observed for norKet and BrKet.  At pH 7.0 and higher, 
baseOLQH HQDQWLRVHOHFWLYH VHSDUDWLRQV ZHUH DFKLHYHG ZLWK REVHUYHG Į¶V RI -1.86 
(norKet) and 1.16 – 1.57 (BrKet). 
 
An adequate enantioseparation of Ket was harder to achieve.  From pH 4.0 to 6.5 no 
enantioselective separation of (R,S)-Ket was observed.  Between pH 7.0 and pH 7.5, the 
REVHUYHG Į IRU .HW UDQJHG IURP  S+  WR  S+  ZLWK D PD[LPXP
UHVROXWLRQ56RIREWDLQHGDWS+%HWZHHQS+DQGS+WKHREVHUYHGĮ
increased from 1.17 to 1.37, the RS values from 0.83 to 1.90. 
 
On the basis of these studies, the pH of the buffer was set at 7.6.  Although the best 
chromatographic separations were achieved at pH 8.5, the stability of the AGP-CSP is 
reduced when the pH of the mobile phase is > 7 {Instruction Manual Chiral-AGP, 
ChromTech AB}.  Thus, the selected pH was a compromise between chromatographic 
separation and column life.  
 
Based upon these results, the mobile phase composition for the validation and clinical 
study were set at 2-propanol : ammonium acetate buffer [10 mM, pH 7.6], (6:94, v/v). 
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Under these conditions, the analysis was completed in less than 20 min.  The relative 
retentions (k’) of (S)-Ket and (R)-Ket were 9.0 and 10.5, respectively and the observed 
HQDQWLRVHOHFWLYLW\ĮZDV)LJXUH$IRU6-norKet and (R)-norKet the k’s were 
DQGUHVSHFWLYHO\DQGWKHREVHUYHGĮZDV)LJXUH%ZKLOHIRU%U.HWWKH
k’s for (S)-BrKet and (R)-%U.HW ZHUH  DQG  UHVSHFWLYHO\ DQG WKH REVHUYHG Į
was 1.31 (Figure 8C).  The enantiomeric elution orders were established by 
chromatographing the separate enantiomers.   
 
 
 
 
 
 
 
 
 
 
Figure 8. Representative chromatogram of the low quality control plasma sample 
(LQC) containing 5 ng/ml of (R)-Ket, (S)-Ket, (R)-norKet and (S)-norKet and 
100ng/ml of (R)-BrKet and (S)-BrKet; where: A: the chromatographic trace obtained 
using single ion monitoring at m/z = 238.1 (Ket); B:  the chromatographic trace 
obtained using single ion monitoring at m/z = 224.1 (norKet); and C: the 
chromatographic trace obtained using single ion monitoring at m/z = 284.0 (BrKet).  
min0 2.5 5 7.5 10 12.5 15 17.5
0
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C
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Previous Ket assays utilizing the AGP-CSP had reported a rapid deterioration of the 
CSP (Svensson et al., 1996). Under the described chromatographic conditions, the 
method was stable and reproducible, allowing us to analyze over 350 plasma standards 
and patient samples on a single analytical AGP column with replacement of the guard 
AGP column after an average of 100 plasma samples analysed.  
 
2.1.3.2 Optimization of the mass spectrometric detection 
 
The chromatograms were monitored using single ion monitoring for Ket at m/z = 238.1, 
for norKet at m/z= 224.1 and BrKet at m/z=284.0 (BrKet).  Each compound was 
injected individually and a full scan mass spectra was obtained and the signals were 
monitored at each of the specific m/z values.  The specific ion data was collected on 
three separate channels and analyzed.  The results of these studies demonstrated that 
there were no overlaps in the mass spectra of the compounds at the m/z values chosen 
for the monitoring.   In addition, the analysis of drug-free blank plasma at these m/z 
values detected no interfering peaks (Figure 9).   
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Figure 9. Representative chromatograms of drug-free plasma obtained using single ion 
monitoring for Ket at m/z = 238.1 (A), norKet m/z= 224.1 (B) and BrKet m/z= 284.0 
(C).  
 
The optimization of the mass spectrometer parameters was carried out using flow 
injection analysis (FIA) in which Ket and norKet standard solutions [50 ng/ml] were 
injected every two minutes. The Ket and norKet signals were optimized by the 
evaluation of changes in their peak height at their respective m/z value in response to 
changes in fragmentor voltage, capillary voltage, nebulizer pressure and drying gas 
temperature. The peak height of (R,S)-Ket and (R,S)-norKet  varied with the fragmentor 
voltage and the optimum response was obtained at 60 V. The value for the fragmentor 
voltage was set to 60 V and the other parameters were evaluated. In this way, the 
optimum conditions based on the maximum peak height were: drying gas flow-rate, 
11.0 L/min; nebulizer pressure, 40 psig; drying gas temperature, 350oC and capillary 
voltage, 1000 V.  
 
min0 2.5 5 7.5 10 12.5 15 17.5
A
B
C
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2.1.3.3 Extraction efficiency (% recovery) 
 
During the development of the extraction method, 3 SPE cartridges were tested. The 
cation exchange cartridges (Oasis MCX, 3 ml / 60 mg) gave low recoveries in the range 
60-75% for the 3 compounds as did the Bond Elute C-18 (1 ml / 30 mg), which yielded 
recoveries of 59-65%. The best recoveries were obtained using the Oasis HLB (1 ml / 
30 mg) where the recoveries ranged from 95.0% to 99.6%, Table 1 and Table 2.  
 
Table 1. Summary of validation statistics for ketamine  
                   
                    
  LQC    MQC    HQC   
          
    R S    R S   R S 
          
Conc.(ng/ml) 5.0 5.0  50.0 50.0  100.0 100.0 
          
Intra-day 
        
N  5 5  5 5  5 5 
Mean  4.9 5.0  48.5 48.4  97.4 97.3 
S.D.  0.1 0.1  1.8 1.4  3.2 3.3 
%CV  1.6 2.2  3.8 2.8  3.2 3.4 
          
Inter-day 
        
N  15 15  15 15  15 15 
Mean  5.0 5.0  50.0 49.8  99.8 99.8 
S.D.  0.3 0.4  2.4 2.3  3.7 4.9 
%C.V.  5.8 7.5  4.8 4.5  3.7 4.9 
          
Accuracy (%) 100.2 100.8  99.9 99.6  99.8 99.8 
Recovery (%) 95.0 95.5  98.0 98.6  99.5 99.6 
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Table 2. Summary of validation statistics for norketamine 
                   
                    
  LQC    MQC    HQC   
          
    R S    R S   R S 
          
Conc.(ng/ml) 5.0 5.0  50.0 50.0  100.0 100.0 
          
Intra-day 
        
N  5 5  5 5  5 5 
Mean  5.0 4.7  49.5 48.9  97.2 97.1 
S.D.  0.2 0.2  0.6 0.9  2.7 2.9 
%CV  3.0 4.0  1.2 1.8  2.8 2.9 
          
Inter-day 
        
N  15 15  15 15  15 15 
Mean  5.1 5.1  49.9 49.5  99.9 99.4 
S.D.  0.2 0.4  3.1 2.7  6.6 5.9 
%C.V.  3.9 7.2  6.3 5.5  6.7 5.9 
          
Accuracy (%) 101.4 102.2  99.7 99.0  99.9 99.4 
Recovery (%) 99.3 99.2  99.0 99.0  99.5 99.0 
    
                
          
 
 
2.1.3.4 Linearity and detection limits 
 
Calibration curves were generated by weighted (1/x) least squares linear regression. The 
linear relationships between peak height ratio and drug-enantiomer concentrations in the 
range of 1 to 125 ng/ml were described by the following equations: y = 0.0315x + 
0.0058, r2 = 1 {(R)-Ket}; y = 0.027x  – 0.0018, r2 = 0.9994 {(S)-Ket}; y = 0.1259x + 
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0.0419, r2 = 0.9995 {(R)-norKet}; y = 0.0688x + 0.0062, r2 = 0.9993 {(S)-norKet}. The 
data were based on 9 replicates of a 7-point calibration curve. 
 
The chromatogram of the LQC (5.0 ng/ml per enantiomer of Ket and norKet) is 
presented in Fig. 2.  The lower limit of quantification (LLOQ) is the concentration of 
the drug, in the matrix, which could be determined with a percentage accuracy within 
acceptable limits (80-100%). LLOQ per enantiomer for Ket and norKet was 1.0 ng/ml  
(n = 15) with an acceptable precision and accuracy for each enantiomer as follows: (R)-
Ket  8.6% and 97.8%, for (S)-Ket  9.2% and 97.4%, for (R)-norKet 7.5% and 98.8% 
and for (S)-norKet  8.7% and 99.3%.  The lower limit of detection (LOD) was defined 
as the concentration of the compound at which the signal versus noise ratio (S/N) was 
equal to 3. For each enantiomer, the LOD for Ket and norKet was 0.25 ng/ml. 
 
2.1.3.5 Accuracy and precision 
 
Accuracy and precision of the method for Ket and norKet were evaluated from 
quintuplicate analysis of each QC standards levels (LQC, MQC and HQC) repeated for 
3 days.  The calculated accuracy was 100.0 % for (R)-Ket , 100.1 % for (S)-Ket,  100.3 
% for (R)-norKet   and   100.2 % for (S)-norKet (Tables 1 and 2). 
 
The intra-day and inter-day precision of the method, determined as % of coefficient of 
variance (%CV) for the LQC, MQC and HQC for Ket and norKet were IRU5-
Ket,   7.5% for (S)-Ket,     IRU 5-norKet and   7.2 % for (S)-norKet. The 
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results of the validation studies demonstrated that the method had excellent accuracy, 
recovery and precision.  
 
2.1.3.6 Stability 
 
Hijazi et al., 2001, have previously reported that Ket and norKet were stable in aqueous 
solutions at –80oC for at least 6 months, and that plasma samples could be transported at 
4oC within 2 days and can be stored at –20oC for 10 weeks without any change in the 
concentrations of Ket and norKet.  The results from this study were consistent with the 
observation by Hijazi et al., 2001 as no significant degradation of the Ket and norKet 
standards or plasma samples was observed. 
 
2.1.4 Application to clinical samples 
 
The validated method has been applied to the analysis of plasma samples obtained from 
a clinical study on Ket in pain management.  A representative chromatogram of a 
patient plasma sample obtained before administration of the drug and 15 min after the 
end of dose 1 (where the target plasma concentrations was 60 ng/ml) is presented in 
Figure 10.  
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Figure 10. The chromatograms from the analysis of plasma samples from a patient 
obtained before the administration of Ket and 15 min after the administration of an 
infusion of 60 ng/ml, where: A: the chromatographic traces obtained using single ion 
monitoring at m/z = 238.1 (Ket), trace 1 – before administration, trace 2 - after 
administration; B: the chromatographic trace obtained using single ion monitoring at 
m/z = 224.1 (norKet), trace 1 – before administration, trace 2 - after administration.  The 
calculated concentrations were: (S)-Ket 27.1 ng/ml, (R)-Ket 28.9 ng/ml, (S)-norKet 3.4 
ng/ml,  (R)-norKet 2.5 ng/ml. 
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The measured concentrations were: S-Ket 27.1 ng/ml, R-Ket 28.9 ng/ml, S-norKet 
3.4ng/ml, (R)-norKet 2.5 ng/ml.  The plasma concentrations of (R)-Ket and (S)-Ket in 
two patients measured before and after doses 1 and 2 are presented in  
Figure 11. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Plasma concentrations of the enantiomers of ketamine, (R)-Ket and (S)-Ket, 
in two patients before and after dosing period 1 and dosing period 2, see Experimental 
Section for description of the clinical protocol.  
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In these two patients, the norKet levels were below our limit of detection during the first 
dosing period.  At the start of dosing period 2, norKet was undetectable in patient 1 and 
1.0 ng/ml of (R)-norKet was observed in patient 2, while at the end of dosing period 2 
(R)-norKet and (S)-norKet were measured in the plasma from patient 1 (2.7 and 1.0 
ng/ml, respectively) and patient 2 (2.7 and 2.8 ng/ml, respectively).  
 
 
2.1.5 Conclusions 
 
The results of these studies demonstrated that an immobilized protein based liquid 
chromatographic column could be used to separate and quantify enantiomeric 
FRPSRXQGV7KHHQDQWLRVHOHFWLYHELQGLQJRI.HWDQG1RU.HWWRWKHLPPRELOL]HGĮ1AGP 
was the same as that determined with free protein. In addition, the bioanalytical assay 
conducted was a simple, sensitive and reproducible method for the enantioselective and 
simultaneous determination of Ket and norKet in human plasma by LC-MS. The assay 
had greater sensitivity than previously reported methods and a run time of less than 20 
min.  Thus, the data indicated that this approach, i.e. using immobilized protein affinity 
chromatography, can be used to probe pharmacologically relevant binding interactions. 
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2.2 8VH RI LPPRELOL]HG Įȕ QHXURQDO QLFRWLQLF DFHW\OFKROLQH UHFHSWRU EDVHG
chromatographic stationary phase in multidimensional on-line screening for 
ligands of ĮȕQHXURQDOQLFRWLQLFDFHW\OFKROLQHUHFHSWRU 
 
 
2.2.1 Introduction  
 
While the work described in section 2.1 was an illustrative example as to how protein 
affinity chromatography and LC-MS are useful tools for the determinations of chiral 
drugs and biological fluids, they can also be used in the study of drug-protein 
interactions. This can go beyond the use of common commercially available protein 
stationary phases such as AGP and HSA to other important proteins which require 
further studies. One such proteint type is the nicotinic acetylcholine receptors. Affinity 
chromatography is a valuable method for rapid determination of a compound’s affinity 
for biopolymers immobilized on stationary phase and whether it is an inhibitor/substrate 
of the biopolymer. The study of the interactions of drugs with these biopolymers can be 
used as a pre-screen to identify all substrates/inhibitors, which could be then moved to a 
more expensive and time consuming functionally assay to determine functional activity.   
 
The health risks associated with tobacco and tobacco smoke have been clearly defined 
and well publicized. As a result, one aspect that is often-overlooked, is the fact that the 
tobacco plant and tobacco smoke contain more than 4,000 compounds (Gundish et al., 
2005), many of which may possess beneficial pharmacological and therapeutic 
properties.  This possibility has been suggested by the observed physiological effects 
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associated with smoking that include alertness, reduced anxiety, muscle relaxation and 
analgesia (Buccafusco et al., 2004), as well as specific disease-related effects, which 
have been observed in Alzheimer’s disease, Parkinson’s disease and schizophrenia. 
(Gundish et al., 2005; Newhouse et al., 2004) 
 
Although tobacco and tobacco smoke have been shown to contain compounds that 
inhibit a number of different targets such as monoamine oxidases (Herraiz et al., 2005), 
the therapeutic responses associated with tobacco smoking have been assumed to be 
primarily due to the interaction of nicotine with neuronal nicotinic acetylcholine 
receptors (nAChRs). This assumption was derived from a number of clinical 
observations including improved cognitive responses and memory in Alzheimer’s 
patients who had received intravenous, subcutaneous or trans-dermal doses of nicotine, 
the lower than expected incidence of Parkinson’s disease in smokers and the prevalence 
of cigarette smoking among patients with schizophrenia (Newhouse et al., 2004). These 
observations have led to the initiation of drug discovery programs which have the 
development of nAChR agonists as the primary focus. (Buccafusco et al., 2004; 
Holladay et al., 1997) 
 
Although current drug discovery programs are primarily concentrated on the 
development of nAChR agonists, nAChR antagonists have been in clinical use for over 
60 years, e.g., d-tubocurarine, a competitive inhibitor of peripheral nAChRs, was 
introduced into clinical anesthesia and surgical muscle relaxation in 1942 (Tassonyi et 
al., 2002).  The growing interest in nAChR antagonists was reflected in a recent review 
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by Dwoskin and Crooks, which identified these agents as “a new direction for drug 
discovery.” (Dwoskin et al., 2001). A possible pharmacological basis for this approach 
is the observation that nAChR agonists rapidly desensitize the receptors, which 
essentially inhibits their function.  Thus, if inhibition and not excitation is the actual 
therapeutic effect, competitive inhibitors or agonists that result in rapid desensitization 
should work equally well. (Dwoskin et al., 2001) 
 
2.2.1.1 Neuronal nicotinic acetylcholine receptors 
 
nAChRs are a family of ligand gated ion channels found in the central and peripheral 
nervous systems that regulate synaptic activity. The receptor is composed of five 
separate trans-membrane proteins (subunits), each containing a large extra-cellular N-
terminal domain, four membrane spanning alpha helices (M1, M2, M3, and M4) and a 
small extracellular C-terminal. domain, Figure 12  (Karlin et al., 2002).   
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Figure 12. Transverse schematic representation of the muscle-type AChR showing the 
domains involved in the specific binding of non-competitive inhibitors from exogenous 
origin.  Top and right panel:  Schematic representation of a section of the AChR at ~46 
Å from the membrane surface viewed from the synaptic cleft.  The ethidium locus can 
be putatively located in the AChR vestibule between both acetylcholine (ACh) binding 
sites.  The ethidium site includes either a region near the ĮȖ฀interface, being this α 
submit the one that bears the high-DIILQLW\ $FK ELQGLQJ VLWH RU D SRUWLRQ RI WKH ȕ
subunit.  Bottom and left panel:  Schematic representation of a section of the AChR at 
the lipid-aqueous interface viewed from the synaptic cleft.  The amino acid chain from 
HDFK VXEXQLW ĮȕȖ฀฀ and δ) crosses the lipid membrane four times (M1-M4).  The 
perimeter of the AChR is surrounded by ~ 45 lipid molecules, i.e., the annular lipid 
domain.  The 23 empty circles around the AChR represent the phospholipid head 
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groups on the extracellular leaflet of the lipid bilayer.  The small black circles between 
subunits and between domains M1/M4 and M3/M4 represent the possible locations for 
non-annular lipid domains.  The high-affinity quinacrine binding site is located at the 
Į0 WUDQVPHPEUDQHGRPDLQQHDU WKHȕ VXEXQLW%RWWRPDQG ULJKWSDQHO 6FKHPDWLF
representation of two M2 transmembrane domains of the AChR subunit.  The amino 
DFLG VLGHFKDLQV IURPERWKĮ0GRPDLQV UHSUHVHQW WKH WUDQVPHPEUDQH฀M2 domains 
represent the traQVPHPEUDQHĮ-helix.  A consensus exists that the interaction of certain 
UHVLGXHVIURPWKHĮVXEXQLWVKRZQKHUHDVILOOHGVSKHUHVLQDGGLWLRQWRWKHUHVSHFWLYH
homologous amino acids from the other subunits (not shown for simplicity), form a 
series of stratified rings disposed from the extracellular to the intracellular side in the 
following manner: outer or extracellular, valine, leucine, serine, threonine, intermediate, 
and cytoplasmic or inner ring.  In addition, some of them are involved in the binding of 
the so-called luminal non-competitive inhibitors.  In particular, the binding site for the 
local anesthetic meproadifen is located close to the mouth of the ion channel, probably 
at the negatively-charged outer or extracellular ring.  The binding site for cembranoids 
and trifluoromethyl-iodophenyldiazirine (TID) is related to both the valine and the 
leucine ring.  Finally, the binding site for chlorpromazine (CPZ), 
triphenylmethylphosphonium (TPMP+), the local anesthetic QX-222, and 
phencyclidine (PCP) includes the leucine, the serine, and the threonine ring.  Reprinted 
from Arias et al., 1998. 
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The five subunits are oriented around a central pore (Hucho et al., 1996; Albuquerque et 
al., 1997) and the resulting transmembrane ion channel is formed by a pentameric 
arrangement of the M2 helical segments contributed by each of the five subunits 
(Changeux et al., 1992) (Figure 12), To date, twelve neuronal subtypes of the nicotinic 
receptor have been identified thus far (Į2-Į10) and (ȕ2-ȕ4). Typically, three Į2-Į6 
combine with two b subunits to form functional heteromeric subtypes of the nicotinic 
receptors. These can combine to form a varLHW\RIVXEW\SHVLQFOXGLQJWKHĮ3b4, Į3ȕ2, 
Įȕ4, Įȕ2, Įȕ ZLWK WKH Įȕ2 being the most targeted therapeutically. The Į7-9 
differ from the rest of the family in that they only combine with themselves to form 
functional homRPHULF VXEW\SHV LQFOXGLQJ WKHĮĮĮ DQGĮ10 nicotinic receptors, 
ZLWKWKHĮ7 nicotinic receptors being the most targeted therapeutically.  
 
The agonist binding site of the neuronal nicotinic receptor is located at the interface of 
the Į and ȕ subunits. The agonist must bind simultaneously to the two agonist binding 
sites of the nicotinic receptor to elicit a pharmacological response. This is the 
predominant target for most therapeutic drugs in development today. In addition to the 
agonist binding site, another site of increasing importance is the non-competitive 
inhibitor (NCI) binding site, where the NCIs bind. NCIs inhibit nAChR function by a 
rapid reversible channel blockade or a shorten channel opening time (Yamakura et al., 
2000) and include mecamylamine (Lloyd et al., 1999), ketamine (Hernandez et al., 
2000), and dextromethorphan (Furuya et al., 1999).  In most cases, the non-competitive 
inhibitory properties of a compound at the nAChR are not its primary pharmacological 
function.  Indeed, whether or not a compound functions as a NCI is usually determined 
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after observation of unexpected pharmacological effects.  For example, ketamine is an 
anesthetic that competitively blocks the N-methyl-D-aspartate receptor (Hernandez et 
al., 2000).  However, ketamine also acts as a NCI at nAChRs and this activity may be 
responsible for some of the drugs side effects. (Hernandez et al., 2000; Zhang et al., 
1998)  
 
2.2.1.2 Įȕ4 nAChR affinity chromatographic columns 
 
Currently, high throughput screening for competitive agonist and antagonists involve 
competitive binding affinity experiments using recombinant receptor systems and 
radiolabelled marker ligands (Holladay et al., 1997).  An alternative method for the 
screening of compounds for competitive and non-competitive inhibitory properties is 
the determination of binding affinities to the nAChR by frontal chromatography.   One 
approach to the direct measurement of absolute and relative binding affinities at the 
nAChR is affinity chromatography using nAChR affinity columns. 
Liquid chromatographic columns containing immobilized D3E4-nAChR or D4E2-
nAChR (NR columns) have been previously reported and used to determine the binding 
affinities of competitive agonists and antagonists (Wainer et al., 1999; Xiao et al., 
1998).  The initial studies with these columns involved displacement chromatography 
with a single marker ligand and a single displacer.   
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In the current studies, a NR column containing an immobilized D3E4-nAChR stationary 
phase has been coupled to a C18 reversed-phase column and a mass spectrometer.  In 
this manner, the NR column could be used to initially sort a mixture of compounds 
through their affinity to the D3E4-nAChR using chromatographic retention as the 
marker.  In these studies, the eluent was directed to waste for the first 8 min of the run 
and then directed onto the C18 column. The compounds contained in the eluent were 
compressed at the head of the C18 column, then resolved using a step-gradient and 
ultimately identified using a mass spectrometer.  The results of the study indicate that 
the coupled NR column – C18 column system can be used for the rapid on-line 
screening of mixtures for potential ligands to the D3E4-nAChR. 
 
2.2.2 Materials and methods 
2.2.2.1 Materials 
Nicotine, epibatidine, nornicotine, anabasine, acetylcholine, benzamidine, 
butyrlcholine, caffeine, glutamic acid, 3-hydroxytyramine, naltrexone, ketamine, 
norketamine ,  2,3-dihydroxybenzoic acid, epinephrine, norepinephrine, cytisine and 4-
dimethylaminopyridine were purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). Tris HCl and cholic acid sodium salt were also purchased from Sigma Chemical 
Co. HPLC grade methanol, ammonium acetate and 0.1 M ammonium hydroxide 
solution were purchased from Fisher scientific (Pittsburgh, PA, USA). All water used 
for preparing solutions was supplied by a Nanopure reverse osmosis water purification 
system (Barnstead, Dubuque, IA, USA).  
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2.2.2.2 Chromatographic System 
 
The coupled-column chromatographic system used in these studies is presented in 
Figure 13.  
 
 
Figure 13. The multidimensional coupled-column chromatographic system used in this 
study composed of a HP-1100 chromatography system (Agilent Technologies, Palo 
Alto, CA, USA), which consisted of a binary gradient pump (P1), autosampler, column 
oven, switching valve and a MS detector. The column containing the immobilized 
nicotinic receptors was connected on-line to a reversed-phase Zorbax C18 column (150 x 
4.6 mm i.d., 5 Pm, obtained from Agilent).  A Rheodyne LabPRO switching valve 
(Ronert Park, CA, USA) was used to connect the two columns. A second isocratic HP 
pump (P2) was used to supply the mobile phase to the C18 column.  Mass spectrometry 
experiments were conducted using a Agilent technologies Mass Selective Detector 
(MSD) operating in positive ion electrospray (ES+) mode.  
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The system was composed of a HP-1100 chromatography system (Agilent 
Technologies, Palo Alto, CA, USA), which consisted of a binary gradient pump (P1), 
autosampler, column oven, switching valve and a diode array detector. The column 
containing the immobilized nicotinic receptors was connected on-line to a reversed-
SKDVH =RUED[ & FROXPQ  [  PP LG  ȝP REWDLQHG IURP $JLOHQW  $
Rheodyne LabPRO switching valve (Ronert Park, CA, USA) was used to connect the 
two columns. A second isocratic HP pump (P2) was used to supply the mobile phase to 
the C18 column.  Mass spectrometry experiments were conducted using an Agilent 
technologies Mass Selective Detector (MSD) operating in positive ion electrospray 
(ES+) mode. 
  
2.2.2.3 3UHSDUDWLRQRIWKHĮȕ1LFRWQLQLF5HFHSWRU&ROXPQ 
 
The nicotinic receptor (NR) column was prepared as previously described (Wainer et 
al., 1999; Xiao et al., 1998).  In brief: Cells from the KX ĮȕR2 cell line (Glennon et 
al., 1994) were suspended in Tris-HCl, [50 mM, pH 7.4] (buffer A), homogenized for 
30 sec with Brinkmann Polytron, and centrifuged at 35,000 x g for 10 min at 4 °C. The 
pellet was resuspended in 6 ml of 2% cholate in buffer A and stirred for 2 h. The 
mixture was centrifuged at 35,000 x g for 30 min, and the supernatant containing NR -
cholate solution was collected.  
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The IAM liquid chromatographic stationary phase (200 mg, IAM-PC stationary phase, 
Regis Chemical Co., Morton Grove, IL, USA) was suspended in 4 ml of the obtained 
detergent solution containing proteins.  The mixture of IAM-detergent-receptor was 
stirred for 1 h at room temperature. The suspension was dialyzed against 2 x 1L buffer 
A for 24 h at 4 °C. The IAM liquid chromatographic support was then washed with 
buffer A, centrifuged and the solid collected.  
 
The IAM liquid chromatographic support containing the NR was packed into a HR5/2 
glass column (Pharmacia Biotech, Uppsala, Sweden) to form a chromatographic bed of 
20 mm x 5 mm i.d.  The NR column was then placed in the chromatographic system 
and used as described below.  
 
2.2.2.4 Chromatographic Procedures 
An ammonium acetate buffer [10 mM, pH 7.4] {Buffer} was used throughout the study. 
The pH of the Buffer was adjusted to 7.4 with 0.1 M ammonium hydroxide. The Buffer 
was used to prepare separate 1 ȝM stock solutions for each compound used in the study. 
A 10 ȝl aliquot of each stock solution was added to a 10-ml test tube and the Test 
Mixture was briefly vortex-mixed.  The stock solutions and Test Mixture were stored at 
40C until use. 
  
Separations on the NR column were achieved using a mobile phase consisting of Buffer 
/ methanol, 95/5 (v/v), at a flow rate of 0.2 ml/min and a column temperature of 35oC. 
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The retention times of each test compound was determined by injecting a 50 ȝl aliquot 
of each stock solution onto the chromatographic system.  The retention times of the 
compounds were monitored by single ion monitoring at the appropriate m/z. 
 
When the Test Mixture was injected onto the chromatographic system, the eluent from 
the NR column was directed through the switching valve to waste for the first 8 min of 
the chromatographic run. At t = 8 min, the switching valve was rotated and the eluent 
from the NR column was directed onto the C18 column.  At t = 20 min, the switching 
valve was rotated and the eluent from the NR column was again directed to waste.  
 
At t = 20 min, the second pump (P2) was engaged and a mobile phase consisting of 
Buffer / methanol, 40/60 (v/v) was pumped through the C18 column at a flow rate of 
1.0 ml/min. The eluent from the C18 column was directed into the mass spectrometer. 
At t = 30 min, the mobile phase was changed to Buffer / methanol, 95/5 (v/v), the flow 
rate reduced to 0.2 ml/min and the mass spectrometer turned off.  
 
2.2.2.5 Mass Spectrometry 
 
Mass spectrometry experiments were performed using an Agilent MSD single 
quadrupole mass spectrometer in positive ion electrospray mode, data was recorded 
using Chem Station (version 6.3) software. The Capillary voltage was set at 2.5 kV and 
the fragmentor at 50 V. The mass spectrometer drying gas temperature was 3500C, with 
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nitrogen supplied as the nebulising gas (11 l/min). Single Ion Monitoring (SIM) and 
Full Scan (FS) modes were employed for these experiments.  
 
2.2.3 Results and Discussion 
 
The retention times of the compounds used in this study are presented in 
Table 3.  
 
Table 3  7KH FRPSRXQGV XVHG LQ WKLV VWXG\ WKHLU UHVSHFWLYH DIILQLWLHV IRU WKH Įȕ
nAChR defined as yes if the compound is reported in Refs. (Holladay et al., 1997; 
Lloyd et al., 1999; Hernandez et al., 2000; Xiao et al., 1998) to bind to the receptor and 
no if it is not reported to bind to the receprtors in Refs. (Holladay et al., 1997; Lloyd et 
al., 1999; Hernandez et al., 2000; Xiao et al., 1998) and the observed retention times on 
the column containing immobLOL]HGĮȕQ$&K5. 
 
No. Compound Affinity for D3E4 Nicotinic 
Acetylcholine Receptor 
Retention 
time (min)  
1 Anabasine No  2.1 
2 Acetylcholine Yes 4.7 
3 Benzamidine No  6.3 
4 Butyrlcholine No  6.0 
5 Caffeine No  2.7 
6 Cystisine No (DE ligand) 4.8 
7 2,3-Dihyroxybenzoic acid No  3.2 
8 4-Dimehtylaminopyridine Yes (D1 ligand)  9.5 
9 Epibatidine Yes 13.1 
10 Epinephrine No  2.1 
11 Glutamic acid No  2.1 
12 3-Hydroxytyramine No  7.1 
13 Ketamine Yes (NCI)   8.3 
14 Naltrexone No  9.8 
15 Nicotine Yes 10.3 
16 Norepinephrine No  2.1 
17 Norketamine Yes (NCI)  8.5 
18 Nornicotine Yes 8.8 
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For compounds with no known affinity for the Įȕ nAChR the retention times ranged 
from 2.1 min to 7.1 min, except for naltrexone, which eluted at 9.8 min.  This result is 
most probably due to the compound’s hydrophobicity.  However, preliminary studies 
with naltrexone indicate that this compound may be a NCI of the Įȕ nAChR, albeit 
ZLWK DQ (& RI ! ȝ0 Kellar, personal communication).  It is unclear what 
naltrexone’s affinity for the Įȕ nAChR contributes to the observed retention. 
 
Cytisine is a marker ligand for the Įȕ nAChR and has displayed no significant 
affinity for the Įȕ nAChR (Holladay et al., 1997).  Previous studies with NR 
columns composed of either the Įȕ nAChR or the Įȕ nAChR have demonstrated 
that NR columns can be used to distinguish between the activities of the two nAChR 
subtypes (Xiao et al., 1998).  The fact that the retention time of cytisine was 4.8 min on 
a NR column containing immobilized Įȕ nAChR is consistent with the previously 
reported selectivity of immobilized nAChR subtypes. 
 
The compounds with a known affinity for the Įȕ nAChR eluted with retention times 
between 8.3 min and 13.1 min except for acetycholine, which eluted at 4.7 min, Table 
3.  Epibatidine has the longest retention of the test compounds, 13.1 min, which is 
consistent with the fact that, of the compounds tested, its has the highest affinity for the 
Įȕ nAChR, Kd = 0.30 nM (Xiao et al., 1998).  The affinity of nicotine for the Įȕ
nAChR is 300-fold less than epibatidine, Kd = 90 nM (Xiao et al., 1998), and the 
compound eluted 2.8 min before epibatidine at 10.3 min.  Nornicotine has a 20-fold 
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lower affinity than nicotine for the Įȕ nAChR and the compound eluted from the NR 
column at 8.8 min.  In whole cell studies, the affinity of acetylcholine has been reported 
at 3-fold lower than nicotine (Holladay et al., 1997).  There are reported assays for the 
determination of the binding affinity of acetylcholine to the isolated Įȕ nAChR.  
However, the reason for the short retention time of this compound on the NR column is 
unknown. 
  
The results indicate that in most cases, magnitude of the chromatographic retention on 
the NR column is a reflection of binding affinity for the Įȕ nAChR.  This suggests 
that the NR column could be used for the direct resolution of a mixture of compounds 
into Įȕ nAChR ligands and non-ligands.  However, the chromatogram of epibatidine 
illustrates that the chromatographic efficiency of the NR column is extremely poor, 
Figure 14a.  
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Figure 14. A representative chromatogram from the chromatography of epibatidine on: 
a. the NR column alone; b. the multidimensional system produced after injection of a 1 
ȝ0VROXWLRQRIHSLEDWLGLQHXVLQJ6,0DQDO\VLVDW>0 + H] 209. An ammonium acetate 
buffer (10mM, pH 7.4) was used for the study. 
 
Indeed, co-injection of epibatidine and nicotine produced a chromatogram with no 
significant resolution of the two compounds even though their peak retention times 
were 2.8 min apart and their affinities differed by 300-fold {data not shown}.  In 
addition, the chromatogram of epibatidine presented in Figure 14a , was produced after 
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the injection of a 1 ȝM solution using SIM analysis at M+H 209.1. Due to the poor peak 
shape, this concentration was near the limit of detection on the mass spectrometer. 
 
Clearly, the selectivity of the system was hindered by the poor chromatographic 
efficiency.  One way of overcoming the chromatographic inefficiency of the NR 
column is to couple it to a more efficient column.  In the resulting multi-dimensional 
system, the NR column would separate nicotinic receptor ligands from non-ligands and 
the second column, in this case a C18 column, would separate the nicotinic receptor 
ligands from each other.  The effect of coupled NR-C18 column system on the 
chromatogram of epibatidine is presented in Figure 14b.   The overall retention time of 
epibatidine from injection onto the NR column to mass spectrometric detection was 
23.7 min. In addition, peak compression on the C18 column increased the sensitivity of 
the method.  The chromatogram in Figure 14b was produced by a 200 nM solution of 
epibatidine and demonstrates that the sensitivity of the analysis has been significantly 
increased. 
 
In order the test the hypothesis that the coupled NR-C18 system could be used to screen 
mixtures for ligands to the Įȕ nAChR, the compounds listed in Table 3 were 
combined to form a Test Mixture.  Based on the individual chromatographic results, a 
cut-off time of 8 min was chosen, i.e. after injection onto the NR column, the eluent was 
directed to waste from 0 to 8 min and then, at the 8 min mark, the eluent was directed 
onto the C18 column.  After 20 min, the C18 column was taken off-line from the NR 
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column and the compounds compressed on the column were eluted into the mass 
spectrometer. 
 
The Test Mixture was chromatographed using the conditions described above.  The 
eluent from the C18 column was monitored in full scan mode and the resulting 
chromatogram is presented in Figure 15.  
 
Figure 15. The chromatogram from the chromatography of the Test Mixture on the 
multidimensional system. Compound list in  
Table 3 was combined to form a test mixture. Based on individual chromatographic 
results the cut-off time of 8 min was chosen, i.e. after injection onto the NR column, 
eluent was directed to waste from 0 to 8 min and then, at the 8 min mark, the eluent was 
directed to the C18 column. After 20min, the compounds on the C18 column were eluted 
into the mass spectrometer. 
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The compounds in the eluent were identified from their (M+H) masses and the eluent 
from the C18 column contained 7 of the 18 compounds from the Test Mixture, Table 4. 
 
Table 4. Compounds eluting from the column containing immobilized DE nAChR 
before 8 min and after 8 min. The data shows that any compound eluting before 8 min 
don’t have affinity for the DE nAChR and the compounds eluting after 8 min have 
affinity for DE nAChR. 
Compounds Eluted at t < 8 min Compounds Eluted at t t 8 min  
 
Anabasine Nornicotine 
Acetylcholine Nicotine 
Benzamidine Epibatidine 
Butyrlcholine Naltrexone 
Caffeine Ketamine 
Glutamic acid Norketamine 
3-Hydroxytyramine Dimethylaminopyridine 
2,3-DHBA  
Epinephrine  
Norepinephrine 
 
Cytisine  
 
 
Of the 7 compounds 6 were known DE nAChR ligands and the seventh was 
naltrexone, which may be a NCI.  
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The sensitivity and specificity of the multidimensional system was investigated by 
performing a Fisher’s Exact Test using GraphPad Instat software {Version 5.05, 
GraphPad Software, Inc, San Diego, CA, USA}. The question addressed was, “can the 
multidimensional system distinguish between ligands and non-ligands to the 
immobilized DE nAChR using a retention time of 8 min as the selector?” The results 
of the test are presented in Table 5 and indicate that sensitivity, specificity, positive and 
negative predictive values of the system are extremely significant.  
 
 
Table 5. Fisher’s Exact Test to determine, “Can the multidimensional system 
distinguish between ligands and non-ligands to the immobilized DE nAChR using a 
retention time of 8 min as the selector?”  The two-sided P value is 0.0025 (extremely 
significant) and the row/column association is statistically significant. 
 
Variable Value 95 % Confidence Interval 
Sensitivity 0.9091 0.5874 to 0.9977 
Specificity 0.8571 0.4210 to 0.9964 
Positive predictive value 0.9091 0.5874 to 0.9977 
Negative predictive value 0.8571 0.4210 to 0.9964 
Likelihood ratio 6.364  
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2.2.4 Conclusions 
 
Thus the study showed that a cell line expressing the Įȕ4 nAChR which was used to 
create an affinity column containing immobilized DE nAChR coupled to a C18 
column which was useful for the on-line screening of mixtures for DE nAChR 
ligands. The method was reproducible, the NR column was stable (the column used in 
these studies has been used for over 1 y) and relatively quick as the total analysis time 
from injection onto the NR column to identification of the compounds was 32 min.  In 
addition, the NR column was also able to identify NCI of the DE nicotinic receptor 
subtype.  Thus the results demonstrate that a stationary phase containing immobilized 
membranes can be used to identify substrate/inhibitors of an expressed 
receptor/transporter.  
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Chapter 3 
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3. P-Glycoprotein 
 
3.1 Introduction 
 
Having demonstrated that a stationary phase containing immobilized membranes can be 
used to identify substrate/inhibitors of an expressed receptor/transporter the next and 
principal phase of the programme was to adapt this methodology to other target 
biopolymers such as P-glycoprotein which over the last decade has been focused upon 
for its role in drug resistance in cancer treatments. 
 
 
Resistance to chemotherapy is a critical issue in the management of breast cancer 
patients. When breast cancer is detected and treated early in the disease process and 
followed by adjuvant chemotherapy there is a decrease in the annual odds of recurrence 
by 24% and death by 15 % (Early Breast Cancer Trialists’ Collaborative Group 1998). 
However, advanced breast cancer remains, largely an incurable disease. In advanced 
stage, the high percentage of non-responders to chemotherapy and of failures following 
initial response highlights the critical role played by drug resistance mechanisms in 
breast cancer management. Conversely, the significant number of initial responses and 
the impact on survival, especially in early disease, suggest that, at least initially, a 
limited number of mechanisms of resistance are involved. Thus, among solid cancers, 
breast cancer represents perhaps one of the best fields for the study of clinical drug 
resistance and of its reversal. 
  
In the last decade considerable attention has been focussed on the role that membrane 
transporter proteins play in drug resistance. Of particular interest are the transporters 
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belonging to the ATP binding cassette protein super-family (ABC-transporter proteins), 
(a superfamily of genes which encode the ABC transporter proteins). ABC transporter 
proteins are one of the largest and most ancient families with representatives in all 
extant phyla from prokaryotes to humans. ABC transporters are transmembrane proteins 
that function in the transport of a wide variety of substrates across extra- and 
intracellular membranes, including metabolic products, lipids, sterols and drugs. These 
proteins are classified as ABC transporters based on the sequence and organization of 
their ATP-binding domains, also known as nucleotide binding folds (NBFs). The ABC 
transporter, P-glycoprotein (Pgp) is of particular interest as it has been observed that 
there is a strong association of Pgp with response rates to chemotherapy and an increase 
in Pgp expression after chemotherapy is coupled with a decrease in the response to 
further treatment. 
 
Different groups have described a multidrug resistant phenotype characterized by 
resistance to the cytotoxic effect of multiple unrelated drugs, such as Vinca Alkaloids 
(antimiotic and anti-microtubule agents which are these days produced synthetically and 
used as drugs in cancer therapy and as immunosuppressive drugs, examples are 
vinblastine, vincristine etc.), epipodophyllotoxins, anthracyclines and actinomycin D, 
following cell selection with just one of these drugs (Biedler & Riehm, 1970; Juliano & 
Ling, 1976). This process was accompanied by decreased intracellular concentration of 
the target drugs due to their active efflux from cells (Riehm & Biedler, 1971; Dano, 
1972; Dano, 1973; Ling and Thompson 1974). Later, it was defined that the same 
mechanism also confers resistance to taxanes (a class of alkaloids produced from plants 
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of the genus Taxus which inhibit the microtubule function and have been used to 
produce various chemotherapy drugs, examples include paclitaxel and docetaxel).and 
can also cause intracellular drug redistribution (Bellamy, 1996). 
 
The protein responsible for this phenotype has been identified as Pgp, a 170 KDa 
plasma membrane glycoprotein (Juliano & Ling, 1976). Pgp is an energy-dependent 
efflux transporter driven by ATP hydrolysis. In humans, two members of the Pgp gene 
family multi drug resistant gene 1 and multidrug resistant gene 3 (MDR1 and MDR3) 
have been identified. The Pgp encoded by this gene functions as a drug efflux 
transporter. The gene MDR1 in humans was isolated and cloned in the 1980's 
(Roninson et al., 1984, Gros et al., 1986, Roninson et al., 1986). Human MDR3 Pgp is 
believed to be active in phospholipid transport. 
 
Pgp is the most extensively studied member of the ATP-binding cassette protein family. 
Pgp and other members of this family function as biological barriers by expelling toxins 
and xenobiotics from cells. In vitro and in vivo studies have demonstrated that Pgp 
plays a significant role in both drug absorption and disposition. Because of its 
localization, Pgp appears to play a significant role in the bioavailability of oral drugs by 
reducing the absorption through the intestinal lumen and in the penetration of drugs into 
the central nervous system (CNS) as well as a minor role in the excretion of drugs out 
of hepatocytes and renal tubules into the adjacent luminal space. 
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3.1.1 Structure of P-glycoprotein (ABC Transporter) 
 
Since the identification of Pgp, major efforts have been made to elucidate the structure 
of the protein in order to gain better insight into its mechanism of action. The cloning of 
genes and structure-function analysis of the protein by genetic and biochemical studies 
have contributed to a better understanding of this transporter. Pgp is a part of a larger 
family of proteins called the ATP Binding Cassette (ABC) protein superfamily, which 
in humans is known to include forty eight ABC proteins 
{www.med.rug.nl/mdl/humanabc.htm}. 
 
The ABC superfamily has been described in previous reviews (Klein et al. 1999, Dean 
et al. 2001), and based on sequence homology, ABC proteins can be grouped into seven 
different subfamilies (A-G). All ABC proteins share an ATP binding domain of 200-
250 amino acids (Nucleotide Binding Domain, NBD). The NBD unit includes two 
short, conserved peptide motifs, the Walker A motif and Walker B motif, which are 
involved in ATP binding, and a third conserved sequence, located between the other 
two, that has been called the ‘ABC signature’, and is unique to the NBD unit.  
  
Many of the ABC proteins are transporters and are characterized by the basic structural 
module “TMD-NBD” (or NBD-TMD) consisting of one ABC unit and a hydrophobic 
transmembrane domain (TMD). The TMD is usually composed of six transmembrane 
segments (helices). To be functional, ABC transporters require a minimum of two 
modules, i.e., two TMDs and two NBD units. ABC proteins can be classified according 
to the number and arrangement of the basic structural modules. In ‘full transporters’ the 
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two TMD-NBD units are part of the same polypeptide chain: (TMD-NBD)2. Some full 
transporters, e.g., several members of the ABC-C subfamily, including multi drug 
resistant protein 1 (MRP1) (ABCC1), have a TMD0L0(TMD-NBD)2 format. This format 
includes a third membrane domain (TMD0), with transmembrane helices connected 
through a linker region (L0) to the (TMD-NBD)2 double module (Klein et al., 1999, 
Borst et al., 2000). The structure of  ‘half transporters’ comprises only one TMD-NBD 
or NBD-TMD module; their activity requires aggregation in multi-protein complexes. 
Full transporters are usually located in the plasma membrane and half transporters in 
intracellular membranes, the half-transporter breast cancer resistance protein (BCRP) 
being one exception (Rocchi et al., 2000).  
 
Pgp is composed of two homologous and symmetrical halves (cassettes), each of which 
contains six transmembrane domains that are separated by an intracellular flexible 
linker polypeptide loop with an ATP-binding motif. Interestingly, the two halves of 
human Pgp have only 43% of the amino acids in alignment, suggesting that the two 
halves might have either evolved independently or have undergone major intron 
movement after a duplication event. Pgp appears approximately cylindrical in electron 
cryomicroscopy studies, with a diameter of about 10 nm, a depth (perpendicular to the 
plasma membrane) of about 8 nm and two lobes of about 3 nm each projecting from the 
cytoplasmic end (Rosenberg et al., 1997). The Pgp molecule has a central pore that, in 
the resting phase, is conical in shape. The base of the cone, which is open to the 
extracellular space, is 5 nm wide (Rosenberg et al., 1997, Loo & Clarke 2001a) (Figure 
16). 
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Figure 16. Schematic Model of Pgp showing two homologous halves. Each half 
consisting of one transmembrane domain (TMD) and one nucleotide binding fold 
(NBF). The central pore, in the resting phase, is conical in shape. The base of the cone, 
which is open to the extracellular space, is 50 Å wide The diameter of the pore at the 
midlevel is 9-25 Å and the cytoplasmic end which corresponds to the apex of the cone 
is virtually closed. Pgp substrate binding area is located around the centre of the pore. 
(adapted from Loo TW & Clarke DM, 2001a) 
 
The diameter of the pore is 0.9-2.5 nm at midlevel through the cell membrane and its 
cytoplasmic end corresponds to the apex of the cone and is virtually closed (Loo & 
Clarke, 2001a). The Pgp substrate binding area is located around the midlevel of the 
pore (Loo & Clarke, 1997; Loo & Clarke, 1999a; Loo & Clarke, 2000).  The results of 
cysteine scanning mutagenesis and crosslinking studies are consistent with a “cyclone 
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model” of Pgp, whereas the two homologous halves of Pgp are arranged in the cell 
membrane in an antiparallel fashion, with transmembrane segments 4-6 and 10-12 more 
directly contributing to delimit Pgp’s central pore  (Loo & Clarke, 1999b).  
 
The Pgp transporter exhibits ATPase activity and translocates different substrates across 
a cell membrane and/or between various cell compartments. Transport of substrates is 
ensured by a tight molecular coupling of the TMDs to the NBD units, and a positive 
cooperation of the two NBD units. Site directed mutagenesis and antibody mapping 
studies suggests that the two cassettes of Pgp interact cooperatively to form a single 
functional unit.  This was proven by cDNA (strong, cloned copies of otherwise fragile 
mRNA, which is the essential messenger element of the genes in the DNA which help 
in coding for the proteins) coding of each individual halves of the Pgp cloned into 
separate plasmids, which did not show any drug stimulated ATPase activity for each 
cassette. The hypothesis of a single functional unit for further supported in the study in 
which the key lysine and cysteine residues in the Walker A motifs of the ATP-binding 
domains were substituted by methionine and alanine, respectively (Takeda et al., 2001). 
The results clearly demonstrated that if one ATP-binding domain was not functional, 
then there was no ATP hydrolysis even when ATP was bound to the other ATP-binding 
domain.  
 
In addition to the ATP binding domains, the intracellular flexible linker loops also play 
a key role in the ATPase activity. Deletion of the central core of the intracellular 
flexible linker region of Pgp resulted in a protein without functional ATPase transport 
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activity. Collectively this data strongly suggested that the two cassettes of Pgp interact 
as a single transporter and that the flexible linker region is important for the correct 
interaction of the two cassettes.  
 
 
3.1.2 Mechanism of Pgp Transport 
  
Several mechanistic models have been proposed to describe the mechanism of drug 
transport activity. The initial hypothesis was that hydrophobic membrane-spanning 
regions and hydrophilic elements of Pgp form an aqueous transmembrane pore through 
which drugs are transported from the cytosol to the extracellular media. However, 
another model suggests that Pgp might extrude drug directly from the cell membrane 
even before they enter the cytoplasm. Recently it has been proposed that Pgp intercepts 
lipophilic drugs as they move through the lipid membrane and flips the drugs from the 
inner leaflet to the outer leaflet and into the extracellular medium. This model is 
consistent with the notion that the lipophilicity of a drug is important in its interaction 
with Pgp (Leonessa & Clarke, 2003).  
 
Raviv and Higgins have suggested a similar model where the Pgp substrates most likely 
diffuse from the inner leaflet of the cell membrane (hydrophobic vacuum cleaner 
model) (Raviv, 1990; Higgins, 1992), and between Pgp’s transmembrane helices to the 
Pgp’s substrate binding area located inside the pore, where they interact mostly with 
non-polar amino acids (Loo & Clarke, 1997; Loo & Clarke, 1999a; Loo & Clarke, 
2000). Interaction with the binding site in the presence of ATP induces ATP hydrolysis, 
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followed by a rearrangement of the protein conformation: movement of Pgp’s N-
terminal and C-terminal halves in opposite directions closes the pore (Loo & Clarke, 
2002), while rotation of the transmembrane ฀- helices (Loo & Clarke, 2001b) may  
contribute to decrease the affinity of the site for the substrates. Ultimately, the substrate 
is pushed either to the extra-cellular phase (“hydrophobic vacuum cleaner” model) or to 
the membrane’s outer leaflet (“flippase model”). 
 
 
3.1.3 ATP and Substrate Binding sites  
 
There are two ATP-binding domains of Pgp, located in the cytosol side, each of which, 
contains three regions, (Gottesman & Pastan, 1993): Figure 17. 
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Figure 17. Two ATP-binding domain(s), which are also called nucleotide-binding folds 
(NBFs) and are located on the cytoplasm side of the phospholipid bilayer. These folds 
are divided into parts or motifs, called Walker A and Walker B, which are separated by 
approximately 90-120 amino acids. In addition, there is a third motif (called LSGGQ 
motif, C motif, or "signature" motif) located after the Walker B motif. Unlike the 
Walker A and Walker B motifs, which are found in other proteins which hydrolyze 
ATP, the signature motif is unique to ABC transporters. These folds form the 
“cassettes” which the protein family is named after. The transmembrane domains and 
nucleotide-binding folds are often arranged in the order NH3+-TM-NBF-TM-NBF-
COO-.  
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Walker A motif (sequences of amino acids residues from 427-435a, 1070-1078b)  
Walker B motif (sequences of amino acids residues from 531-542a, 1172-1182b)  
Signature C motif (sequences of amino acids residues from 551-556a, 1196-1201b)  
a First ATP-binding domain 
b Second ATP-binding domain 
Walker A and B can be seen in Figure 18. 
 
Figure 18. Pgp transporter consisting of 655 amino acids. The Walker A and B motifs 
of the NBF are circled. 
 
Recently it has been reported that a highly conserved lysine residue within the Walker 
A motif of histidine permease, an ABC transporter, is directly involved with the binding 
of ATP, and a highly conserved Asp residue within the Walker B motif serves to bind 
the Mg2+ ion. Loss of activity is observed during mutation of any one of these residues, 
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thus suggesting that the ATP-binding sites may be restricted to the Walker A motifs of 
Pgp (Hung et al., 1998).  
  
Senior and Gadsby (1997) conducted vanadate-trapping studies to propose a so-called 
alternate ATP-binding site model, which showed that although both ATP-binding sites 
are capable of binding ATP, only one site participates in the catalysis at a given time, 
and the conformation of this catalytic site precludes the other site from hydrolyzing 
ATP.  
 
Unlike the ATP-binding sites that are restricted to the Walker A motifs of ATP-binding 
domains, many substrate-binding sites have been identified throughout the 
transmembrane domains (TM) of Pgp. Using photoaffinity probes two substrate binding 
sites were found in TM6 and TM 12 (Greenberger 1993; Bruggemann et al., 1989). In 
addition to these regions, a region that includes TM7 and TM8 has also been reported to 
be photolabelled specifically by an analogue of paclitaxel (Wu et al., 1998) However, 
mutational studies also suggest that amino acid substitutions that affect substrate 
specificity are scattered throughout Pgp including TM1, TM4, TM6, TM10, TM11 and 
TM12 (Ueda et al., 1998). Recently Taguchi et al., (1997a, 1997b) suggested that three 
amino acids (His61, Gly64 and Leu65) in TM1 are involved in the formation of a 
binding pocket that plays a key role in determining the suitable substrate size for Pgp. 
Mutational analysis has also shown the importance of the intracellular linker loops in 
substrate recognition. 
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In summary, these results suggest that drug-binding sites are scattered throughout the 
Pgp molecule, including the TM, intracellular loops and even the ATP-binding 
domains. 
 
 
3.1.4 Substrate Recognition   
 
One of the most intriguing aspects of Pgp is that a single integral membrane protein can 
recognize and transport so many drugs with a wide array of chemical structures, ranging 
from a small molecular weight of 250 atomic mass unit (amu) (cimetidine) to a large 
molecular weight of 1202 amu (cyclosporin) (Pan et al., 1994, Wu et al., 1995). 
Although most of the drugs transported by Pgp are basic or uncharged, there are many 
exceptions. The only common feature is that most of the Pgp substrates are hydrophobic 
in nature, perhaps suggesting that the partitioning into the lipid membrane of cells is the 
first step for the interaction of a substrate with the active site of Pgp. Some 
representative Pgp substrates are presented in Table 6. 
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Table 6.  A wide range of Pgp subtrates, majority of which are known cardiovascular 
and anti-cancer drugs, depicting the broad substrate specificity of the Pgp transporter 
and showing the importance of Pgp in drug resistance. (Leonessa & Clarke, 2003) 
Anthracyclines (doxorubicin, daunomycin, epirubicin) 
Acridines (Amsacrine) 
Azatoxins (Azatoxin) 
Benxzoheptalene compounds (colchicines) 
Benzothiazepines (diltiazem) 
Dihydropyridines  (azidopine, nicardipine) 
Epipodophylllotoxins (etoposide) 
Isoquinolines  (cepharantine) 
Macrolides (FK506) 
Organometallic cations (99mTC-sestamibi) 
Peptides (actinomycin D, bleomycin, cyclosporin A, valinomycin) 
Phenothiazines (chlorpromazine) 
Phenylalkylamines (verapamil, tiapamil) 
Pyrrolo-indoles (mitomycin C) 
Quinolines (Chloroquine, Quinidine) 
Rhodamines (Rhodamine 123) 
Steroids (aldosterone, corticosterone, cortisol, dexamethasone, testosterone)  
Taxanes (taxol, taxotere) 
Vinca Alakaloids (vincristine, vinblastine) 
Other (digoxin, Hoechst 33342, etc.) 
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Significant efforts have been made to establish structure-activity relationships 
(QSAR’s) (Quantitative structure-activity relationships are mathematical relationships 
linking chemical structure and pharmacological activity in a quantitative manner for a 
series of compounds. Methods which can be used in QSAR include various regression 
and pattern recognition techniques) for Pgp substrates. Initially, it was assumed that a 
basic nitrogen atom was necessary for the interaction of substrates with Pgp, for 
example, studies of colchicine and its analogues suggested that the nitrogen atom of the 
acetamido group at the seventh position, was essential for Pgp recognition (Tang-Wai  
et al., 1993). However, compounds lacking a nitrogen atom, such as cortisol, 
aldosterone and dexamethasone, are also good Pgp substrates (Ueda et al., 1992). 
 
Studies have shown that both lipophilicity and number of hydrogen bonds of 
compounds are probably the most important parameters in determining the affinity of 
compounds to Pgp (Chiba et al., 1998; Ecker et al., 1999). The higher the lipophilicity 
or the larger the number of hydrogen bonds, the better the Pgp transporter substrate.  
 
Similarly it was also suggested that both lipophilicity and number of hydrogen bonds 
are important determinants for substrate and Pgp interactions (Seelig and 
Landwojtowicz, 2000). This indicates that partitioning into lipid membrane is the rate 
determining step for the interaction of a substrate with Pgp. It was also suggested that 
dissociation rate of the Pgp substrate complex is controlled by the number of hydrogen 
bonds. Seelig (1998) also studied the structure of hundred Pgp substrates and proposed 
that in addition to lipophilicity and number of hydrogen bonds, some essential structural 
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elements are required for an interaction with Pgp. The recognition elements of 
substrates are formed by two or three electron donor (hydrogen-bonding acceptor) 
groups with a fixed separation: 2.5 + 0.3Å or 4.6 + 0.6Å. Additionally, the surface area 
and amphiphilic characteristic of the substrate also appear to play a significant role in 
determining its Pgp activity (Osterberg & Norinder, 2000). 
 
Although a wealth of information on the relationship between physicochemical 
properties of substrates and Pgp activity has been generated in recent years, a clear 
structure-activity relationship for the prediction of Pgp substrates has not yet been 
established. The lack of a clear structure-activity relationship for substrate recognition is 
attributed mainly to the structural complexity of Pgp (Chiba et al., 1996).  
 
 
 
3.1.5 Pgp mediated drug-drug interactions 
 
The interaction between Pgp substrates does not always follow simple kinetics. The 
type of interactions can be classified into four major categories, 
 
x Competitive Inhibition, where two substrates act on the same site of Pgp and 
that only one or the other can bind at any one time. 
x Non-competitive Inhibition, where the two substrates are able to bind 
simultaneously to Pgp at two distinct sites that are functionally independent. 
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x Cooperative Interactions, where the binding interactions occur when the 
binding of a second compound to the protein increases the affinity of a 
marker ligand.   
x Anti-Cooperative Interactions, where the binding interactions occur when 
the binding of a second compound to the protein decreases the affinity of a 
marker ligand. 
   
The complexity of the molecular mechanism for Pgp inhibition hinders the ability to 
predict potential Pgp mediated drug-drug interactions either quantitatively or 
qualitatively. Indeed one possible reason for the failure of the co-administration of Pgp 
modulators and anticancer agents to improve therapeutic profiles of the 
chemotherapeutic agents could be that the modulators also inhibit the Pgp protective 
function of normal cells, leading to cytotoxicity. 
 
3.1.6 Effects of chemotherapy on Pgp expression 
 
Both the processes of induction and of selection could be involved in an effect of 
chemotherapy on Pgp expression. In vitro studies have shown that treatment of 
neoplastic cells with chemotherapeutic agents can induce the expression of Pgp 
(Chaudary & Roninson, 1993). This induction appears to be independent of whether the 
anticancer drugs are substrates for Pgp, and may be part of a response to different stress 
stimuli, including irradiation, genotoxic stress and inflammation (Sukhai & Piquette-
Miller, 2000). Conversely, treatment with anticancer drugs to which Pgp confers 
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resistance would be expected to enrich cancer in Pgp+ cells by a process of selection 
and should be specific for drugs that are MDR1 substrates. 
 
3.1.7 Importance of Pgp in Drug Discovery 
 
The elucidation of the 2.9 billion-letter nucleotide base pair sequence of the human 
genome is a key resource for any kind of drug discovery. Recent reports, in which 313 
genes were screened in individuals of diverse ethnic origins indicated that 
polymorphisms would be observed at a rate of one single nucleotide polymorphism 
(SNP) in every 185 nucleotides, and individualized therapy based on the genome 
sequence of each individual would pave the way for modern medicines (Stephens  
et al., 2001). Therefore, for this individualized pharmacotherapy (tailor - made 
pharmacotherapy), the genetic polymorphisms of drug metabolizing enzymes and drug 
transporters have been extensively investigated and established as a key factor 
responsible for interindividual differences in pharmacokinetic and pharmacodynamic 
profiles. It is estimated that approximately 500-1200 genes code transporters and, as this 
area of research is still in its infancy, the importance of this fact is only now beginning 
to be understood.  
 
Pgp (MDR1) plays the most important role among these transporters, since the 
biological fate of a number of structurally unrelated drugs is defined by the MDR1 
gene. To date, a total of 28 SNPs have been found at 27 positions on the MDR1 gene. A 
polymorphism in exon 26 at position 3435, a silent mutation, has been found to be of 
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key importance due to its effects on MDR1 expression and pharmacokinetic activity. In 
addition, recent investigations have raised the possibility that MDR1 and related 
transporters play a fundamental role in regulating apoptosis (mechanism of programmed 
cell death necessary to remove cells whose DNA has been damaged to the point at 
which cancerous change is liable to occur) and immunology, and are related to 
susceptibility to certain diseases, suggesting the possibility of disease diagnosis based 
on MDR1 genotyping. 
 
Panwala et al., (1998) indicated that mdr1a-/- knock-out mice were susceptible to a 
severe and spontaneous intestinal inflammation under specific pathogen free conditions. 
These observations suggested that susceptibility to inflammatory bowel diseases 
depended on MDR1 expression and function, and therefore on MDR1 genotype. Also, it 
was noted that several drugs central to the therapy are substrates of MDR1.  
 
Also there is increasing evidence that the risk of HIV related infections is linked to 
MDR1 expression and function. Lee et al., (2000) showed that HIV viral production is 
greatly reduced when MDR1 was over-expressed, suggesting that the cells with high 
levels of MDR1 expression are relatively resistant to HIV infections. Additionally, 
since retroviral drugs are substrates of MDR1, therapeutic outcome of treating HIV 
infections also depends on the MDR1 genotype. In addition, susceptibility to renal cell 
carcinoma is consistent with the hypothesis that a lower MDR1 expression level offers 
less protection from the accumulation of carcinogenic materials in the renal tubules, and 
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therefore the development of the diseases in other tissues with MDR1 expression might 
be related to the level of MDR1 expression and function. 
 
 
3.1.8 Role of P-Glycoprotein in pharmacokinetics and pharmacodynamics 
 
Although the physiological function of Pgp is still not fully understood, the role of this 
efflux transporter in pharmacokinetics is becoming increasingly appreciated. In humans, 
Pgp is found on the apical surface of columnar epithelial cells of small and large 
intestines, the biliary canalicular membrane of hepatocytes, the apical surface of 
epithelial cells of the proximal tubules of kidney and the apical surface of endothelial 
cells in blood capillaries of the brain (Thiebaut et al,. 1987; Cordon-Cardo et al., 1990). 
Because of its strategic localization, Pgp transport functionally can limit cellular uptake 
of drugs from the blood circulation into the brain and placenta, and from the 
gastrointestinal lumen into the enterocyte. On the other hand, this transporter can also 
enhance the elimination of drugs from hepatocytes, renal tubules and intestinal 
epithelial cells into the adjacent luminal space. Therefore, it is very important to 
distinguish the localization of Pgp in cells in relation to drug movement-either uptake of 
drugs into cells or excretion of drugs out of cells. It has been well established that 
MDR1 confers an intrinsic resistance to normal tissues by exporting unnecessary or 
toxic exogenous substances or metabolites out of the body. Therefore, the expression of 
Pgp (MDR1) throughout the body affects the pharmacokinetic profiles of drugs, which 
are its substrates.  
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3.1.9 Distribution of intestinal Pgp 
 
Immunohistological studies with human jejunum and colon using MRK16 antibody 
revealed that high levels of Pgp are observed in the apical surface of columnar epithelial 
cells (Thiebaut et al., 1987). The distribution of Pgp is also not uniform along the length 
of the intestine, appearing to increase progressively from the stomach to the colon with 
a low level in the stomach, with an intermediate level in the jejunum and a high level in 
the colon (Fojo et al., 1987). The uneven distribution of intestinal Pgp seems to have a 
significant impact on the absorption of Pgp substrates, as has been demonstrated in a 
clinical study with cyclosporin (Fricker et al., 1996).  
 
 
3.1.10 Role of intestinal Pgp in drug absorption 
 
Evidence of the involvement of intestinal Pgp in drug absorption was first shown in 
vitro with Caco-2 cells in which Pgp was highly expressed.  The B (Basolateral)-to-A 
(Apical) transport of substrates like vinblastine and docetaxel was 10 and 20 fold, 
respectively, greater than the A-to-B transport, and the A-to-B transport was further 
enhanced in the presence of verapamil and MRK16 by blocking the Pgp efflux function 
(Hunter et al., 1993a; 1993b). Similar studies were carried out for intestinal transport of 
cyclosporin and demonstrated that Pgp played an important role in drug absorption by 
limiting drug transport from intestinal lumen (Augustijins et al., 1993). 
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3.1.11 Localization of Pgp in brain 
 
Localization of Pgp in the brain has been a widely disputed topic that has become the 
centre of much controversy in recent years. Beaulieu et al., (1997) provided very 
convincing evidence for Pgp being predominately localized in the luminal membrane of 
endothelial cells of rat brain capillaries facing blood circulation. Also the co-enrichment 
of Pgp and glucose transporter 1 in brain capillary luminal membranes compared with 
whole brain membrane preparations strongly suggests that Pgp is expressed 
predominantly in the luminal membrane of brain endothelial cells. Western blot analysis 
has also revealed higher expression level of Pgp in endothelial cells compared to 
astrocytes (Barrand et al., 2001). Collectively, these results consistently suggest that 
brain Pgp is predominantly expressed on the apical surface of endothelial cells of 
capillaries. 
 
3.1.12 Role of Pgp in brain uptake 
 
Tsuji et al., (1992), were the first to give experimental evidence that Pgp is involved in 
drug transport in the blood brain barrier (BBB). Kinetic studies have shown that efflux 
transport of vincristine (substrate of Pgp) from bovine brain endothelial cells was 
inhibited by verapamil, resulting in a significant increase in intracellular drug 
concentration. Similar results were also reported by Tatsuta et al., (1992). The 
unidirectional transport of vincristine from the basolateral side to the apical side was 
demonstrated in the polarized monolayer of mouse epithelial cells. Similarly, efflux 
transport of cyclosporin was also observed in cultured endothelial cells of bovine and 
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mouse brain capillaries (Tsuji et al., 1993 & Shirai et al., 1994). Immunostaining with 
Pgp antibody (MRK16) also demonstrated an exclusively apical localization of Pgp in 
human brain endothelial cells (Biegel et al., 1995). These in vitro studies have provided 
evidence of functional involvement of Pgp in the BBB penetration of drugs. Also its has 
been shown from mdr1a and mdr1a/1b-knockout mice studies that the brain is more 
sensitive to changes in Pgp function than other tissues. Therefore, Pgp inhibitors should 
be used with more caution to avoid potential neurotoxicity.  
 
 
3.1.13 Bioavailability & drug design 
 
Generally, drug transporters such as MDR1 and drug metabolizing enzymes like 
cytochrome P450s (CYPs) are the two major biological factors, which affect the 
pharamcokinetics (oral bioavailability) of drugs. Recently it has been demonstrated that 
Pgp and CYP3A4 (a member of the cytochrome P450 mixed-function oxidase system, 
which arguably is the most important enzyme involved in the metabolism of xenobiotics 
in the body. It is involved in oxidation of the largest range of substrates of all the CYPs 
and present in the largest quantity of all CYPs in the liver) share a significant overlap in 
substrate specificity (Wandel et al. 1999). Owing to this finding it could be said that the 
disappointing therapeutic effects of Pgp inhibitors in cancer therapy are due to the fact 
that high concentrations of Pgp inhibitors would also produce CYP3A4 inhibition. The 
duality of effects of these Pgp inhibitors on both Pgp and CYP3A4 would result in 
multiple effects at different tissue sites so that inhibition of Pgp will increase tumor 
 92 
concentration, increase oral absorption, and increase central nervous system penetration. 
In addition, inhibition of CYP3A4 would further enhance oral absorption and decrease 
hepatic metabolism with consequent further increase in plasma concentration. Thus the 
therapeutic/toxic effects of the change will depend on whether CYP3A4 is involved in 
activation or detoxification of the drugs in question. A less potent Pgp inhibitor but one 
with minimal or no CYP3A4 inhibitory effect would be more desirable. The 
development of potent Pgp selective agents that minimize the risk of CYP3A4-mediated 
metabolic interactions with the anticancer drug regimen, would produce improved 
therapeutic specificity and efficacy.   
 
 
3.1.14 Comparison of in-vitro screening assays for Pgp 
 
Several in vitro screening assays have been used to identify and classify compounds as 
Pgp substrates or inhibitors For example, drug stimulated ATPase activity can be 
determined by monitoring the release of inorganic phosphate by a colorimetric reaction 
(Sarkadi et al., 1992; Urbatsch et al., 1994). However this assay cannot distinguish 
between substrates and inhibitors and also only measures activity indirectly. Another 
approach is the use of fluorescent indicators (Nelson et al., 1998; Wang et al., 2001) 
where inhibition of Pgp leads to cellular accumulation of a fluorescent dye, such as 
rhodamine123 (Eytan et al., 1997) or calcein AM (Tiberghien et al., 1996). These 
fluorometric assays can also be automated with sufficient suitability for high throughput 
screening. However, unambiguous identification of inhibitors or substrates of Pgp may 
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be difficult due to the presence of multiple binding sites. Not only does it not directly 
measure transport but also it needs to be run in conjunction with monolayer efflux 
assay, to prevent false negative results.  
 
Kinetic data indicating non-competitive interactions between substrates and inhibitors 
of Pgp (Litman et al., 1997; Pascaud et al., 1998), as well as photoaffinity labeling 
studies (Dey et al., 1997), suggest the presence of at least two distinct binding sites. The 
two sites have distinct but overlapping substrate specificities and exhibit positive 
cooperativity. Also a third drug-binding (non-transporting) site with positive allosteric 
properties for drug transport has been reported (Shapiro et al., 1998). Thus, inhibition 
data obtained from Pgp interaction studies may depend on the kind of substrate used, as 
suggested for drug interactions at CYP3A4 (Korzekwa et al., 1998).  
  
Clearly then it is very difficult to classify test compounds as transporters and inhibitors 
by a single assay because different experimental systems and test conditions produce 
different classifications.  A well defined strategy should be used to identify potential 
inhibitors and substrates of Pgp. Possibly an indirect fluorescence assay could be used 
as a primary screen followed by ATPase or transcellular transport assay to distinguish 
substrates and inhibitors. The results can be further confirmed at later stages of drug 
development by a direct transport assay, followed by in vivo experiments (e.g. Pgp 
knock-out mice) (A knockout mouse is a genetically engineered mouse one or more of 
whose genes have been made inoperable. Knockout is a route to learning about a gene 
that has been sequenced but has an unknown or incompletely known function. Mice are 
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the laboratory animal species most closely related to humans in which, the knockout 
technique can be easily performed, so they are a favorite subject for knockout 
experiments, especially with regard to genetic questions that relate to human 
physiology). 
 
Recently the use of bio-affinity chromatography, which is based upon target 
biopolymers in a flow system has been considered as a valuable method in identifying 
substrates for different biopolymers. This method can be used to rapidly determine a 
compound's affinity for biopolymers and whether it is an inhibitor/substrate of the 
transporter. This is a key element in drug discovery and drug development programmes. 
Therefore the method can be used as a prescreen to identify all substrates and inhibitors, 
which could be subsequently moved onto a more expensive and time consuming 
functional assays to determine functional activity. 
 
Wainer et al., (2000) recently developed a chromatographic approach utilizing 
stationary phases containing membranes from cells expressing the Pgp transporter.  
These cellular membranes were immobilized on a liquid chromatography stationary 
phase containing an "immobilized artificial membrane" (IAM) stationary phase, to form 
Pgp-IAM phases.  The Pgp-IAM phases were used in frontal affinity chromatographic 
studies to determine the binding affinities {Kd values} of Pgp substrates and inhibitors 
and to identify competitive, allosteric and enantioselective interactions in ligand binding 
to Pgp. In their study showing the enantioselective binding of mefloquine enantiomers 
to Pgp using a Pgp-IAM stationary phase they suggested that competitive binding 
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experiments on the Pgp-IAM columns could be a rapid method for the identification of 
synergistic pairs for specific clinical targets (Wainer et al., 2001). 
 
 
3.1.15 Aims & Objectives 
 
Building upon the experience gained in related research studies (Chapter 2) involving 
immobilized protein that took place in the initial phase of this research programme, the 
general aim was to develop suitable chromatographic platforms for Pgp investigations 
which have reproducible and with acceptable run times and appropriate detections 
systems. The first phase was to evaluate the cell lines for Pgp expression and activity.  
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3.2 Evaluation of doxorubicin toxicity in Pgp-(+) LCC6/MDR1 vs. Pgp-(-) LCC6 
human breast cancer cells. 
 
3.2.1 Introduction 
 
In the past years, a number of experimental agents, including vinblastine, verapamil, 
cyclosporin, and trifluroperazine, have been studied with various efficacies in reversing 
multi drug resistant phenotype in cancer cells. The application of these compounds is, 
however, very limited due to their unfavorable toxicities and/or their significant effects 
on the metabolism and pharmacokinetics of the concurrently administered 
chemotherapeutic agents (Hegewisch, 1996; Tan, 2000). However the general aim of 
this experiment was to confirm the functionality of the Pgp-positive LCC6/MDR1 cell 
line through comparison with the Pgp-negative LCC6 cell line by studying the effect of 
the cytotoxicity of doxorubicin on the effect of cell growth. 
 
 
3.2.2 Cell culture 
 
 
The parental MDA-MB-435 cells were originally provided by Dr Janet Price (MD 
Anderson Cancer Center, Houston, Texas, USA), and were established from a pleural 
effusion in a 31 year old Caucasian woman with metastatic breast cancer (Cailleau et 
al., 1974, 1978). The patient had received no prior systemic therapy. MDA-MB-435 is 
one of the few human breast cancer cell lines that produces reproducible lung 
metastases from solid tumours (Price et al., 1990; Meschter et al., 1992). The MCF-
7ADR clone 5 cells are a cloned population of MCF-7ADR, and were kindly provided by 
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M. Johnson (Lombardi Cancer Center, Georgetown University, Washington DC, USA). 
MDA-MB-435, MCF-7ADR close 5, MDA-435/LCC6 and MDA435/LCC6MDR1 (multi 
drug resistant gene 1) cells were routinely maintained in improved minimal essential 
medium (IMEM; Biofluids, Rockville, Maryland, USA) containing phenol red and 
supplemented with 5% foetal calf serum. 
 
3.2.3 Experimental 
 
LCC6 and LCC6/MDR1 cells were plated in 96 well plates (2 plates per cell line) with 
FHOOVȝOPHGLDSHUZHOOLQZHOOV7KHSODWHVZHUHLQFXEDWHGDWÛ&LQ
CO2 atmosphere and 90% relative humidity (RH) for 72 h. The cells were then treated 
with 200ul of varying concentrations of doxorubicin (0, 3, 8, 20, 51, 128, 320, 800 & 
2000 nM) in media and incubated for 24 h. The treatment was stopped and the media 
ZDVH[FKDQJHGZLWKȝORIIUHVKJURZWKPHGLDDQGUH-incubated at 37Û&IRUIXUWKHU
7K7KHFHOOFXOWXUHVZHUHWKHQIL[HGVWDLQHGE\H[FKDQJLQJVSHQWPHGLDZLWKȝO
of crystal violet solution (0.5 % in 25 % methanol) per well. The plates were then rinsed 
with water and dried. After drying, the crystal violet attached to wells was re-dissolved 
in sodium citrate 0.1 M in 50% ethanol. Absorbance was evaluated using an ELISA 
reader spectrophotometer at 540 nm and the resulting data were used to evaluate the 
amount of cells. The absorbance directly correlates with cell number in this assay. 
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3.2.4 Results & Discussion 
 
In order to study the effect of cytotoxic drug doxorubicin on Pgp cell growth it was 
decided to adopt the experimental approach of investigating the comparative effects of a 
range of eight different concentrations of doxorubicin on cell growth in the two cell 
lines. More specifically, the approach would be to evaluate cell growth in terms of 
crystal violet staining of cells grown in 96-well plates, six days after initial seeding. 
 
The cell survival curves were obtained for each cell line at varied concentrations of 
doxorubicin (Table 7). The toxicity of each drug was expressed as an IC50, defined as 
the concentration inhibiting cell density by 50% at the end of the treatment. The IC50 for 
LCC6 and LCC6/MDR1 were 16.33 nM and 341.20 nM respectively. Since Pgp 
transporter is an efflux pump which transports substrates out of the cell. The results 
indicated that the drug doxorubicin is exported much more out of the LCC6/MDR1 cell 
line compared to the LCC6 cell line. Therefore it was apparent that the control cell line 
was much more sensitive to doxorubicin as compared to the positive LCC6/MDR1 cell 
line, proving that the LCC6/MDR1 cell line had a stable, active and over-expressed Pgp 
transporter as compared to the control cell line LCC6.  
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Table 7. Cell Survival (%) at different concentrations of cytotoxic drug doxorubicin. 
Absorbance was evaluated using an ELISA reader spectrophotometer at 540 nm and the 
resulting data were used to evaluate the amount of cells. The absorbance directly 
correlates with cell number in this assay (n = 3). 
Concentration nM Cell Survival (%) 
LCC6 
Cell Survival (%) 
LCC6/MDR1 
0 100.00 + 0.00 100.00 + 0.00 
3 83.82 + 0.75 98.41 + 0.95 
8 75.72 + 1.60 97.14 + 0.28 
20 42.70 + 1.48 97.98 + 0.35 
51 31.17 + 0.30 92.21 + 0.81 
128 34.81 + 0.41 91.40 + 0.45 
320 29.70 + 0.88 52.48 + 1.23 
800 17.19. + 069 33.62 + 1.10 
2000 11.83 + 0.68 29.46 + 0.85 
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Figure 19. Plot of log [doxorubicin] (nM) vs. cell survival at different concentrations of 
cytotoxic drug doxorubicin for Pgp(+) cell line and the Pgp(-) cell line. The absorbance 
was evaluated using and ELISA reader at 540 nm and the resulting data were used to 
evaluate the % cell survival. The absorbance directly correlates with the cell number in 
this assay (n = 3). IC50 values were calculated as the concentration inhibiting cell 
density by 50 % at the end of the treatment. 
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3.2.5 Conclusion 
 
The Pgp (+) LCC6/MDR1 cell line had a twenty fold higher IC50’s than the Pgp (-) 
LCC6 cell lines for doxorubicin. This indicated that the efflux protein Pgp was over-
expressed in the LCC6/MDR1 cell line as compared to the LCC6 cell line. Therefore it 
has been demonstrated that there is a significantly higher concentration of Pgp in the 
Pgp (+) LCC6/MDR1 cell line as compared to the Pgp (-) LCC6 cell line. Thus the cell 
line producing the active protein Pgp was available to perform functional studies and 
make immobilized biopolymer columns containing Pgp. Also the control cell line had a 
considerably lower presence of the protein which would make it a good control cell 
line. 
 
 
3.3 Substrate accumulation of vinblastine in Pgp (+) LCC6/MDR1 vs. Pgp-(-) 
LCC6 Human breast cancer cells. 
 
 
3.3.1 Introduction 
 
The general aim of this study was to confirm the differential functionality of Pgp (+) vs. 
Pgp (-) cell lines. In a similar fashion to the previous experiment (Section 2.2) Pgp 
being an efflux protein, the ability of each cell line to influence the intracellular 
accumulation of cytotoxic drug (Figure 20) should be different depending upon the 
expression of the efflux Pgp transporter. For example, vinblastine diffuses through the 
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lipid bilayer into the intracellular space via passive diffusion. In the presence of the Pgp 
transporter the vinblastine molecule is translocated from the inner leaflet of the 
membrane to the outer membrane leaflet or the extracellular space. A vinblastine 
substrate accumulation study was carried out on the control and the positive cell line to 
show how each cell line accumulates varied concentration of the substrate depending 
upon the number of active Pgp binding sites.  
 
 
 
 
Figure 20. Molecular structure of vinblastin (Vinca alkaloid). It binds to tubuline, 
thereby inhibiting the assembly of microtubules. It is a substrate of Pgp with 
hydrophobic properties. Effective against cancers of the white blood cells such as 
lymphoma, non-small cell lung cancer, breast cancer and testicular cancer 
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3.3.2 Experimental 
 
Pgp (+) LCC6/MDRI and Pgp (-) LCC6 human breast cancer cell lines were plated at 
2.5 x 105 cell  / well into 24-well culture dishes, in routine growth media, and incubated 
at 37Û&)RUW\-eight hours later, the Pgp (+) LCC6/MDRI and Pgp (-) LCC6 cell lines 
were treated by replacing the growth media with media containing 5 nM 3H-vinblastine 
(specific activity 254 GBq) and the control wells were plated with growth media 
containing 5 nM cold vinblastine. After a three hour incubation, the treatment was 
stopped by washing each well with phosphate buffered saline (0.5 ml / well) and left to 
dry at room temperature. Cell monolayers were removed by trypsinization (1 ml) and 
diluted with 10 ml of scintillation fluid (Ecosinct A). Vinblastine accumulation was 
radiometrically assessed by scintillation spectrometry (n=4).  
 
 
3.3.3 Results & Discussion 
 
Pgp transporter has a ligand binding-domain, which is on the extracellular side of the 
protein for importers and on the cytoplasmic side for exporters. It contains a 
translocation pathway, which is a cavity which a specific molecule can use to travel 
through the protein. When an ATP molecule binds to each cassette, it induces a 
conformational change in both the nucleotide-binding folds and the transmembrane 
domains, allowing the molecule to travel through the translocation pathway. Vinblastine 
a Pgp substrate passes through the lipid bilayer through passive diffusion and binds to 
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ligand binding domain (cavity) and in presence of ATP is translocated to the outer 
leaflet or the extracellular space (Figure 21). 
 
Figure 21. Vinblastine molecule bound to the ligand binding domain in the cavity of 
the Pgp transporter and when the nucleotide binding fold binds to an ATP molecule, a 
conformational change opens up the pathway and translocates the lipid to the 
extracellular membrane. 
 
The vinblastine accumulation for each of the cell lines is shown in Table 8. There was a 
significant difference p<0.0001 in the vinblastine accumulation between the two cell 
lines indicating that the Pgp (+) cells had overexpression of the efflux protein Pgp. 
Vinblastine is a Pgp substrate and therefore intracellular concentration of vinblastine 
should be less in cells that express Pgp as compared to cells that do or express Pgp. The 
Pgp (+) cell line had a six fold lower substrate accumulation of vinblastine as compared 
to the Pgp (-) cell line, thus indicating that there were at least six fold more active Pgp 
sites present on the Pgp (+) cell line as compared to the Pgp (-) cell line.  
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Table 8. Vinblastine accumulation was carried out on Pgp (+) and Pgp (-) cells plated 
on 24 well culture dishes and incubated with 5nM [3H]-vinblastine for 3 h.  The cell 
monolayers were removed with trypsination (1ml) and then measured by scintillation 
counting in disintegrations per minute (DPM).  
 
 
Cell Line Vinblastine accumulation (DPM) (n = 4) 
Pgp (+) LCC6/MDR1   929 + 64 
Pgp (-) LCC6 5532 + 599 
  
 
3.3.4 Conclusion 
 
The results of the experiment proved that the substrate accumulation of vinblastine was 
much lower in the control cell line as compared to the test cell line. Also the Pgp protein 
present in the test cell lines is active as it actively effluxes vinblastine out of the cells. 
Thus this shows that the Pgp protein is abundantly present on the Pgp (+) cell line and 
therefore the cell line could now be used in the planned subsequent experiments to 
prepare immobilized biopolymer stationary phases. Also since the Pgp protein is over 
expressed in the Pgp (+) cell line as compared to the control cell line Pgp (-) which 
doesn’t have the transfected Pgp gene, parallel experiments carried out with the Pgp (+) 
and Pgp (-) cell line would depict a knock-in/knock out model. The two columns have 
been charactereised by its functionality, and the functionality is due to the Pgp and 
therefore there is no need to quantify the protein. This is an advantage for this method 
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as quantification the low amount of protein would pose a problem. Also the membranes 
are immobilized on the column, the number of bindings sites don’t change for the 
column over a long period. This is seen as the retention time and Kd values remain 
reproducible over a period of six months. 
 
 
 
 
3.4 Preparation of and frontal chromatographic studies with IAM based columns 
with Pgp(+) and Pgp(-) membranes  
 
3.4.1 Introduction 
 
As discussed earlier (Chapter 1) there are many ways in which transporters can be 
exploited in chromatographic systems. However, on basis of recent experience in the 
laboratory, it was decided to follow the example of recent work done by Moaddel et al., 
(2000) and adopt an immobilized IAM system. Similarly the chromatographic processes 
would be monitored by use of radio-labeled markers. 
 
 
3.4.2 Experimental 
3.4.2.1 Materials 
Vinblastine (Vb), dithiothreitol (DTT), 3-[3-(cholamidopropyl)dimethylammonio]-1-
propane sulfate (CHAPS), glycerol, leupeptin, pepstatin, phenyl methyl sulfonyl 
fluoride (PMSF), EDTA, sodium hydroxide, tris[hydroxymethyl]aminomethane 
(Trizma) and tris[hydroxymethyl]aminomethane hydrochloride (Tris–HCl) (used to 
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prepare the Tris buffer), avidin, glutaric dialdehyde and aminopropyltrimethoxy silane 
(APTS) were purchased from Sigma (St. Louis, MO, USA). [3H]-Vinblastine (254 
GBq) and [3H]-cyclosporin A (259 GBq) were purchased from Amersham Pharmacia 
Biotech (Piscataway, NJ, USA). 6-[(biotinoyl) amino] hexanoic acid (Biotin-X) was 
purchased from Molecular Probes (Eugene, OR, USA). Open tubular capillaries 
(100 ȝP i.d.) were purchased from Polymicro Technologies (Pheonix, AZ, USA).  
 
3.4.3 Preparation of Pgp(-) and Pgp(+) membranes 
 
3.4.3.1 Cell lines 
 
Pgp(-) membranes were obtained from the MDA435/LCC6 (human breast cancer) cell 
line. The Pgp(+) membranes were obtained from the MDA435/LCC6MDR1 cell line 
prepared from the MDA435/LCC6 cell line by transduction with a retroviral vector 
carrying MDR1 cDNA (Pgp) as previously described by Leonessa et al., (1996). 
 
3.4.3.2 Solubilization of the membranes 
 
The MDA435/LCC6 or MDA435/LCC6MDR1 cells (100  x 106 cells) were placed in 
15 ml of homogenization buffer (Tris-HCl [50 mM, pH 7.4] containing 50 mM NaCl, 8 
µM leupeptin, 1 µM PMSF and 8 µM pepstatin). The suspension was homogenized for 
3 x 30 s at the setting of 12.5 on a Model PT-2100 homogenizer (Kinematica AG, 
Luzern, Switzerland). The homogenate was then centrifuged at 700 x g for 5 min and 
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the pellet containing the nuclear proteins was discarded. The supernatant was 
centrifuged at 100,000 x g for 35 min at 4oC and the resulting pellet containing the 
cellular membranes was collected. The pellet was then re-suspended in 10 ml of 
solubilization buffer (Tris HCl 50 mM pH 7.4, 250 mM NaCl, 1.5% CHAPS, 2 mM 
'77  0 306)  ȝ0 SHSVWDWLQ $  JO\FHURO and the resulting mixture was 
rotated at 150 rpm using an orbit shaker (Lab-line Model 3520, Melrose Park, IL, USA) 
for 18 h at 4 ºC. The resulting solution was centrifuged at 60,000 x g for 22 min and the 
solubilized solution was then mixed with 160 mg IAM particles and was rotated at room 
temperature for 3 hours at 150 rpm using an orbit shaker (Lab-line Model 3520, 
Melrose Park, IL, USA). The suspended particles were then dialyzed against dialysis 
buffer (Tris HCl [50 mM, pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM benzamidine) 
for two days. The dialysed solution was centrifuged for 3 min at 4 oC at 700 x g and the 
supernatant was discarded. The pellet (LCC6/LCC6MDR1-IAM) was washed with 
running buffer A (Tris-HCL [10 mM, pH 7.4] containing 1 mM CaCl2, 0.5 mM MgCl2) 
and centrifuged.  This process was repeated until the supernatant was clear.  
 
 
3.4.4 Preparation of chromatrographic column 
 
The LCC6-IAM and LCC6/MDR1-IAM (180 mg) were packed into a HR 5/2 glass 
columns  (Amersham Pharmacia Biotech, Uppsala, Sweden)  using a rabbit pump at 
setting 5 to yield a 150 mm x 5 mm (i.d.) chromatographic beds, to produce the Pgp(+)-
IAM and Pgp(-)-IAM columns.  
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3.4.5 Chromatographic system 
 
The chromatographic system was composed of a Shimadzu LC-10Advp pump, 50 ml 
VXSHUORRS$PHUVKDP3KDUPDFLD8SSVDOD6ZHGHQDQ,186V\VWHPȕ-Ram model 3 
radioflow detector (IN/US, Tampa, FL, USA) with a dwell time of 2 s and the output 
data was analyzed using the Laura lite 3 (IN/US) programme.  
 
3.4.6 General procedures 
 
In these studies, the mobile phase consisted of the marker ligand [3H]-Vb in 5 ml of 
ammonium acetate (10 mM, pH 7.4) delivered at a flow rate of 0.2 ml/min. At the 
beginning of each experimental series, the mobile phase was run through the Pgp(+)-
IAM column until an elution profile showing both front and plateau regions was 
observed. Increasing concentrations of the unlabelled marker or unlabelled displacer 
were then added to the mobile phase and the frontal chromatographic experiments were 
repeated. When Vb was studied, the mobile concentration of [3H]-Vb was 0.65 nM and 
the added concentrations of Vb were 50, 125, 250, and 500 nM.  
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3.4.7 Results and Discussion  
 
 
3.4.7.1 Characterisation of the immobilized Pgp-IAM column 
 
 
Quantitative affinity chromatography is an extremely well documented approach used 
for the measurement of ligand-protein interactions (Jaulmes and Vidal-Madjar, 1989). 
Displacement chromatographic techniques can be used to observe binding interactions 
between two or more ligands binding at the same or separate sites. Thus in this manner, 
competitive and allosteric (cooperative or anticooperative) interactions can be readily 
identified.  
 
In this study the Pgp transporter was immobilized on an immobilized artificial 
membrane (IAM) and used to study the binding interactions between the transporter and 
the ligands (Figure 22). 
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A.       B. 
Figure 22. A. IAM chromatography packing material composed of single chain ether 
phospholipids containing Ȧ-carboxyl groups in the alkyl chain immobilized on 
aminoopropyl silica. The phospholipids surface is stable with organic solvents and 
aqueous buffers between pH 2 to 8. IAM have an area per molecule of 66-104 Å2. The 
similar area per molecule of these IAM and mobile phosolipid in liposomes indicated 
that the lipid environments were similar. B. IAM chromatographic surfaces prepared by 
covalently immobilizing cell membrane phospholipids to solid surfaces at monolayer 
densities. IAM surfaces mimic fluid cell membranes (lipid bilayer). This figure 
indicates that solute partitioning between IAM bonded phase and the aqueous mobile 
phase is similar to the solute partitioning between liposomes and the aqueous phase.  
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The activity of the Pgp transporter immobilized on IAM stationary phase Pgp(+)-IAM 
was  determined using frontal displacement (affinity) chromatography with [3H]-Vb as 
the marker ligand, and Vb as the displacer.  The Pgp-IAM was used to determine the 
binding affinities (Kd values) of Pgp substrates and inhibitors and to identify 
competitive, allosteric and enantionselective interactions in the ligand binding to Pgp 
(Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Comparison of the frontal chromatograms of 0.5 nM [3H]-Vb (5ml) on the 
LCC6/MDR1 Pgp(+)-IAM-column (red), LCC6 Pgp(-)-IAM column (blue) and IAM 
column (green). Elution profiles show both the front and plateau regions of the frontal 
chromatogram. Radioactivity was measured as counts per minute (CPM) using a liquid 
scintillatioQUDGLRIORZGHWHFWRU,186V\VWHPȕ–Ram model 3) and the output data is 
analyzed using a Laura lite programme with a dwell time of 2 s.  Running buffer 
consisted of ammonium acetate [10 mM, pH 7.4] and the flow rate was 0.2 ml/min.   
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However the run times often ranged from 1 to 3 h. Also as could be seen from the 
elution profile of the blank IAM column, (Figure 23) a significant portion of this long 
run time was the result of strong lipophilic interactions between the substrate/inhibitors 
which are hydrophobic in nature and the IAM backbone which is very lipophilic. Due to 
these long retention times and accompanying long equilibration and wash times, the 
Pgp-IAM stationary phases were not suitable for use in the rapid determination and 
characterization of Pgp binding interactions. Further, the frontal chromatography of 
[3H]-Vb showed two distinct peaks indicating that multiple binding sites were present 
which made it difficult to use [3H]-Vb as the marker ligand. These multiple binding 
sites could also be attributed to surface of the IAM which has two binding pockets, one 
on the surface and another in a deep cleft. 
 
In order to decrease the retention time of the Pgp substrates/inhibitors various methods 
were employed but they were not very successful. For example, varied cell number 
ranging from 100 million to 500 million were used in order to cover as much surface 
area of the IAM as possible. This produced shorter retention times but still did not allow 
for the rapid determinations of binding affinities. Also, 5% methanol was used to 
decrease the long run times, but this introduction of methanol reduced the lifetime of 
the column drastically, presumably the alcohol interfering with the tertiary structure of 
the transporter. A further problem was that the results were not reproducible indicat ing 
that the methanol could be denaturing the protein so that the protein would loose its 
activity and the structure of its binding site. 
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3.4.8 Conclusion  
 
Although the IAM stationary phase was an ideal choice to study the nicotinic 
acetylcholine receptors (Moaddel, 2000), this was not the case for the Pgp transporter. 
Pgp substrates are predominantly lipophilic, as access to the binding pockets is located 
deep in the lipid bilayers. Therefore there were more non-specific interactions with the 
IAM stationary phase as compared to the specific interactions between ligands and the 
target protein. 
 
Thus owing to the hydrophobic nature of the IAM columns and the Pgp substrates like 
vinblastine (very lipophilic), it became difficult to remove the non-specific interactions 
created by the interaction between the IAM backbone and the substrates. Therefore the 
use of the biopolymeric stationary phase became impractical, due to the large retention 
times and also long wash times (18 h). Also the use of radioactivity was a deterrent as 
although radioactive isotopes have higher sensitivity and help in removing for the 
background interference from other analytes, it has its drawbacks as it is highly 
hazardous and all ligands aren’t readily available. Also it requires the use of special 
equipment and stricter safety precautions. Also certain times the commercial purity is a 
question mark. Thus as many of the ligands for Pgp are not readily available with 
radioactive tags other method of detection like mass spectrometry was carried out, 
giving the advantage of being able to use a more wide range of substrates for the 
analysis and characterization of the Pgp column. 
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3.5 Pgp PEEK Columns (Vanadate Trap) 
 
3.5.1 Introduction  
 
Given these short comings of these conventional IAM columns, it was necessary to find 
a backbone and support which would decrease the non-specific interactions and provide 
a faster elution profile. 
 
The initial approach to decrease the amount of non-specific interactions with the IAM 
backbone was to pack the support into a peek-WXELQJ FROXPQ  ȝP LG [  FP
which had a smaller diameter. Also using this approach would also mean less utilization 
of the cell extract and different reagents and also IAM which is very expensive. This 
was an important factor as the vanadate trapping experiment could lead to a disruption 
of the active site of Pgp. The importance of intended vanadate trapping is that it allows 
for the determination of non-competitive inhibitors of this transporter. Similar effects on 
the transport cycle of Pgp had been observed with vanadate trapping (Rao & Nuti et al., 
2003) (Figure 24). 
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Figure 24. ATP dependant Pgp transport cycle showing Pgp transporter in its different 
transformational states. 2a. resting phase of Pgp, 3. pre-catalytic stage, 4. catalytic 
stage, 5. post-phosphate stage, 6. post ADP (adenosine triphospate) stage. Stages 6 to 9 
are for the second ATP cycle which helps Pgp get back to the original resting phase 1. 
 
Vanadate-trapping of the Pgp transporter in state 4 is a more desirable approach than 
using ATP as it is cheaper, the effect lasts longer and a vanadate containing mobile 
phase can be used with mass spectrometry. In summary, the aim of the next phase of the 
research programme was not only to establish a more pragmatic approach to the frontal 
chromatography by using a Pgp-PEEK tubing micro-capillary column but also to apply 
it to the study of the effect of vanadate on the specific retention of Vb. 
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3.5.2 Experimental 
 
3.5.2.1 Preparation of membranes 
 
The preparation of Pgp (+) and Pgp(-) membranes used in this study was as described in 
section 3.4.3 
 
3.5.2.2 Preparation of chromatographic column 
 
PGP-(+)-IAM and Pgp-(-)-IAM was packed into PEEK tubing column (762 Pm id x 40 
cm) using a rabbit pump at a flow rate at 50 Pl/min  ammonium acetate [10 mM, pH 
7.4] as mobile phase. 
 
3.5.2.3 Vanadate-trapping 
 
100 mM stock solution of sodium orthovanadate was prepared in de-ionised water by 
acidifying with 1M HCl. Running buffer composed of Tris [50mM pH 7.4], 150mM 
NH4Cl, 5mM MgSO4, 0.02% NaN3 (sodium azide), 2mM ATP and 0.3M sodium 
orthovanadate was prepared and run through the column for 120 min. The column was 
incubated at 37Û&IRUPLQ7KHLPPRELOL]HG3JSWUDQVSRUWHUZDVWUDSSHGLQWKHILUVW
ATP cycle using the vanadate trapping. Zonal elution studies were carried out to 
determine the effect of the vanadate trapping. Mobile phase containing ammonium 
acetate [10mM, pH 7.4], 0.1 nM vanadate was used during the study. These studies 
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were carried out using mass spectrometric detection on the Micromass QTOF1-MS 
(Waters, Milford, MA). 
 
 
 
3.5.3 Results and Discussion 
 
Pgp is an ATP dependent drug efflux pump, which passes through a number of phases 
during the transport cycle (Figure 24 {b}).  The transport cycle is ATP dependent and 
Pgp exhibits a robust drug substrate-stimulating ATPase activity. Previous studies with 
the Pgp-IAM HR5/2 glass column, had suggested that when ATP was not present in the 
mobile phase, the Pgp transporter was frozen in state 2a (Moaddel et al., 2002). 
 
Under these conditions, the immobilized Pgp transporter binds to characterized Pgp 
substrates, such as Vb but there is no demonstrable affinity for non-competitive 
inhibitors such as CysA. The addition of ATP to the mobile phase produces a 
conformational shift in the immobilized Pgp resulting in its transition to state 4. In this 
state, the vanadate treated Pgp did not bind to Vb, but had a significant affinity for 
CysA. 
 
The importance of the use of the ATP trapped (vanadate trapped) Pgp is that it allows 
for the determination of non-competitive inhibitors of this transporter. The results of 
these studies are presented in Figure 25. 
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Figure 25. Effect of vanadate trapping on a the retention of Vb on a Pgp(+)-IAM PEEK 
tubing column where  A  Vb on “vanadate-trapped column”, B   Vb on “ATP-saturated 
column” and C Vb on peek tubing column without any vanadate trapping. Running 
buffer consisted of ammonium acetate [10 mM, pH 7.4] and the flow rate was 50 
ȝOPLQ 
 
Under zonal elution conditions Vb had a retention time of 40.0 min and in the presence 
of 3 mM ATP, the retention time decreased to 10.4 min. With the vanadate trap the 
retention time of Vb was 6.0 min (Figure 7). The results of this study suggested that the 
Pgp transporter was trapped in the first ATP cycle using the sodium ortho vanadate. On 
the other hand there was a significant difference in the effect of vanadate on Vb 
retention. Thus the results showed that vanadate trapping caused conformational change 
in the Pgp binding site which lead to an inhibition (decrease) in binding of the substrate 
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Vb to Pgp. This could be used to screen compounds for their non-competitive inhibition 
activity for Pgp. However the PEEK-tubing columns generated a high back pressure at 
the flow rates that had been used and thus could not be used reproducibly for more than 
six runs. Also there was loss of column packing due to the high back pressure which 
resulted in poor peak shape. 
 
 
3.5.4 Conclusion 
 
As anticipated the run times were reduced. Also due to the higher proportion of Pgp to 
the IAM the contribution of the non-specific interaction were minimized. Therefore the 
reduction in the chromatographic bed to 1/3 the size the HR5/2 column and the resulting 
reduction in the retention time to approx 40 min for Vb provided the means to exploit 
the use of these columns for studying the Pgp in its different conformational state.  
 
Therefore, Pgp being an ATP dependent drug efflux pump, exhibited a robust drug 
substrate-stimulating ATPase activity and vanadate blocking effectively trapped Pgp in 
a non-covalent stable transition state conformation. Zonal elution studies carried out on 
the vanadate trapped column would help in identification of non-competitive inhibitors 
of Pgp.  
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3.6 Caco-2 permeability measurements and stimulation of membrane-based 
ATPase activity. 
 
 
The following studies were performed as a collaborative effort with Purdue Pharma in 
the US. The results from their assay were used in conjunction with the results of the Pgp 
open tubular column to provide a comparison between the various techniques. The 
experimental details for the two assays are given below. 
 
3.6.1 Materials 
 
Human colorectal adenocarcinoma (Caco-2) cells were obtained from American Type 
Culture Collection. Buffer components were obtained from Baker Chemicals.  Other 
necessary reagents and all test chemicals were obtained from Sigma Chemicals.  
Delbecco’s Modified Eagle’s Medium (DMEM) without phenol red, foetal bovine 
serum, trypsin/0.5% EDTA, pen/strep and Hank’s buffered salt solution (HBSS) were 
obtained from Invitrogen Corporation (Carlsbad, CA).  Electric resistance measuring 
device (EVOM-X) and 96-well plate electrode (STX 100M) were purchased from 
World Precision Instruments Inc.  Multiscreen Caco-2 96-well plates were purchased 
from Millipore (Bedford, MA) 
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3.6.2 Caco-2 assay 
 
Caco-2 permeability experiments were conducted using a previously described method 
(Balimane et al., 2004), which was modified to meet the conditions of this study. Caco-2 
cells at passage 20 were stored in liquid nitrogen upon arrival from ATCC.  A cell bank 
was prepared and frozen at passage 23.  These cells were then thawed in a 37 °C water 
bath (1-2 min).  Freezing medium was removed by suspending the contents of one vial 
in 10 ml of propagation medium in a 50 ml centrifuge tube followed by centrifugation 
at 700 x g for 5 min at 4°C.  The cell pellets were re-suspended in DMEM and seeded at 
106 / T75 flask.  Flasks were incubated at 37°C and 5% CO2 for several days until 
reaching 60-80 % confluence.  
 
Confluent cells were detached using a trypsin-EDTA solution followed by the addition 
of propagation medium to neutralize trypsin, and then the cells were pelleted by 
centrifugation at 700 x g for 5 min at 4 °C.  Supernatants were removed and cell pellets 
were re-suspended in assay medium and counted using a hemocytometer.  Cells were 
seeded into 96-well plates at 104 cells per well into apical chambers.  The basolateral 
FKDPEHUVZHUHILOOHGZLWKȝORI'0(08QLWVZHUHDVVHPEOHGDQGSODFHG LQDQ
incubator for at least 24 days to allow for monolayer formation, feeding three times per 
week.  
 
Assay plates that were 24-30 days in culture were used in this assay.  To acclimate cells 
to transport buffer, DMEM was removed from both the apical and basolateral chambers 
and replace with apical buffer at 85 Pl/well and basolateral buffer at 250 Pl/well.  After 
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30 min at 37°C and 5% CO2 trans-epithelial electric resistance (TEER) was measured.   
TEER values of greater than 1500 ohms were considered acceptable for use.  Usually 
TEER values were about 2000-3000 ohms after 24 days culture.  Permeability assays 
were performed in both directions.  
 
Test compounds were dissolved in DMSO to yield 10 mM stock.  Compounds were 
further diluted to a final concentration of 30 µM in corresponding transport buffer 
depending on the direction of the transport assay. 
 
In order to determine PappA-B test compounds were added in apical buffer (5mM HES 
at pH 6.5) (85 Pl/well) to apical chambers in replicates of four and blank basolateral 
buffer was added to basolateral chambers (5mM HEPES at pH 7.4) (250 Pl/well).  
Plates were incubated for 2 h on an orbital shaker at a 37°C and 5% CO2. In order to 
determine PappB-A, test compounds in basolateral buffer (250 Pl/well) were added to 
basolateral chambers in replicates of four and blank apical buffer was added to apical 
chambers (85 Pl/well).  Plates were incubated for 1 h on an orbital shaker in a 37 °C and 
5% CO2 incubator.  After incubation, supernatants from apical and basolateral chambers 
were transferred to separate 96-well plates and submitted for LC-MS analysis along 
with neat solutions of the compounds in either buffer.  Neat solutions were analyzed 
and used as zero-time calculations.  The apparent permeability coefficients (Papp) were 
calculated in both directions as described previously (Balimane et al., 2004). 
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3.6.3 Membrane based ATPase assay 
 
Membrane ATPase experiments were conducted using a previously described method 
(Wang et al., 2000; Garrigues et al., 2002), that was modified to meet the conditions of 
this study.  Potassium phosphate at 2.5, 1.25, 0.63, 0.31, 0.15, 0.75 mM and vehicle 
control were prepared in Tris-Mes buffer in a final assay volume of 60 Pl/well. A 
standard curve was plotted using Excel. The equation of the line generated was used to 
calculate the nmol of phosphate released in the test samples. 
 
Stock solutions of each test compound were prepared in 100% DMSO at a 
concentration of 2 mM.  Serial dilutions of the stock solutions were prepared using 
phosphate buffer, pH 7.4.    The above concentrations were re-diluted in Pgp membrane 
solutions in the following step to yield the final test concentration. 
 
The assay was initiated by suspending Pgp membranes in 4.5 ml of Tris-Mes Buffer 
then transferring 147 Pl/well of Pgp membrane solution into a 96-ZHOO SODWH  ȝJ
protein per well).  This was followed by the transfer of 3 Pl of test compound solution 
from the chemistry plate to an intermediate plate.  The membrane / compound solutions 
prepared above were split into five 30 Pl/well aliquots and transferred into an assay 
plate, yielding four replicates per concentration, and discarding the remaining solution.  
This was followed by the addition of 10 Pl/well of sodium orthovanadate solution into 
background wells and 10 Pl/well of Tris-Mes buffer into test wells.  ATP solution was 
added at 20 Pl/well to all wells.   The final assay volume was 60 Pl/well.  Plates were 
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incubated at 37 °C for 20 min after which the reaction was stopped with 30 Pl/well 
sodium dodecyl sulphate (SDS) solution.  SDS solution was also added to potassium 
phosphate standards.  Ammonium molybdate was added at 40 Pl/well followed by 
160 Pl/well ascorbic acid solution to test samples, background wells and standards 
wells.  The plates were incubated for 10 min and absorbance read using a Victor2 plate 
reader at 690 nm.  Absorbance values of signal plate were subtracted from those in the 
background plate.  The resulting absorbance values were converted to nmol phosphate 
released using the phosphate standard curve equation of the best-fit line.  Emax values 
were determined using GraphPad prism. 
 
 
 
3.7 Preparation of open tubular (OT) based columns with Pgp(+) and Pgp(-) 
membranes and frontal chromatographic studies with radio-labelled markers. 
 
 
3.7.1 Introduction 
 
While the Pgp-IAM stationary phase produced accurate and reproducible data, there 
was still scope for further improvement with respect to the chromatographic run times. 
A significant portion of the chromatographic retention was the result of strong lipophilic 
interactions between the substrates/inhibitors and the IAM backbone. Due to long 
retention times, the Pgp-IAM stationary phase was not suitable for use in the rapid 
determination and characterization of Pgp binding interactions. The objective of this 
study was to reduce the non-specific interactions arising from the chromatographic 
backbone.  This could be approached through a different immobilization technique 
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(covalent immobilization) of cellular membranes from Pgp expressing cells Pgp (+) 
membranes onto the inner surface of an open tubular capillary to create a Pgp (+)-OT 
column.   
 
3.7.2 Materials 
Vinblastine (Vb), verapamil, imipramine, fexofenadine, ritanovir, doxorubicin, 
ketoconazole, prazosin, (-)-nicotine, atenolol, imipramine, loratidine, domperidone, 
labetalol, benzamidine, dithiothreitol (DTT), 3-[3-
(cholamidopropyl)dimethylammonio]-1-propane sulfate (CHAPS), glycerol, leupeptin, 
pepstatin, phenyl methyl sulfonyl fluoride (PMSF), EDTA, sodium hydroxide, 
tris[hydroxymethyl]aminomethane (Trizma) and tris[hydroxymethyl]aminomethane 
hydrochloride (Tris–HCl) (used to prepare the Tris buffer), avidin, glutaric dialdehyde 
and aminopropyltrimethoxy silane (APTS) were purchased from Sigma (St. Louis, MO, 
USA). [3H]-Vinblastine (254 GBq) and [3H]-cyclosporin A (259 GBq) were purchased 
from Amersham Pharmacia Biotech (Piscataway, NJ, USA). Biotin-X (6-[(biotinoyl) 
amino] hexanoic acid) was purchased from Molecular Probes (Eugene, OR, USA). 
Open tubular capillaries (100 ȝP i.d.) were purchased from Polymicro Technologies 
(Pheonix, AZ, USA). 
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3.7.3 Preparation of Pgp(-) and Pgp(+) membranes 
 
3.7.3.1 Cell lines 
Pgp(-) membranes were obtained from the MDA435/LCC6 cell line. The Pgp(+) 
membranes were obtained from the MDA435/LCC6MDR1 cell line prepared from the 
MDA435/LCC6 cell line by transduction with a retroviral vector carrying MDR1 cDNA 
(Pgp) as previously described by Leonessa et al., 1996.  
 
3.7.3.2 Solubilization of the membranes 
 
The MDA435/LCC6 or MDA435/LCC6MDR1 cells (200×106 cells) were placed in 
10 ml of homogenization buffer (Tris–HCl [50 mM, pH 7.4] containing 50 mM NaCl, 
8µM leupeptin, 1 ȝ0306)DQG ȝ0SHSVWDWLQ7KHVXVSHQVLRQZDVKRPRJHQL]HG
for 3×15 s at the setting of 15 on a model PT-2100 homogenizer (Kinematica AG, 
Luzern, Switzerland). The homogenate was centrifuged at 450×g for 7 min and the 
pellet containing the nuclear proteins was discarded. The supernatant was centrifuged at 
100,000×g for 35 min and the resulting pellet containing the cellular membranes was 
collected, resuspended in 2 ml of solubilization buffer (Tris–HCl [50 mM, pH 7.4] 
containing 500 mM NaCl, 15 mM CHAPS (1.5%), 2 mM DTT, 10% glycerol), and the 
resulting mixture was rotated at 150 rpm using an orbit shaker (Lab-line model 3520, 
Melrose Park, IL, USA) for 18 h at 4 °C. The resulting solution was centrifuged at 
50,000×g for 25 min, the pellet was discarded and the supernatant containing the 
 128 
solubilized Pgp (-) or Pgp (+) membranes was used for the immobilization onto the 
open tubular capillary.  
 
 
3.7.4 Immobilization of the Pgp membranes on the open tubular capillary 
 
3.7.4.1 Preparation of the capillary 
A peristaltic pump (Minipulse 2, Rainin, Woburn, MA, USA) set at 50 (a flow rate of §
10 ȝOPLQZDVXVHG WKURXJKRXW WKHSURFHGXUH $JODVV FDSLOODU\  FP×100  ȝP i.d.) 
was conditioned with a solution of 1 M NaOH for 30 min followed by water for 15 min 
and then air for 5 min. The capillary was incubated at 95 °C for 1 h. An aqueous 
solution of 90:10 (v/v) water: APTS was passed through the capillary for 5 min then 
incubated in the oven at 95 °C for 30 min, this was duplicated again and the capillary 
was left open to air overnight. The following morning, a 1% gluteraldehyde solution in 
phosphate buffer (50 mM, pH 7.4) was run through the capillary for 60 min followed by 
250 ȝORIZDWHU7KHQDVROXWLRQRIDYLGLQ mg in 2 ml of phosphate buffer [50 mM, 
pH 7.4]) was run through the capillary for 30 min, after which both tips of the capillary 
were submerged in the avidin solution and the capillary was incubated for 5 days at 
4 °C. Subsequently, the capillary was washed for 15 min with Tris buffer (10 mM, pH 
7.4) prior to continuing to the next stage. 
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3.7.4.2  Immobilization using biotin-X 
A solution of biotin-X (14 mM in 3:1 (v/v) DMSO : phosphate buffer [50 mM, pH 7.4]) 
was run through the capillary for 1 KDWȝOPLQDQGERWKWLSVRIWKHFDSLOODU\ZHUH
then submerged in the solution overnight. The following day the solution containing the 
solubilized Pgp(+) or Pgp(-) membranes was run through the column for 2 h (Figure 
26). 
 
 
Figure 26. Schematic for the preparation of the open tubular column. The silica OT 
columns were first etched with NaOH. This facilitated the exposure of all the available 
hydroxyl  groups of silica capillary. APTS was added which covalently attaches with 
the open tubular wall generating a free amine. This free amine then reacts with glutaric 
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dialdehyde through a Schiff base reactions (eliminates a molecule of water) and 
generates a free aldehyde. The free aldehyde is then reacted with avidin (a protein with 
four identical subunits). The free amino acids in the avidin react with the free aldehyde 
(Schiff base reaction). The resultant Schiff base is stable as the whole reaction is carried 
out at neutral pH. Biotin X is then added. Biotin X has a fmol binding affinity for avidin 
and the lipophilic arm of biotin X, will insert itself into the interstial space of the 
solubilized Pgp membranes. This helps anchor the membranes onto the activated 
surface of the glass capillary (i.e. OT column). 
 
3.7.4.3 Reagent removal 
 
The open tubular capillary was capped on both ends with dialysis membrane, secured 
using copper wires and placed in a glass beaker containing the dialysis buffer (Tris 
buffer [10 mM, pH 7.4] containing 150 mM NaCl, 1.0 mM EDTA, 1.0 mM 
benzamidine) and dialysed at 4 °C and rotated overnight at 110 rpm using the orbit 
shaker. The following day, solubilized Pgp (+) or Pgp (-) membranes were again passed 
through the capillary for 2 h at 10 ȝOPODQGWKHGLDO\VLVZDVUHSHDWHG2QWKHWKLUGGD\
the column was attached to a Shimadzu LC-10Advp pump (Shimadzu Corp. Columbia, 
MD, USA) and equilibrated by rinsing the column with ammonium acetate (10 mM, pH 
7.4) for 1 h at 50 ȝOPLQ 
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3.7.5 Chromatographic system 
 
The chromatographic system was composed of a Shimadzu LC-10Advp pump, 50 ml 
VXSHUORRS$PHUVKDP3KDUPDFLD8SSVDOD6ZHGHQDQ,186V\VWHPȕ-Ram model 3 
radioflow detector (IN/US, Tampa, FL, USA) with a dwell time of 2 s and the output 
data was analyzed using Laura lite 3 (IN/US) programme.  
 
 
3.7.6 General procedures 
 
In these studies, the mobile phase consisted of the marker ligand [3H]-Vb and [3H]-
CysA in 5 ml of ammonium acetate (10 mM, pH 7.4) delivered at a flow rate of 
50 ȝOPLQ $W WKH EHJLQning of each experimental series, the mobile phase was run 
through the Pgp(+)-OT column until an elution profile showing both front and plateau 
regions was observed. Increasing concentrations of the unlabelled marker or unlabelled 
displacer were then added to the mobile phase and the frontal chromatographic 
experiments were repeated. When Vb was studied, the mobile phase concentration of 
[3H]-Vb was 0.65 nM and the added concentrations of Vb were 50, 125, 250, and 
500 nM. When cyclosporine A (Cys A) was studied, the mobile phase concentration of 
[3H]-CysA was 0.6 nM and the added concentrations of [3H]-CysA were 1 nM, 2 nM, 
and 3 ȝ0 
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3.7.7 Calculation of dissociation constants 
 
Using the frontal chromatograms, the association constants of the competitive ligands 
(CL), KCL, as well as the number of the active and available binding sites of 
immobilized receptors, P, were calculated using the following equations [(1) and (2)]  
 
(VmaxíV)í1=(1+[M]KM)(Vmin[P]KM)í+(1+[M]KM)2(Vmin[P]KMKCL)í[drug]í (1) 
 
(VíVmin)í=(Vmin[P]KCL)í+(Vmin[P])í[M] (2) 
 
where, V is the retention volume of the marker ligand (M); Vmax the retention volume of 
M at the lowest concentration and in the absence of drugs; Vmin the retention volume of 
M when the specific interaction is completely suppressed. The value of Vmin is 
determined by running M in a series of concentration of drugs and plotting 1/(VmaxíV) 
versus 1/[CL] extrapolating to infinite [CL]. From the above plot and a plot of 
1/(VíVmin) versus [M], dissociation constant values, Kd, for M and CL can be obtained 
as can the number of active binding sites on the immobilized protein [P].  
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3.7.8 Results and Discussion 
 
Since the objective was to reduce the non-specific interactions between the 
chromatographic backbone and hydrophobic substrates/inhibitors and to achieve better 
reproducibility and less back pressure, an alternative approach which it was thought 
offered some promise was the immobilization of cellular membranes expressing Pgp(+) 
and Pgp(-) onto the inner surface of an open tubular (OT) capillary to create a Pgp(+)-
OT and Pgp(-)-OT columns. The immobilization was carried out using biotin-
streptavidin coupling as described initially in an experimental approach used by Berger 
& Wood (1975); and Hofmann & Kiso (1976). This biotin-streptavidin coupling can 
had also been used to immobilize lipid membranes using biotinylated liposomes and 
streptavidin-coupled gel beads (Yang et al., 1998; Yang et al., 2000). The latter 
approach was used for this immobilization.  
 
3.7.8.1 Characterization of the immobilized Pgp(+)-OT 
 
The activity of the Pgp transporter immobilized in the Pgp(+)-OT was determined using 
frontal displacement chromatography with [3H]-Vb as the marker ligand, Vb and 
ketoconazole as the displacers (Figure 27). 
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Figure 27. Structure of Ketoconazole and vinblastine know substrates of Pgp. 
  
Vb was representative of a high affinity ligand with a Kd in the nM range and 
ketoconazole as a low affinity ligand with a Kd LQ WKH ȝ0 UDQJH  (OXWLRQ SURILOHV
showing both front and plateau regions were obtained for the marker alone and after the 
addition of the displacers (Figure 28). Using this approach, the affinity of the displacer 
for the immobilized Pgp, expressed as the dissociation constant (Kd), and number of 
available binding sites [Bmax] were determined for Vb and ketoconazole (Table 9).  The 
Kd values obtained on the Pgp-OT were calculated using linear regression analyses and 
correlation coefficients were used to determine the correctness of fit rather than 
standard deviations from the norm. 
 
The Kd value obtained for Vb, 97 nM (r2 = 0.902) was comparable to the values 
previously obtained on the Pgp-IAM (71 nM, Zang et al., 2000; and 24 nM, Lu et al., 
2001) and from membrane filtration studies (37 nM, Ferry et al., 1995; and 36 nM, 
Callaghan et al., 1997). The Kd obtained for ketoconazole, 12.1 ȝm (r2 = 0.845), was 
also comparable to the Kd YDOXHRIȝ0REWDLQHGXVLQJ$73K\GURO\VLVUDWHVWXGLHV
 135 
(Wang et al., 2002). For both substrates, there was less than a 10-fold difference in the 
Kd values determined using different experimental techniques, which indicated that this 
method was comparable to the previously established membrane filtration assays. Thus, 
the results demonstrated that the immobilized Pgp retained its ability to specifically 
bind known Pgp substrates, and could discriminate between a solute with nM affinity 
for the transporter 9EDQGRQHZLWKDȝ0DIILQLW\IRUNHWRFRQD]ROH 
 
Table 9. Comparison of Kd values determined on the Pgp-OT column with those 
obtained on the Pgp-IAM and membrane binding studies. 
      Pgp-OT  Pgp-IAM   Literature 
 Kd 
(nM) 
Bmax or 
P 
(nmol) 
Kd 
(nM) 
Bmax or   
P 
(nmol) 
Kd 
(nM) 
Vinblastine 97 
(r2=0.902) 
3 71 ± 11a 
24 ±   8b 
 
546 ± 60a 37 ± 10c 
36 ±   5d 
Ketoconazole 12,140 
(r2=0.845) 
1.5 NR NR 8,600 nMe 
NR not reported 
a
  Zhang et al., 2000. 
b
 Lu et al., 2001. 
c
 Ferry et al., 1995 
d
 Callaghan et al., 1997. 
e
 Wang et al., 2002. 
 136 
 
 
 
 
 
 
 
 
 
Figure 28. Frontal chromatographic study of the displacement of [3H]-vinblastine by 
ketoconazole on the Pgp(+)-OT column using a mobile phase containing 0.3125 nM 
[3H]-vinblastine, where: A = mobile phase; B = after the addition of 200 nM 
ketoconazole to the mobile phase; C = after the addition of 500 nM ketoconazole to the 
mobile phase; D = after the addition of 10,000 nM ketoconazole to the mobile phase. 
 
There appeared to be a 200 fold disparity in the number of active sites (Bmax) between 
the Pgp(+)-OT column and the Pgp(+)-IAM column, 3 nmol versus 546 nmol, 
respectively. This probably reflected the reduction in the total amount of membranes 
immobilized on the surface of the open tubular column relative to the amount 
immobilized on the IAM particles, and thereby, a reduction in the total amount of Pgp. 
One consequence of the reduced amount of available Pgp binding sites on the Pgp(+)-
OT was a significant reduction in the relative capacity of the column. On the Pgp(+)-
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OT, the half-KHLJKWRIWKHVDWXUDWLRQFXUYHZDVUHDFKHGDIWHUWKHDSSOLFDWLRQRIȝORI
a 0.625 nM solution of [3H]-Vb (Figure 29A), while it took 15 ml of a 1 nM solution to 
reach the same break-through on the Pgp-IAM column (Lu et al., 2001). Since both 
VWXGLHVXVHGDIORZUDWHRIȝOPLQWKHH[SHULPHQWVWRRNDQGPLQUHVSHFWLYHO\
Also, since the immobilization process utilized crude membrane preparations and not 
the purified (or even semi-purified) Pgp protein, it was difficult to assess the total 
amount of material that has been immobilized on the support. One way of addressing 
this issue is to measure the total amount of immobilized protein as a reflection of the 
extent of membrane immobilization. In the previous studies with the Pgp-IAM support, 
the results from a bicinchoninic acid protein assay (micro-%&$HVWDEOLVKHGWKDWȝJ
of protein were immobilized per mg of support. In this study, the total amount of 
immobilized protein could not be measured by the micro-BCA, which has a sensitivity 
RIȝJSURWHLQPO7KLVUHVXOWZDVFRQVLVWHQWZLWKWKHDVVXPSWLRQWKDWDVLJQLILFDQWO\
reduced amount of Pgp-containing membranes had been immobilized within the open 
tubular column.  
 
Frontal studies with the Pgp (-)-OT using the same conditions as the Pgp (+)-OT, i.e. 
0.625nM [3H]-9EDQGDIORZUDWHRIȝOPLQSURGXFHGHOXWLRQSURILOHVVKRZLQJERWK
front and plateau regions (Figure 29 B), with significant decrease in retention time as 
compared to the Pgp (+)-OT. Also the addition of Vb or ketoconazole to the mobile 
phase did not displace the curve. Thus the results from the frontal chromatographic 
studies with the Pgp (-)-OT demonstrated that the retention on Pgp (+)-OT was the sum 
of specific interactions with the Pgp transporter and other specific and non-specific 
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interactions arising from the components of the cellular membrane. Since the Pgp (+) 
and Pgp (-) membranes are obtained from the same cell lines, the only significant 
difference between them is the presence of the expressed Pgp in the Pgp (+) 
membranes. Thus, with the exception of interactions with Pgp, a compound 
chromatographed on the Pgp (+)-OT and Pgp (-)-OT should experience the same 
specific interactions with surface receptors and transporters and non-specific 
interactions with membrane components. Also the retention times and Kd obtained for 
the columns are very reproducible and the number of binding sites remain constant for a 
long period of time. 
 
Figure 29. Frontal chromatographic study of the retention of [3H]-vinblastine on the 
Pgp(+)-OT column (chromatogram A) and Pgp(í -OT column (chromatogram B) using 
a mobile phase containing 0.625 nM [3H]-vinblastine. Radioactive decay was measured 
in counts per minute and the chromatogram was summed up in 1-min intervals and 
smoothed using the Laura lite program.. 
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3.7.8.2 Effect of ATP on the chromatographic properties of the Pgp-(+)-OT column 
 
Frontal chromatography with [3H]-CysA on the Pgp(+)-OT and Pgp(-)-OT gave 
retentions times of 7.2 and 7.0 min respectively. Addition of 3mM ATP to the running 
buffer resulted in changes in retention for CysA, which increased from 7.2 min to 14.0 
min for the Pgp(+)-OT column. No change was observed for the Pgp(-)-OT column 
(Table 10).   
 
Table 10. Effect of ATP on the retention of 3H-CysA for Pgp-(+) and Pgp-(-) OT 
columns. Retention times were extrapolated from the frontal chromatogram as half the 
time required for saturation. Running buffer consisted of ammonium acetate [10 mM, 
pH 7.4], 1mM MgCl2 , 3mM ATP and the flow UDWHZDVȝOPLQ(OXWLRQSURILOHZLWK
both the front and plateau regions of the frontal chromatogram were used to extrapolate 
the retention time k’ as half the time required for saturation (plateau). Radioactivity was 
measured as counts per minute (CPM) using a liquid scintillation radioflow detector 
,186 V\VWHP ȕ–Ram model 3) and the output data is analyzed using a Laura lite 
programme with a dwell time of 2 s.     
 
Mobile phase Pgp(+) (min) 
k’ 
Pgp (-) (min) 
k’ 
With 3mM ATP 14.0 7.2 
Without 3mM ATP 7.2 7.0 
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The concentration of ATP was based on previously reported studies of by Sonveaux N 
et al., 1996. Also with the addition of 3mM ATP to the running buffer, [3H-CysA] was 
displaced from the Pgp(+)-OT column by addition of unlabelled CysA. The results from 
the CysA displacement studies were used to calculate a Kd value of 0.4 nM for CysA 
binding to the immobilized Pgp. This was comparable to previously reported value of 
18nM by Ferry et al., (1995). Thus addition of ATP to the running buffer produced a 
cooperative allosteric interaction that increased the binding affinity of Pgp for CysA. 
These ATP induced changes in the chromatographic interaction between the ligand 
CysA and the immobilized Pgp was consistent with the shift in the tertiary structure of 
the transporter as reflected in earlier work by Sonveaux et al., (1996) and Lu et al., 
(2000). 
 
 
3.7.9 Conclusion 
 
The main conclusion from this study was that the immobilized Pgp liquid 
chromatographic stationary phase appeared to reproduce the Pgp substrate binding as 
determined by classical filtration binding assays. The data from this study indicated that 
membranes from a cell line expressing a target receptor or transporter can be 
immobilized on the surface of glass capillaries with retention of the target’s binding 
activity, and that this activity can be measured using displacement frontal 
chromatographic techniques. The results from this study also demonstrated that since 
cellular membranes are immobilized, instead of the purified target, the membranes 
contribute specific and non-specific off-target binding to the observed chromatographic 
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retention. This necessitates the construction of a second open tubular capillary column 
using membranes from a cell line that does not express the target receptor or 
transporter. The target (-) column can then be used as a control for the target (+) 
column. This approach should be applicable for use with any membrane bound target 
where “knock-in” or “knock-out” cell lines are available.   
 
The observed binding was highly sensitive to changes in the protein’s tertiary 
conformation caused by Pgp interactions with substrates and ATP, and reflected 
changes occurring in the functional cycle of Pgp. Thus this affinity based 
chromatography seemed to represent a promising tool in the quick identification of 
potential substrates / inhibitors and also showed potential as a useful probe of the 
transport mechanism. 
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3.8 Rapid-frontal chromatography with mass spectrometric detection 
 
 
3.8.1 Introduction 
 
Having characterized the Pgp-OT columns for their functionality and also proven that it 
is a quick means of identifying potential substrate/inhibitors and their relative Kd 
values, which were comparable with membrane binding assays, it was then considered 
that this technology could be even more versatile if mass spectrometric detection could 
be exploited. It was expected that this technique would provide for a rapid high 
throughput determination of potential substrates of Pgp and would be probably robust, 
quick and consume less reagents as compared to other assays. Also parallel screening 
capability in conjunction with MS would help as a tool for the pre-screening of potential 
lead candidates. Accordingly the aim of the next phase of the programme was to 
demonstrate the suitability of MS detection and then, hopefully, proceed to the use it to 
analyse a wide range of drugs 
 
 
3.8.2 Chromatographic system 
 
The chromatographic system consisted of a series 1100 liquid chromatography/mass 
selective detector (LC/MSD) (Agilent Technologies, Palo Alto, CA, USA) equipped 
with a vacuum de-gasser (G 1322 A), a binary pump (1312 A), a manual seven-port 
injector with a 500 ȝO ORRS PRGHO QR  5KHRG\QH 5RKQHUW 3DUN &$ 86$ D
mass selective detector (MSD) (G1946 B) supplied with atmospheric pressure 
ionization electrospray (API-ES) and an on-line nitrogen generation system (Whatman, 
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Haverhill, MA, USA). The chromatographic system was interfaced to a 250 MHz 
Kayak XA computer (Hewlett-Packard, Palo Alto, CA, USA) using ChemStation 
software (Rev B.10.00, Hewlett-Packard).  
 
3.8.3 Chromatographic conditions 
 
The mobile phase was composed of ammonium acetate (10 mM, pH 7.4) and the 
experiments were carried out at a flow rate of 50 ȝOPLQ DW DPELHQW WHPSHUDWXUH7KH
parameters on the MSD were set at 11 l/m for the drying gas flow, 350 °C for the drying 
gas temperature, 50 psi for nebulizer pressure, and 60 V for the fragmenter.  
 
3.8.4 General procedures 
 
The test ligands were Vb, labetalol, loratidine, fexofenadine, propanolol, imipramine, 
domperidone, verapamil, doxorubicin, ketoconazole, prazosin, ritonavir, tamoxifen, 
nicardipine, celecoxib, hydrocortisone and nicotine. Each compound was prepared as a 
1 nM solution and a 500 ȝODOLTXRWZDVDSSOLHGXVLQJWKHLQMHFWLRQORRSRQWKHPDQXDO
injector. The compounds were monitored using single ion monitoring (M+1) at the 
following m/z values: 455.6 (verapamil); 385.1 (prazosin); 812 (Vb); 532.0 
(ketoconzaole); 163.2 (nicotine); 543.6 (doxorubicin). The studies were carried out in 
triplicate.  
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3.8.5 Results and Discussion 
 
 
 
3.8.5.1 Comparison of rapid frontal chromatography using the Pgp(+)-OT and Pgp(-)-
OT with Caco-2 permeability measurements and stimulation of membrane-based 
ATPase activity. 
 
The determination of the interaction between lead drug candidates and Pgp has typically 
been conducted as part of non-clinical development, and has primarily depended on the 
use of a Caco-2 cell monolayer model.  In this approach, a compound is identified as a 
substrate based on the ratio of the value of the apparent permeability coefficient (Papp) in 
the basal-to-apical direction (PappB–A) to Papp in the apical-to-basal direction (PappA-B).  
According to one generally accepted criterion, a compound is designated as a Pgp 
substrate if PappB-A / PappA-B exceeds 2.0 (Polli et al., 2001).  Caco-2 experiments may 
also be used to compare the value of Papp for a test compound in the B - A or in the A - 
B direction, in the absence and presence of a well-documented Pgp inhibitor such as 
GF120918 (Lentz et al., 2000). 
 
The Caco-2 model appears to be a reasonable and reliable method to estimate intestinal 
transcellular permeability or the fraction of intestinal absorption in humans and the 
involvement of Pgp in drug absorption.   As a result, Caco-2 monolayers cultured in 12- 
or 24-well formats are now often included in lead optimization during drug discovery 
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and a 96-well format may be employed much earlier during lead selection (Balimane, 
2004) when a moderate throughput is desirable. 
 
While the Caco-2 model provides valuable information on Pgp interactions, alternative 
acellular techniques with higher throughput have been developed to provide information 
on Pgp interactions during lead selection.  One of these methods is based upon 
substrate-stimulated ATPase activity of Pgp in isolated cell membranes, which is 
measured through the appearance of inorganic phosphate (Swhab et al., 2003; Polli et 
al., 2001).  However, the results from the two assays do not always correlate as some 
compounds identified as substrates in the ATPase assay do not appear to undergo 
significant transmembrane permeability in Caco-2 monolayers.  This is true of 
midazolam, which has high passive permeability, which produces a fast transcellular 
flux that may overcome Pgp-mediated efflux (Tolle-Sander et al., 2003).  Conversely, 
some compounds identified as substrates in the Caco-2 model (e.g., vincristine, 
colchicine) fail to stimulate ATPase activity (Barecki-Roach et al., 2003).   
 
Clearly, it can be difficult to classify new compounds as inhibitors, non-transported 
substrates or substrates with a single assay (Swhab et al., 2003; Polli et al., 2001).  The 
problem is further complicated by poor intra-assay reproducibility.  For example, the 
Caco-2 model is sensitive to cell culture and experimental conditions and inhibitor 
selection.  In addition, both assays typically use testing concentrations in the 10-ȝ0
range, which may exceed solubility limits in cell culture media.  Furthermore, 
differences may also arise from differences in classification criteria and nomenclature.  
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Therefore, it has been recommended that for high-throughput screening for Pgp 
interactions a combination of methods should be used (Swhab et al., 2003; Polli et al., 
2001).  In an attempt to clarify this confusing situation, Polli et al., 2001 have 
developed a rather complex classification system, based on the results of screening a 
variety of medicinal compounds in Caco-2 monolayers and for ATPase activity.  
 
The disparity between the Caco-2 and ATPase assays is reflected in the results obtained 
for the 15 compounds used in this study (Table 11). 
 
 
Table 11. Results from the Caco-2 permeability, ATPase membrane and chromatographic assays conducted in this study, 
Caco-2 cells were seeded into wells on a 96-well plate at 104 cells per well and cultured for 25-27 days at 37°C and 5% CO2. 
Compounds were incubated with monolayers for 2 h at a final concentration of 30 ȝM in both directions.  X denotes the 
assessment that the compound is a Pgp substrate, N denotes the assessment that the compound is not a Pgp substrate and ND 
denotes that the compound was not assessed in this study.  PappA-B and PappB-A are the apparent permeability coefficients in 
the apical-to-basal and basal-to-apical directions, respectively.  In the open tubular column model compounds exhibiting a 
value for ¨t d 0.1 min are designated as a Pgp substrate. 
. 
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Caco-2 
 
Permeability 
 
Assay        
n =4 
Membrane 
 
ATPase 
 
Assay 
 
Chromatographic 
n = 4 
Retention 
 
Model 
 
4. Compound 
PappA-B 
(cm/s x 
10-6) 
PappB-A /PappA-B 
Pgp 
Substrate 
Emax 
(nmol PO4) 
Emax @ 
ȝPRO 
Pgp 
Substrate 
Pgp(+)-OT 
(min) 
Pgp(-)-OT 
(min) 
¨W 
(min) 
Domperidone 2.3 45.0 + 27.0 X 37 250 X 23.5 ± 0.7 2.0 ± 0.0 21.5 
Ritonavir 0.5 36.5 + 12.1 X 45 1 X 13.2 ± 0.3 2.1 ± 0.0 11.1 
Vinblastine 1.4 31.1 + 18.5 X 20 6 X 14.1 ± 0.5 1.6 ± 0.2 12.5 
Labetalol 3.5 8.9 + 6.9 X 35 100 X 14.8 ± 0.4 1.9 ± 0.1 12.9 
Doxorubicin 4.6 8.6 + 5.4 X <5 - N 10.3 ± 0.2 9.7 ± 0.2 0.6 
Prazocin 14.9 7.1 + 6.2 X 37 100 X 10.4 ± 0.1 3.1 ± 0.4 7.3 
Verapamil 24.6 3.4 + 1.0 X 50 250 X 4.1 ± 0.4 2.9 ± 0.0 1.2 
Loratadine 10.3 2.0 + 0.5 X 45 6 X 7.4 ± 0.9 2.1 ± 0.1 5.3 
Ketoconazole 29.9 2.1 + 1.2 X 30 10 X 1.7 ± 0.0 1.6 ± 0.0 0.1 
Imipramine 41.1 1.8 + 0.7 N 30 100 X 2.1 ± 0.1 1.2 ± 0.2 0.9 
Nicardipine 31.8 1.4 + 0.7 N 30 10 X 1.9 ± 0.1 1.8 ± 0.0 0.1 
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Atenolol 1.1 1.4 + 0.5 N 20 100 X 1.6 ± 0.3 1.2 ± 0.0 0.4 
Fexofenadine 5.1 1.0 + 0.9 N 10 100 N 1.8 ± 0.0 1.8 ± 0.0 0.0 
Tamoxifen ND ND ND 15 50 N 13.0 ± 0.0 13.1 ± 0.0 -0.1 
Nicotine ND ND ND <5 - N 2.3 ± 0.1 2.4 ± 0.4 0.0 
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Of the thirteen compounds assessed by both methods, one compound (doxorubicin) was 
identified as a Pgp substrate in the Caco-2 assay, but not in the ATPase assay, while 
three compounds (imipramine, nicardipine, atenolol) were identified as substrates in the 
ATPase assay but not by the Caco-2 method.  The ATPase assay is essentially a 
qualitative assessment of whether a compound is a Pgp substrate, i.e. a yes/no 
determination, while the Caco-2 method gives both a qualitative assessment and a 
quantitative ranking.  Thus, it was not possible to correlate the results from the two 
assays by linear regression.  Instead, a Fisher’s Exact Test was used to evaluate the 
relationship between the two data sets, i.e. if a compound is identified as a Pgp substrate 
in one test, will it be identified as a substrate in the other.  The results indicated that one 
method could not reliably predict the results from the other, with a two-sided P value of 
0.2321.  
 
The compounds were also chromatographed on open tubular chromatographic columns, 
which contained immobilized cellular membranes obtained from either the 
MDA435/LCC6 cell line, which does not express Pgp, or from the 
MDA435/LCC6MDR1 cell line, which expresses Pgp.  Thus, the resulting Pgp(-)-OT 
and Pgp(+)-OT columns were prepared from essentially the same cell line, with the 
difference being the presence of Pgp in the MDA435/LCC6MDR1 membranes. The 
columns were placed in a liquid chromatography system utilizing mass spectrometric 
detection and parallel rapid frontal chromatography experiments were conducted.  
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Chromatograms containing front and plateau regions were obtained for each compound 
on both columns (Figure 30). The retention times were calculated using the half-heights 
of the breakthrough curves, and were reproducible with an average variation of ~5% (n 
= 3), (Table 11Table 13). 
. 
 
 
 
 
 
 
 
 
 
 
Figure 30. The frontal chromatographic traces produced by A: loratadine, B: 
nicardipine, C: tamoxifen, on Pgp(+)-OT and Pgp(-)-OT. Frontal chromatograms were 
obtained using MSD. The parameters on the MSD were set at 11 l/m for the drying gas 
flow, 350 °C for the drying gas temperature, 50 psi for nebulizer pressure, and 60 V for 
the fragmenter. A 1 ml aliquot of a 1 nM solution of each compound was injected onto 
the column at a flow UDWHRIȝOPLQDQGWKHFRPSRXQGVZHUHPRQLWRUHGXVLQJVLQJOH
ion monitoring (M+1).  The experiments were carried out at room temperature using a 
mobile phase composed of ammonium acetate [10 mM, pH 7.4].  
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Chromatographic retention of a compound on a chromatographic phase containing an 
immobilized protein is the result of both specific and non-specific interactions.  Thus, 
the observed retention of a compound on the Pgp(-)-OT reflects physicochemical 
interactions of the compound with the immobilized membranes as well specific 
interactions with receptors and drug importers other than Pgp, which are present  in the 
membranes.   The same interactions occur on the Pgp(+)-OT with the added specific 
interaction with the expressed Pgp.   The specific interaction between a compound and 
Pgp can be identified by subtracting the retention on the Pgp(-)-OT from the retention 
on the Pgp(+)-OT, the ¨ W   The necessity of the parallel chromatographic approach is 
illustrated by the data obtained with ritonavir and tamoxifen.  Both compounds were 
retained on the Pgp(+)-OT column for 13 min, which was over 3-times longer than 
verapamil, and initially appeared to be Pgp substrates.  When the ¨W values were 
determined, it was evident that the observed retention of ritonavir on the Pgp(+)-OT 
was due to interactions with the expressed Pgp, while the retention of tamoxifen was 
not. 
 
Previous studies with an immobilized Pgp column had demonstrated that in the absence 
of ATP, the transporter binds substrates and competitive inhibitors, but not non-
competitive inhibitors such as cyclosporin-A (Garrigues et al., 2002).  Thus, it was 
reasonable to assume that, under the experimental conditions utilized in this study, the 
specific retention observed on the Pgp(+)-OT, i.e. ¨ WUHIOHFWHGWKHELQGLQJRIVXEVWUDWHV
and competitive inhibitors to this transporter and that ritonavir is a Pgp substrate while 
tamoxifen is not. 
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The correlation of the ¨ WYDOXHVZLWK WKHUHVXOWV IURPWKH$73DVHDQG&DFR -2 studies 
was used to test this assumption.   Since the ATPase assay is a qualitative 
determination, Fisher’s Exact Test was used to compare the data sets.  The comparison 
used a ¨ W FXWRII RI   PLQ DV WKH LQGLFDWLRQ RI D 3JS VXEVWUDWH  :LWK WKLV
specification, there was a significant correlation (p = 0.0088) between the tests, 
indicating that the chromatographic method could be substituted for the ATPase assay.  
 
The chromatographic and Caco-2 methods were also compared using the Fisher Exact 
Test to determine their relative abilities to qualitatively predict if a compound was a Pgp 
substrate.  The parameters set at ¨Wd 0.1 min as an indicator of a PappB-A : PappA-B ratio 
of < 2.0.  Previous studies using Caco-2 monolayers had identified tamoxifen and 
nicotine as Pgp-nonsubstrates with a PappB-A : PappA-B ratio < 2.0, and although their 
PappB-A : PappA-B ratios were not determined in this study, the ¨ WYDOXHVZHUH  Table 
11).  Thus, the experimental cohort of all fifteen test compounds were analyzed using 
the Fisher Exact Test and a significant correlation (P = 0.0110) was observed between 
the two data sets.  This indicated that the chromatographic method could be used to 
provide a simple yes/no answer to the question “is compound X a Pgp substrate?” 
 
 
Since the Caco-2 assay provided quantitative results, the data from the Caco-2 and 
chromatographic studies were also compared using linear regression analysis.  The data 
sets correlated with an r2 = 0.7444 (y = 1.911x – 0.3570, p = 0.0001), indicating that the 
chromatographic method can be used to rank compounds relative to the extent of Pgp 
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transport as extensive, moderate, minimal or not at all.  This result was consistent with 
the assumption that retention on the Pgp(-)-OT mirrors the PappA-B and represents the 
passive absorption of a compound through the Caco-2 membranes while retention on 
the Pgp(+)-OT and PappB-A reflected the contribution of Pgp to drug export.  Thus, it 
was not surprising that there was a statistically significant relationship between ¨WDQG
PappA-B: PappB-A.  
 
3.9 Conclusion 
 
The main conclusion from this study was that the immobilized Pgp liquid 
chromatographic stationary phases could be used to study drug-protein binding for a 
variety of substrate/inhibitors and appeared to be comparable to the binding as 
determined by classical filtration binding assays. Also the immobilized Pgp columns 
could be used to study the proteins tertiary structure in its different conformational 
forms and its interactions with different substrate/inhibitors in the presence vanadate 
trapping. The study showed that the immobilized Pgp did have enough flexibility to 
have transition into one of the other conformational forms of the Pgp cell cycle. This 
leads to an encouraging path in designating various drugs as non-competitive inhibitors 
of the Pgp transporter.  
 
The study of Pgp transporter immobilized onto open tubular columns demonstrated that 
the Pgp(+)-OT and Pgp(-)-OT column could be used in addition to or in place of the 
ATPase and/or Caco-2 assays as a screen for Pgp substrates.  Using a single parallel 
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screening system, which permitted simultaneous chromatography on two columns (Lu 
L  et al., 2001), and a 1-hour time period (30-min frontal chromatography, 30-min 
wash), a single pair of columns could be used to screen at least 150 compounds a week 
and 600 compounds during the 4-week life time of the columns.   
 
The method is simple, utilizes standard liquid chromatography – mass spectrometry 
equipment and avoids solubility problems since it utilizes Q0 UDWKHU WKDQ ȝ0
concentrations. Accordingly the chromatographic method represents a significant 
advance over the current whole cell and membrane-based assays. Also the method 
provides advantage over other assays as it can be run in parallel with control columns to 
screen out for other non-specific interactions. Also it provides more insight into the 
characteristic between drug-protein binding which could be further used in the 
development of pharmacophores for the Pgp transporter. The technique is robust, 
reproducible and uses fewer reagents quantities, which would be quite important when 
screening for large libraries of compound and also can be automated to a large extent. 
Therefore the immobilized Pgp columns could be used as a secondary screen for the 
predevelopment of lead candidates. Thus this affinity based chromatography seemed to 
represent a promising tool in the quick identification of potential substrates /inhibitors 
and also showed potential as a useful probe of the transport mechanism. 
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4. Organic Cation Transporter (OCT) 
 
 
4.1 Introduction 
 
 
Having demonstrated that a stationary phase containing immobilized Pgp membranes 
can be used to identify substrate/inhibitors of the expressed Pgp transporter the next 
phase of the programme was to adapt this methodology to other target biopolymers such 
as human organic cation transporter 1 (hOCT1). 
 
 
4.1.1 Overview 
 
The body is continuously exposed to a variety of toxins and metabolic waste products. 
To rid itself of these endogenous metabolites, it is equipped with various detoxification 
mechanisms such as metabolizing enzymes and transport proteins, which mediates their 
inactivation and excretion. 
 
Many of these compounds are positively charged and are termed as organic cations. 
Drugs belonging to a wide variety of clinical classes, including antihistamines, 
DQWLDU\WKPLFV VNHOHWDO PXVFOH UHOD[DQWV DQG ȕ-adrenoceptor blocking agents- are 
organic cations. In addition, several endogenous bioactive amines- such as dopamine, 
choline and N-methylnicotinamide (NMN)- are also organic cations. Since many of the 
molecules are positively charged at physiological pH, membrane transporters such as 
the OCT are generally involved in the absorption, distribution and elimination of these 
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compounds. Thus together with metabolizing enzymes, transmembrane transporters are 
important determinants of drug metabolism and drug clearance.  
 
Transport proteins play an essential role in the detoxification mechanisms mediating the 
inactivation and excretion of environmental toxins and metabolic waste products 
(Jonker & Schinkel, 2004). A large number of the transport proteins are found in the 
liver, kidney and intestines, all of which play a role in the excretory process.  The 
largest family of transporters is the solute carrier (SLC) superfamily with 255 members 
in humans. Most members are highly specialized transporters. However, a number of 
these transporters are polyspecific, generalized transporters that play a major role in the 
elimination process. Of the polyspecific transporters, two have become of great interest 
in the drug development process, namely, SLC21 and SLC22. The SLC21 family 
(organic anion transporter) has nine members; these proteins transport large anionic, 
amphipathic compounds. The SLC22 family has twelve members in humans and rats 
including organic cation transporters, carnitine transporter, and several organic anion 
transporters. The organic cation transporters: OCT1, 2 and 3 belong to the SLC22 
family of transport proteins.  
 
The OCT1 (organic cation transporter) was the first isolated OCT in rats and was shown 
to have 556 amino acid protein with 12 transmembrane domains (alpha helices) 
(Lahjouji, 2001), and three glycosylation sites of the type NXT/S on the large 
hydrophilic extracellular loop between the first and second transmembrane domain 
(Figure 31). This was determined with specific peptide antibodies using permeabilized 
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and non-permeabilized stable transfected human embryonic kidney (HEK) 293 cells 
(Meyer-Wentrup et al., 1998). 
 
Figure 31. Schematic of the secondary structure of the OCT1 protein. The human 
OCT1 was shown to encode for 554 amino acids with 12 transmembrane domains and 3 
glycosylation sites on the extracellular loop between the first and second 
transmembrane domain and had a molecular weight of 61 KDa. This was determined 
with specific peptide antibodies using permeabilized and non permeabilized stable 
transfected human embryonic kidey (HEK) 293 cells. (Meyers et al., 1998; Jonker et 
al., 2004).  
  
The homologous cation transporters to OCT1 and OCT2 have been cloned in the rat, 
human, pig and rabbit. The human genes of hOCT1 and hOCT2 have been localized on 
chromosome 6q26 where they lie in close proximity (less than 500 kb) (Koehler et al., 
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1997). The functional characterization of expressed OCT transporters from various 
species suggest that the OCT1, OCT2 and OCT3 transporters are polyspecific 
facilitative diffusion systems for small organic cations which operate in an electrogenic 
fashion and differ in respect to substrate specificity and localization. In the kidney of rat 
and human, OCT2 is strongly expressed. All species strongly expressed OCT1 in the 
liver, suggesting that OCT1 is the most important electrogenic cation transporter in the 
liver.  Transport activities have also been determined for hOCTN1 and hOCTN2. 
hOCTN1 is transcribed in the kidney, bone marrow, trachea and many other organs and 
it mediates pH sensitive transport of tetra ethylammonium (TEA) and contains a 
sequence motif for nucleotide binding. hOCTN2 is strongly expressed in the heart, 
placenta, skeletal muscle, kidney, and pancreas and more moderately in the liver, lung 
and brain. The relevant function of hOCTN2 appears to be sodium-dependent, high 
affinity transport of carnitine 
 
 
4.1.2 Conserved Amino Acids in the OCT-Family 
 
Comparison of the twenty OCT family members suggested that forty-one amino acid 
residues are conserved between all members including seven proline, four glutamate, 
four arginine and four cysteine residues. Only ten of these conserved amino acid 
residues are localized in the presumed membrane spanning alpha-helices, and nine 
conserved amino acid residues belong to the intracellular loop which is typical for the 
major facilitator superfamily (Marger & Saier,1993; Gingrich et al., 1992). The four 
cysteine residues conserved are localized in the large extracellular loop thus suggesting 
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the functional importance of this loop in containing disulphide bridges which may 
protrude into the membrane as has been described for the (Na+,K+)ATPase (Fiedler B & 
Schneider G, 1996; Schneider H & Schneider G, 1997). This suggests that the inhibition 
observed for the renal cation transport by sulphydryl reagent could be due to the 
reaction with these cysteine residues (Katsura et al., 1993; Sokol et al., 1986a & b). 
 
The first step in the elucidation of the molecular mechanism of the cation transport by 
OCTs is the identification of the cation binding sites present on the transporter. Since 
the involvement of electrostatic interactions is probable, conserved negatively charged, 
aromatic and polar amino acids within transmembrane alpha-helices or on extracellular 
loops may participate in binding domains. Therefore acidic amino acid residues or 
amino acid residues with negative partial charge that are conserved in the cation 
transporters but not in the anion transporters should be identified. There are seven acidic 
amino acids that are conserved in the electrogenic cation transporters of the 
OCT1/OCT2 subfamily but not in the anion transporters and the OCTN1/OCTN2 cation 
transporter subfamily: two glutamate and three aspartate residues in the large 
extracellular loop, one aspartate residue in TM8 and other one in TM11. In the cation 
transporters, hOCTN1, hOCTN2 and in the anion transporters this latter aspartate 
UHVLGXH LV UHSODFHG E\ DUJLQLQH 7KH ʌ-electrons of tryptophan, as well as partial 
negatively charges on the serine and threonine residues, may participate in electrostatic 
cation binding, it is therefore relevant that five threonine, three tryptophan and four 
serine residues are conserved in the OCT1/OCT2/OCT3 transporter subgroup but not in 
the anion transporters. Also further mutagenesis experiments would help in elucidating 
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as to which of the negatively charged or polarized domains on the large extracellular 
loop and in the transmembrane alpha-helices are involved in cation binding and 
transport. 
 
4.1.3 Functional properties of expressed cation transporters 
 
 
Cation transport by the OCT transporters has been studied in a variety of expression 
systems like oocytes, human embryonic kidney cells, HeLa cells and also insect cells. 
Tracer uptake studies in these systems showed that the uptake of small organic cations 
like TEA and 1-methyl-4-phenylpyridinium (MPP) was induced by most of the OCT 
transporters, and could be inhibited by a variety of organic cations with varied 
molecular structures, including high affinity inhibitors like quinine, quinidine, cyanine 
863 and decynium 22. This data suggested that the OCT1 and OCT2 type transporters 
from different species operate in a similar fashion, i.e. they all appear to electrogenic 
facilitative diffusion systems for small organic cations that work independently of the 
sodium and proton gradients. However the OCT1 and OCT2 subtypes do exhibit 
differential substrate specificities that are species specific. In general these transporters 
have substrates with cations smaller in size and more hydrophilic suggesting that they 
are identical to substrates of a type 1 cation transporter which can be distinguished from 
a type 2 cation transporter which in the same membrane would transport more 
hydrophobic cations such as quinine and d-tubocurarine (Elferink et al., 1995; Mol et 
al., 1988; Steen et al., 1991; 1992) 
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Bush et al., (1996) showed that the apparent Km values for TEA and choline decreased 
with increasing potential in rOCT1 subtype indicating that the transport system had to 
be electrogenic and that the cation binding site involved in the transport may be 
localized within the electrical field of the membrane potential. Also preliminary 
experiments performed on the rOCT1 and hOCT2  transporters showed that efflux of 
organic cations could be demonstrated directly by measuring the release of [3H]-MPP 
from oocytes and HEK 293 cells. Also transporter mediated MPP efflux was observed 
even when no cations were present in the bath (i.e.trans-zero state), thus showing that 
the OCT1 and OCT2 transporters could function as uniporters.  
 
Koepsell et al., (1999) measured rOCT1 mediated [14C]TEA influx experiments at 
different TEA concentrations in the presence of various concentrations of NMN a 
transported cation and quinine a nontransported inhibitor, in order to elucidate whether 
non-transported inhibitors interact at the same cation binding site. The results showed a 
competitive inhibition for NMN whereas quinine proved to be a non-competitive 
inhibitor, thus suggesting that an allosteric cation binding site might be present. This 
site could be localized close to the cation transport site but is not protected by 
transporter cations. Recently it has been observed that cation transport can be inhibited 
by the organic anion probenecid which is known to be a classical high affinity inhibitor 
of the renal anion transporter (Roch-Ramel et al., 1992). This can be explained since the 
two transporters the anion and the cation transporters belong to the same family thus 
indicating that there might be a presence of degenerated probenecid binding site (Hsyu  
et al.,1988; Cacini et al., 1982; Sheikh et al.,1976). 
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Comparison of the Ki values of various organic cation inhibitors (transported and 
nontransported) suggests that these cations may reflect organic cation binding affinities 
of two allosterically interacting cation binding sites, thus when modeling the binding 
sites of these transporters each group of cations should be considered separately. Also 
the comparison of the Ki values for several of the expressed members of the OCT1/2 
subfamily suggests that there is a difference in the affinity patterns in both inter and 
intra species (Ullrich et al., 1991; 1992; 1993; 1997). rOCT1 has much higher affinity 
for some cations (mepiperphenidol and procainamide), a similar affinity for others 
(decynium 22 and quinidine) and lower affinity for corticostereone as compared to 
rOCT2. Also the cation specificity pattern of the human subtype’s hOCT1 and hOCT2 
are distinctly different from their rat counterparts. There is no systemic pattern of the 
OCT1/2 subtypes from the human and the rat. Trying to summarize the species 
difference between human and rat, it may be stated that for several ligands hOCT1 has 
lower affinity than rOCT1 (exceptions are corticosterone and desipramine). 
Stereospecificity for quinine and quinidine was determined for rOCT1 but not for 
rOCT2 and hOCT1.   All in all the data from various experiments shows that there is 
distinct difference in substrate specificities of OCT1/2 type transporters which are 
species specific and cannot be used to predict the overall homology of these 
transporters. This suggests that the development of an immobilized mammalian 
expression system (hOCT1, hOCT2, hOCTN1/2) to facilitate the study of drug 
interactions and transport in vitro and the development of drugs that specifically target 
cells that express each of these OCTs would be useful.  
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Zhang L & Giacomini M, (1999) developed a mammalian expression system for 
hOCT1 and tried to functionally characterize the transporter based on various 
substrate/inhibitor interactions. Different TEA uptake studies showed that organic 
cations including clonidine, quinine, quinidine and verapamil significantly inhibited 
TEA uptake. They also found that Ki values of several compounds interacting with the 
hOCT1 differed substantially from the corresponding rat OCT, rOCT1, and the human 
kidney-specific OCT, hOCT2, determined in other studies. They showed that the 
multivalent cation vecuronium interacted with the hOCT1 in the micromolar 
concentrations (Ki  ȝ0VXJJHVWLQJWKDWWKHQDWXUHRIK\GURSKRELFPRLHW\SOD\HG
an important role in the potency of interactions of multivalent cations with hOCT1. 
Also they determined the effect of neutral molecules like corticosterone and midazolam 
on the transport of TEA via hOCT1. It had been previously thought that corticosterone 
entered the cell through simple diffusion but their most recent studies demonstrated that 
corticosterone is a potent inhibitor of TEA uptake mediated by hOCT1 which is 
consistent with the findings of Grundemann et al., (1994, 1997) that showed that 
corticostereone also interacts with the rOCT1. Studies on the neutral compound 
midazolam showed that the Ki of the compound in inhibiting the TEA transport in 
hOCT1 is in the same range of its Km of metabolism by CYP3A. Also since hOCT1 is 
primarily expressed in the liver, which is the major metabolism site for midazolam, it is 
possible that the transport rate limits the metabolism of midazolam. Collectively the 
data suggests that hOCT1 is polyspecific not only for organic cations but also for 
various neutral compounds. This implies that the positive charge(s) of a molecule may 
not be the only structural requirement for interaction with the hOCT1 transporter.   
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Blaschke and Giacomini, (1987); Drayer, (1986); Levy and Boddy, (1991), have shown 
that the differences in the pharmacological activities of stereoisomeric compounds and 
that stereoselective metabolism of these compounds play an important role in 
understanding the nature of the function of this transporter. Giacomini et al., examined 
the potency of various isomers in inhibiting TEA uptake in hOCT1 transfected cells. 
The diastereomers of quinine and quinidine did not show a significant difference in IC50 
values, whereas S-(+)-disopyramide was approximately 2 fold less potent than R-(-)-
disopyramide (29.9 +  ȝ0 vs. 15.4 +  ȝ0 )XUWKHU H[SHULPHQWV ZLWK RWKHU
stereoisomers would therefore be needed to establish the possibility of 
enantioselectivity of this transporter.   
 
Zhang & Giacomini et al., (1998), studied the interaction of a series of a series of n-
tetraalkylammonium (n-TAA) compounds (alkyl chain length, N, ranging from 1 to 6 
carbons) with hOCT1 in a transiently transfected human cell line, HeLa. A systematic 
determination of the effect of hydrophobicity on inhibition potencies of compounds 
interacting with hOCT1 was found. Furthermore, the effect of hydrophobicity on the 
rate of transport by hOCT1 was also determined.  A reversed correlation of IC50 values 
with alky chain lengths or partition coefficients (log P) was observed. Tran-stimulation 
and trans-inhibition studies revealed that with increasing alkyl chain lengths (N>2), n-
TAA compounds were more poorly translocated by hOCT1 although their potency of 
inhibition was increased. Similar results were also observed for the nonaliphatic 
hydrocarbons.   In summary, the longer the alkyl chain length i.e., the more 
hydrophobic and bulkier, the higher the affinity of the TAA compounds for hOCT1, and 
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slower the rate of transport (i.e. poorer substrate) by hOCT1. The correlation observed 
between the IC50 and the P values could be used to predict the IC50 of various N-TAA 
compounds interacting with hOCT1. Thus a balance between hydrophobic and 
hydrophilic properties is required for efficient transport of organic cat ions by hOCT1. 
 
 
4.1.4 OCT1 and OCT2 type distribution 
 
 
Renal secretion is a major pathway of elimination for many clinically used organic 
cations. In addition, transport of toxic organic cations into the kidney may lead to 
nephrotoxicity. Over the past decade, the mechanism of renal organic cation transport 
has been investigated in a number of different tissue preparations and cell culture 
models. 
 
The studies have shown that multiple organic cation transporters exist in the basolateral 
membrane (BLM) and BBM of the kidney. These transporters are found primarily in the 
proximal tubule and, to a lesser extent, in the distal tubule. Several potential-sensitive 
organic cation transport mechanisms have been described at the BLM region, indicating 
that the transport across the BLM is down the electrochemical gradient.  
 
In contrast, at the BBM, organic cation-proton antiport mechanisms have been 
described.   In this case, organic cations are transported from inside the cell into the 
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tubule lumen in exchange for a luminal proton. These two systems working together 
result in net secretion of organic cations from the blood to the tubule fluid.  
 
Although renal cation transport systems in the basolateral and luminal membranes of 
proximal tubules have been characterized in great detail, a localization of the cloned 
transporters on the basis of functional in vivo data remains speculative. In situ 
hybridization with specific probes, RT-PCR experiments with dissected tubuli and 
immunohistochemical experiments with specific antibodies are required to localize the 
cloned transporters. In addition, distinct species differences concerning the tissue 
distribution and histochemical localization of the OCT1 and OCT2 transporters have 
been observed. For example the rOCT1 from rat is expressed in the kidney and liver, 
whereas human hOCT1 is only expressed in the liver. On the other hand the tubular 
localization and membrane localization of hOCT2 has not been unequivocally 
determined. In situ hybridization and immunohistochemistry revealed that hOCT2 is 
mainly expressed in the distal convoluted tubules and localized at the luminal 
membrane.  
 
Overall it may be said that the OCT1 has wide tissue distribution with primary 
expression in the kidney and liver.  To date five organic cation transporters have been 
cloned; OCT1, OCT2, OCT3, OCTN1 and OCTN2. Based on their functional 
characteristics, namely sensitivity of membrane potential OCT1/2/3 are likely to be 
found within the BLM of epithelial cells in the kidney. Hence these transporters are 
most likely to be involved in the first step in the renal secretion of drugs. However, so 
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far, only rOCT1 has been convincingly localized to the BLM of the kidney. Therefore 
caution is warranted until definitive localization studies for the other isoforms are 
reported. In contrast, OCTN1 is thought to transport organic cations in exchange for 
protons, which is consistent with a renal BBM transporter. However localization and 
further studies are still needed to confirm these speculations. Although OCTN2 
transports the small zwitterion carnitine in a sodium dependent fashion, it is different 
from other organic cation transporters which transport cations in a sodium-independent 
manner.   
 
The OCTs are believed to mediate the bidirectional transport of small hydrophilic 
compounds (50-350 amu) with usually one charged amine moiety. Not all of the 
compounds that have been shown to have an effect on the OCT are transported by the 
OCT. Compounds that have been identified as being transported by the OCT include, 
but are not limited to: tetraethylammonium, 1-methyl-4-phenyl pyridinium (MPP), 
verapamil, quinine, quinidine, antidiabetics, dopamine’s and norepinephrine.  
    
 
Therefore with the identification of the OCT family a new age in the elucidation of 
renal cation excretion and reassertion has begun. Review of the research till today 
suggests that the OCT family contains subfamilies of different polyspecific transporters 
that may translocation cations and anions. The OCT1/OCT2 subfamily contains 
polyspecific facilitated diffusion systems for small organic cations. Out of the two other 
known subfamilies of OCT, one may be related to rOCT3. This may also mediate the 
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transport of polyspecific electrogenic cations but may show a different membrane 
localization and substrate specificity as the OCT1/OCT2 subfamily. A third subfamily 
of transporters known as the OCTN1/OCTN2 may be high affinity sodium co 
transporters of zwitterionic solutes.  
 
Thus in order to understand the role of the cation transport in the kidney all transporters  
must be identified, localized and functionally characterized. Also since the polyspecific 
transporters for the cations, anions and non-charged solutes have overlapping substrate 
specificities, it is very important that while studying the interactions of drugs and their 
renal toxicity all the different types of polyspecific transporters are considered.  
 
Overall, it is clear that the future holds a demanding challenge in elucidating the 
molecular mechanisms of these polyspecific electrogenic cation transporters. Therefore 
it is vital that these proteins be crystallized, their tertiary structure determined by X-ray 
crystallography and the cation binding sites characterized by affinity labeling, site-
directed mutagenisis and biochromatography and QSAR modeling; Also because OCT 
exhibits marked species variance it is of high importance that we identify, clone, 
characterize and localize all the human cation transporters. The expression systems with 
these transporters i.e. immobilized protein based stationary phases, will help us in 
identifying new drugs with optimized secretion properties. Also the knowledge 
regarding the structure-activity relationship of these cation binding sites and their 
transport mechanism will help to design drugs that modulate transporter activities. 
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4.2 Drug Uptake studies for hOCT1 & MDCK cell lines 
 
 
 
4.2.1 Experimental 
 
4.2.1.1 Materials 
 
Phosphate buffer saline 1X (PBS), Ecoscint A, MEM, foetal bovine serum, NaOH and 
N-[3H]-methyl-4-phenyl pyridinium acetate ([3H]-MPP) (9.7 MBq) were purchased 
from American Radiolabeled Chemicals, Inc (St.Louis, MO). [3H]-Dopamine (1.67 
TBq), [3H]-propranolol (1.22 TBq), [3H]-verapmail (9.25 MBq) and [3H]-nicotine (3.2 
TBq) were purchased from Amersham Biosciences Inc (Piscataway, NJ, USA) and 
[3H]-methamphetamine was obtained from the National Institute of Drug Abuse 
 
4.2.1.2 Method 
 
The Madin-Darby carnine kidney cells (MDCK) and the hOCT1 cell line were plated at 
2.5 x 105 cells/well into 24 well culture dishes, in routine growth media [MEM Eagle’s 
with Earle’s balanced salt solution supplemented with 100 units/ml penicillin, 100ug/ml 
streptomycin (transfected cells are antibiotic resistant thus the antibiotics help in 
stopping infections), and 10% (v/v) foetal bovine serum (FBS)], and incubated at 37Û&
After 48 h, the cells were treated by replacing the growth media with 0.5 ml media 
FRQWDLQLQJȝ0RIWKHIROORZLQJOLJDQGV>3H]-N-methyl-4-phenylpyridinium (MPP), 
[3H]-dopamine, [3H]-propranolol, [3H]-verapamil and [3H]-nicotine. All treatments were 
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carried out in triplicate. After 90 min incubation, the treatment was stopped. The 
supernatant was collected and diluted with 3ml of scintillation fluid (Ecoscint A). 
Subsequently, the plates were washed with cold phosphate buffered saline (0.5ml/well) 
twice and left to dry at room temperature. Cell monolayers were removed with 0.5ml 
NaOH (0.2N) and diluted with 3 ml of scintillation fluid (Ecosinct A). Drug 
accumulation was radiometrically assessed by a liquid scintillation counter (Beckman 
Model).  
 
 
4.3 Preparation of IAM based columns with MDCK and hOCT1 membranes 
 
 
4.3.1 Materials 
 
 
(R,S)-verapamil (9.25 MBq), (R,S)-psuedoephedrine, (R,S)-atenolol, (R,S)-propanolol, 
(R,S)-alpha methylbenzylamine, [3H]- N-methyl-4-phenyl pyridinium iodide (MPP), 
[14C]- tetraethyl ammonium (TEA), quinine, quinidine, nicotine, dopamine, vinblastine,  
benzamidine, sodium chloride, magnesium chloride, cholate, leupeptin, phenyl methyl 
sulfonyl fluoride (PMSF), EDTA, Trizma, CHAPS were purchased from Sigma 
Chemical (St. Louis, MO) and metamphetamine was obtained from the National 
Institute of Drug Abuse. HPLC grade methanol, ammonium acetate and 0.1 M 
ammonium hydroxide solution were purchased from Fisher Scientific (Pittsburgh, PA). 
N-[3H]-methyl-4-phenyl pyridinium acetate ([3H]-MPP) (9.7 MBq), [14C]-tetraethyl 
ammonium ([14C]-TEA) (6.3 Bq), [3H]-nicotine (3.2 TBq), [3H]-dopamine (1.67 TBq), 
[3H]-verapamil (9.25 MBq) and [3H]-propranolol (1.22 TBq) were purchased from 
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American Radiolabeled Chemicals, Inc (St Louis, MO). Immobilized artificial 
membrane PC stationary phase (IAM-PC, 12 micron particle size, 300 Û$ SRUH VL]H
was purchased from Regis Chemical Co. (Morton Grove, IL, USA).  A HR 5/2 glass 
column was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).  
 
 
4.3.2 Preparation of hOCT1(-) and hOCT1(+) membranes 
 
4.3.2.1 Cell lines 
 
hOCT1(-) (MDCK) and the hOCT1(+) cell lines were obtained from K.Giacomini from 
the University of California San Francisco. Madin-Darby carnine kidney cells (MDCK) 
and the transfected MDCK with mutant hOCT1 cDNA inserts  were maintained in 
MEM Eagle’s with Earle’s balanced salt solution supplemented with 100 units/ml 
SHQLFLOOLQȝJPOVWUHSWRP\FLQDQGYY)%6LQ&22 / 95% air. 
 
 
4.3.3 Solubilization of the membranes 
 
 
The MDCK or hOCT1-MDCK cells (100  x 106 cells) were placed in 15 ml of 
homogenization buffer (Tris-HCl [50 mM, pH 7.4] containing 50 mM NaCl, 8 µM 
leupeptin, 1 µM PMSF and 8 µM pepstatin). The suspension was homogenized for 3 x 
30 s at the setting of 12.5 on a Model PT-2100 homogenizer (Kinematica AG, Luzern, 
Switzerland). The homogenate was then centrifuged at 700 x g for 5 min and the pellet 
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containing the nuclear proteins was discarded. The supernatant was centrifuged at 
100,000 x g for 35 min at 4oC and the resulting pellet containing the cellular membranes 
was collected. The pellet was then re-suspended in 10 ml of solubilization buffer (Tris 
+&OP0S+P01D&O&+$36P0'770306)ȝ0
pepstatin A, 10% glycerol) and the resulting mixture was rotated at 150 rpm using an 
orbit shaker (Lab-line Model 3520, Melrose Park, IL, USA) for 18 h at 4ºC.  
 
 
4.3.4 Immobilization of the solubilized membranes 
 
The resulting solution was centrifuged at 60,000 x g for 22 min and the solubilized 
solution was then mixed with 160 mg IAM particles and was rotated at room 
temperature for 3 h at 150 rpm using an orbit shaker (Lab-line Model 3520, Melrose 
Park, IL, USA). The suspended particles were then dialyzed Tris HCl [50 mM, pH 7.4] 
containing 150 mM NaCl, 1 mM EDTA, 1 mM benzamidine for 2 days. The dialyzed 
mixture was centrifuged for 3 min at 4 oC at 700 x g and the supernatant was discarded. 
The pellet (hOCT1/MDCK-SP) was washed with running buffer A (Tris-HCl [10 mM, 
pH 7.4] containing 1 mM CaCl2, 0.5 mM MgCl2) and centrifuged.  This process was 
repeated until the supernatant was clear.  
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4.4 Frontal chromatography with radio-labeled markers 
 
 
4.4.1 Chromatographic system  
 
The chromatographic system was composed of a Shimadzu LC-10Advp pump, 50 ml 
superloop (Amersham Pharmacia, Uppsala, 6ZHGHQDQ,1866\VWHPȕ-Ram Model 3 
radioflow detector (IN/US, Tampa, FL, USA) with a dwell time of 2 s and the output 
data was analyzed using Laura lite 3 (IN/US) running on a PC. 
 
 
4.4.2 Determination of binding affinities using frontal chromatography  
 
The hOCT1 (+) and hOCT1 (-)-IAM (180 mg) was packed into a HR 5/2 glass column 
to yield a 150 mm x 5 mm (ID) chromatographic bed. The column was then connected 
to a LC-10AD isocratic HPLC pump (Shimadzu, Columbia, MD, USA). The mobile 
phase consisted of running buffer A delivered at 0.2 ml/min at room temperature.  
Detection of the [3H]-MPP was accomplished using an on-line scintillation detector 
,186V\VWHPȕ-ram Model 3 (Tampa, FL, USA) with a dwell time of 2 s using Laura 
lite 3. 
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4.4.3 Chromatographic studies: 
 
 
The marker ligand used in these studies was [3H]-MPP (20 pM). In the chromatographic 
studies, a 50-ml sample Superloop (Amersham Pharmacia Biotech) was used to apply 
WKHPDUNHUOLJDQGDQGDVHULHVRIGLVSODFHUOLJDQGV56YHUDSDPLOȝ0
R-verapamil (5 nM, 10 nM, 25 nM, 50 nM, 100 nM, 200 nM), S-verapamil (1, 2, 5, 10, 
ȝ0TXLQLQHȝ0TXLQLGLQHȝ0QLFRWLQH
ȝ0GRSDPLQHȝ0YLQEODVWLQH
ȝ0033KLJKS0DQG033ORZȝ0WKURXJKWKH
hOCT1-IAM column to obtain elution profiles showing a front and plateau regions.  
 
 
4.4.4 Data analysis 
 
 
The dissociation constants, Kd, for the marker and displacer ligands were calculated 
using a previously described approach (Moaddel et al., 2002].  The experimental 
approach is based upon the effect of escalating concentrations of a competitive binding 
ligand on the retention volume of a marker ligand that is specific for the target receptor.   
For example, if the hOCT1 receptor is the target, MPP can be used as the marker ligand 
(Dresser et al., 2001; Koepsell et al., 1999).  Then the association constants of MPP, 
KMPP, and the test drug, Kdrug, as well as the number of the active binding sites of the 
immobilized hOCT1 receptor, P, can be calculated using Eqn 1. 
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(V -Vmin)-1 = (Vmin [P] KMPP)-1 + (Vmin >P@-1 [MPP@  (Eqn 1)   
where, V is retention volume of MPP; Vmin, the retention volume of MPP when the 
specific interaction is completely suppressed (this value can be determined by running 
>3H@-MPP in a series of concentration of drugs and plotting 1/( Vmax -V) versus 1/>drug@ 
extrapolating to infinite >drug@). From the above plot and a plot of 1/(V - Vmin) vs. 
>MPP@, dissociation constant values, Kd, for >3H@-MPP and the drugs can be obtained. 
The data was analyzed by non-linear regression with a sigmoidal response curve using 
Prism 4 software (Graph Pad Software, Inc., San Diego, CA, USA) running on a 
personal computer.  
 
 
4.5 Membrane Binding Assays 
 
 
The membrane binding assays were carried out as previously described (Ferry, 1995; 
/X E %ULHIO\  ȝO RI >14C]-7($  ȝ0 ZDV LQ FX Eated with hOCT1 (+) and 
hOCT1  (-) membranes (150 ȝg/ȝODQGȝORIFROGYLQEODVWLQe (0.5, 1, 5, 10, 50, 100, 
500 ȝM) in solubilizing buffer (Tris-HCl [50 mM, pH 7.4] containing 250 mM NaCl, 
1.5% CHAPS, 2 mM dithiothreitol, 2 ȝM leupeptin, 2 ȝM PMSF, 2 ȝM pepstatin, 10 % 
glycerol) at room temperature for 2 h, before bound and free drug were separated by 
rapid filtration through Whatman GF/C filters (pre-wetted with solubilizing buffer with 
0.1% BSA). The filters were dried and then placed in liquid scintillation vials 
containing 3 ml of scintillation liquid for counting on the liquid scintillation counter. 
The data was analyzed by non-linear regression with a sigmoidal response curve using 
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Prism 4 software (Graph Pad Software, Inc., San Diego, CA, USA) running on a 
personal computer.  
 
4.6 Pharmacophore – Methods 
 
 
Molecular modelling employed in pharmacophore development was done using 
HyperChem V 6.0 software (HyperCube Inc., Gainesville, FL). Chemical structure of 
every processed compound was modelled using the same procedure. At first the model 
was constrained manually with special attention being paid to correct stereochemistry. 
Then the structure was subjected to procedure >build< employed in HyperChem to 
obtain reasonable spatial geometry. In the last step a short minimization of the system 
energy was done using AM1 semi-empirical method (200 steps or root-mean-square of 
the gradient less than 0.5 kcal/mole). 
 
In the case of chiral molecules, the procedure >invert< was used to obtain both 
enantiomers as real mirror images and both enantiomers were at the stereogenic center. 
The molecules were overlaid and analyzed in relation to their chromatographically 
determined Kd values and the structural attributes common to the pharmacophore were 
identified. HyperChem software was employed to measure distances and angles 
between these attributes. 
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4.7 Results and Discussion 
 
 
 
4.7.1 Characterization of the hOCT1 and MDCK cell lines 
 
 
In order to check for whether the hOCT1 transporter is active and is expressed in the 
MDCK-hOCT1 cell line efflux studies were carried out on the hOCT1 and MDCK cell 
lines. This study would help in the characterization of the cell lines for further use in the 
immobilization onto HR 5/2 columns based on an IAM backbone. The results of the 
efflux studies are presented in Figure 32 and demonstrate that there was a significant 
efflux of [14C]-TEA from the pre-incubated hOCT1-MDCK cells but not from the 
MDCK cells.  The data indicated that the hOCT1-MDCK cells accumulated [14C]-TEA, 
but not the MDCK and that the hOCT1 was functioning in the hOCT1-MDCK cells. 
Thus the transfected cell line can be now used to create columns where the hOCT1 
protein can be immobilized onto a chromatographic backbone made up of IAM. 
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Figure 32. [14C]-TEA efflux studies carried out on hOCT1-MDCK (+) cell line and 
MDCK (-) cell line. ȝORI[14C]-7($ȝ0ZDVLQFXEDWHGZLWKHDFKFHOOPHPEUDQHV
and varied concentrations of cold vinblastine were added. The bound and free drug were 
separated by rapid filtration through Whatman GF/C filters and place in liquid 
scintillation vials for counting on the liquid scintillation counter (n = 3). The data was 
analysed by non-linear regression with a sigmoidal response curve obtained using 
Graph Pad Prism 4 software. 
 
 
4.7.2 Characterization of the immobilized hOCT1(+)-IAM   
 
Having proved that the MDCK-hOCT1 cells expressed the hOCT1 transporter in its 
active form, as compared to the control cell line which does not express the transporter, 
the cell lines could now be used to prepare chromatographic biopolymeric stationary 
phases. The hOCT1 transporter was successfully immobilized on the IAM stationary 
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phase; this was initially shown by comparing the retention time of [3H]-MPP on the 
hOCT1(+)-IAM and comparing it with MDCK-IAM (hOCT1(-)) (Figure 33). MPP is a 
known substrate of hOCT1 transporter with a Ki of 12.3 ȝ0 (Giacomini et al., 1998). In 
order to characterize the hOCT transporter it is necessary to use known substrates like 
MPP and TEA as it helps correlate the results of the chromatographic studies with those 
obtained with cellular studies (from literature). The elution profiles contained both front 
and plateau regions on both columns. The midpoint of the breakthrough curve occurred 
at 10 min on the hOCT1(-)-IAM column and 17 min on the hOCT1(+)-IAM column, 
representing breakthrough volumes of 2.0 ml and 3.4 ml respectively (Figure 33). Since 
the void volume elution time of the chromatographic system, column and detector was 
0.7 min, the results indicated that the [3H]-MPP was retained on both columns. 
However there was significant increase in retention time of MPP for the hOCT1(+)-
IAM  as compared to the MDCK-IAM column. This differential retention indicated that 
the hOCT1 transporter was functionally immobilized on the IAM based column. Also 
the IAM backbone did not interfere with the substrate-protein binding in this case as 
generally the substrates for the hOCT1 transporter are all hydrophilic and generally 
charged. Thus the non-specific interactions caused due to the strong lipophilic 
properties of the IAM, which led to long retention times in the Pgp based columns were 
not an issue for the OCT transporter. 
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Figure 33. Comparison of the frontal chromatograms of 20 pM [3H]-MPP on the 
hOCT1-column (red) and on the MDCK-column (hOCT1-(-)) (black) showing the front 
and plateau regions for each column. The detection of  [3H]-MPP was accomplished 
using an on-line liquid scintillation detector (IN/US system, ȕ-ram model 3) with a 
dwell time of 2s using Laura Lite 3 program. The breakthrough curves occurred at 10.0 
min for hOCT1-(-) and 17.0 min for the hOCT1-(+). Running buffer consisted of Tris 
[10 mM, pH 7.4] 1 mM CaCl2, 0.5 mM MgCl2 and the flow rate was 0.2 ml/min.  
 
 
The retention of MPP on both the hOCT1(+)-IAM and hOCT1(-)-IAM columns was 
consistent with the observation that MPP accumulates in both the hOCT1 (+) and hOCT 
(-) cell lines. However the intracellular concentration of MPP was 10-fold higher in the 
hOCT1(+) cell line. This suggested that MPP interacted with membranes from the 
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MDCK cell at specific and non-specific sites, other than exclusively at the hOCT1, and 
at the same site plus the hOCT1 with membranes from the hOCT1-MDCK. 
 
These differences in the combination of specific and non-specific interactions between 
the control and the expressed cell lines and the resulting effect on the chromatographic 
retention had also been previously demonstrated with the Pgp(+)-OT and the Pgp(-)-
OT. The studies with the Pgp transporter had demonstrated that the specific interactions 
with the expressed Pgp could be measured using displacement chromatography and 
Pgp-specific markers. 
 
The activity of the immobilized hOCT1 transporter was further confirmed in this study, 
E\WKHDGGLWLRQRIȝM nicotine, a competitive inhibitor of the hOCT1 (Dresser et al., 
2001), to the running buffer. It had no effect on the retention of [3H]-MPP on the 
hOCT1(-)-,$0 FROXPQ +RZHYHU DGGLWLRQ RI  ȝ0 DQG  ȝ0 QLFRWLQH RQ WKH
hOCT1(+)-IAM column produced significant and concentration dependent decreases in 
retention of [3H]-MPP. The results indicated that on the hOCT1(-)-IAM column, the 
retention of [3H]-MPP occurred at sites other than the hOCT1 and that the binding 
affinity of the immobilized hOCT1 could be further probed using affinity displacement 
chromatography. 
 
Binding activity of the immobilized hOCT1 transporter was therefore determined using 
frontal displacement chromatography with [3H]-MPP as the marker ligand and MPP, 
verapamil, vinblastine, quinine, dopamine, nicotine and quinidine as displacers.  Frontal 
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displacement was seen between all the ligands tested and MPP in a competitive manner, 
the chromatogram of nicotine is shown in Figure 34. Using this approach, the affinity of 
the displacer for the immobilized hOCT1, expressed as the dissociation constant (Kd) 
and number of available binding sites (Bmax) were calculated using equation 1, (Table 
12). A representative analysis is shown in Figure 35. 
  
 
 
 
 
 
 
 
 
Figure 34. The effect of the addition of increasing concentrations of nicotine on the 
chromatographic retention of 20 pM [3H]-MPP+ on the hOCT1(+)-IAM column from 
no nicotine in the mobile phase (black trace), WR  ȝ0 cold nicotine in the mobile 
SKDVH EOXH WUDFH WR  ȝ0 cold nicotine in the mobile phase (green trace). The 
detection of  [3H]-MPP was accomplished using an on-line liquid scintillation detector 
(IN/US systemȕ-ram model 3) with a dwell time of 2 s using Laura Lite 3 program). 
Running buffer consisted of Tris [10 mM, pH 7.4] 1 mM CaCl2, 0.5 mM MgCl2 and the 
flow rate was 0.2 ml/min.  
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Figure 35.  The relationship between chromatographic retention volume expressed as 
(V – Vmin) and increasing mobile phase concentrations of nicotine on the hOCT1(+)-
IAM column.  Running buffer (Tris [10 mM, pH 7.4], 1mM CaCl2, 0.5 mM MgCl2) at 
room temperature at 0.2 ml/min. 10 ml samples of 20 pM [3H]-MPP supplemented with 
a range of concentrations of cold nicotine DQGȝ0ZDVUXQDQG WKHVLJQDO
was recorded every 2 s. The elution volume data was used to calculate the dissociation 
constant of the ligand (n = 3). The Kd value of nicotine was calculated by non linear 
regression with Prism (GraphPad Software) using one site binding equation to be (20.15 
ȝ0 
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Table 12. Binding affinities expressed as Kd YDOXHVȝ0FDOFXODWHGE\IURQWDODIILQLW\
chromatography using the immobilized hOCT1(+)-IAM column, compared to Ki’s 
calculated by uptake studies (Dresser et al., 2000). All compounds selected were known 
hOCT1 substrates/inhibitors and were selected as their inhibition rate constants (Ki) 
were published in the literature which would help to compare the literature values with 
the data obtained from frontal displacement chromatography. (n = 2) 
Compounds Kd ȝ0 Bmax ( nmoles) 
 
Ki ȝ0 
Verapamil 2.80  ± 1.09 3.14 ±  0.59 2.9a 
Quinidine 6.33 ± 1.48 10.42 ± 1.02 17.5a, 5.4b 
Methyl Phenyl 
Pyridinium 
1.80 ± 1.28 
(6.06±2.87) x10-6 
0.513 ± 0.207 
(10.48 ± 2.35)x10-6 
12.3 a 
Quinine 10.18 ± 2.06 8.10 ± 0.94 22.9a 
Nicotine 20.15 ± 6.06 208 ± 38 53.2b 
Dopamine 198 ± 112 840 ± 256 487.2b 
Vinblastine 7.28 ± 6.93 2.63 ± 1.67 21.5 
a: Zhang et al. 1998 
b: Bednarczyk, et al. 1989.  
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A linear regression analysis was carried out between the binding affinities obtained by 
frontal chromatography on the hOCT1 column with those obtained by membrane 
binding studies reported in the literature (Zhang et al., 1998; Bednarczyk, et al., 1989) 
to determine if differences represent a qualitative difference or a quantitative difference. 
A linear relationship was observed with an r2 value of 0.9987 (p < 0.001, very 
significant) with all the tested ligands except for vinblastine (no cellular uptake data 
available), which was analyzed in this study and was calculated to have a Kd of 21.48 
ȝ07RHQVXUHWKDWWKHr2 observed was not an artifact, since the Kd for dopamine is at 
least 40 fold different from the remaining tested ligands, the correlation analysis was 
carried out without dopamine resulting in an r2 of 0.9363 (p = 0.0016, significant). This 
indicated that the binding to the immobilized hOCT1 was consistent with those from the 
membrane binding assays and had only a relative difference.   
 
The number of available binding sites for all the ligands was similar (1-10 nmoles) 
except for nicotine (208 nmoles) and dopamine (840 nmoles). These compounds were 
also tested on the MDCK column to determine if there was any specific binding 
occurring to any other protein other than the hOCT1 transporter. No displacement was 
seen with nicotine or GRSDPLQHDWFRQFHQWUDWLRQVRIȝ0DQGȝ0UHVSHFWLYHO\
The significant increase in the amount of available binding sites for nicotine and 
dopamine can be explained in terms of affinity and specificity. It is believed that at a 
reduced affinity, these ligands bind to numerous sites en route to the specific binding 
site on the hOCT1 protein. 
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An interesting result obtained with the hOCT1 column, that had not been reported 
elsewhere, was the discovery of a second high-affinity site for MPP on the hOCT1 
transporter, i.e. 6 pM (Table 12). Subsequently, the displacer ligand was increased and a 
second site ZKLFK KDG DQ DIILQLW\ IRU 033 RI  ȝ0 ZDV IRXQG 7KH ODWWHU VLWH LV
consistent with the binding affinity values for MPP reported elsewhere. However, the 
former high affinity site had not been reported to date and this was the first time that 
two binding sites for MPP had been identified. It should be noted that although with the 
methods used here a pM binding at the high affinity site was observed, qualitatively this 
could have been out by an order of magnitude. In order to calculate binding affinities in 
frontal chromatography there are two assumptions that must be held. The one which 
was not held in this case was that the concentration of the marker ligand should be 
significantly lower than the binding affinity of the marker. In the case of the high 
affinity MPP site, the concentration of the marker was 20 pM and the reported affinity 
was 6 pM. In spite of the limitations of frontal chromatography, the column had 
successfully identified a second high affinity site for MPP.  On the basis of the results 
found in this study it may be concluded that the immobilized hOCT1 transporter can be 
used to screen for know substrate/inhibitors in a rapid and precise manner. 
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4.7.3 Enantioselectivity on the hOCT1 column  
 
 
Previous studies on the hOCT1 had demonstrated that diisopyramide enantioselectively 
inhibited hOCT1 mediated uptake of TEA (Zang et al., 1998). In these studies, the IC50 
value of (R)-diisopyramide was about 2 fold lower than that of (S)-diisopyramide, 15.4 
ȝ0 DQG  ȝ0 UHVSHFWLYHO\ $Q LQWHUHVWLQJ result was observed for the hOCT1 
column which showed differences in the affinity for the enantiomers of verapamil 
(Table 13). 
  
In the frontal chromatography studies, low concentrations of (R)-verapamil produced 
significant displacements of [3H]-MPP+ while significantly higher concentrations of (S)-
verapamil were required to displace the marker (Figure 36).  
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Figure 36. Frontal affinity chromatography showing enantioselectivity for the 
enantiomers of verapamil. The chromatogram shows the displacement of 20 pM [3H]-
MPP+ on the hOCT1(+)-IAM column by ȝ05-YHUDSDPLOUHGWUDFHDQGȝ0
(S)-verapamil (blue trace) which were added to the mobile phase. The detection of  
[3H]-MPP was accomplished using an on-line liquid scintillation detector (IN/US 
system ȕ-ram model 3) with a dwell time of 2 s using Laura Lite 3 program). The 
mobile phase consisted of Tris [10 mM, pH 7.4] 1 mM CaCl2, 0.5 mM MgCl2 and the 
flow rate was 0.2 ml/min.  
 
The results demonstrated that (R)-verapamil had a 58-fold lower Kd value than (S)-
YHUDSDPLO  DQG  ȝ0 UHVSHFWLYHO\ Table 13).  Since enantiomers have the 
same physiochemical properties, the observed difference had to be due to specific 
interactions with immobilized biopolymers.  Since no enantioselectivity was observed 
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on the column containing the control membranes, the difference between (R)- and (S)-
verapamil must be a result of specific interactions with the immobilized hOCT1.  Thus, 
the immobilized transporter retained the ability to enantioselectively bind to substrates 
and inhibitors. Further experiments were carried out to study the enantioselective 
propertiHV RI WKH K2&7 WUDQVSRUWHU (QDQWLRPHUV RI SURSUDQRORO DWHQRORO Į-
methylbenzylamine and psuedoephedrine were studied on the hOCT1 and it was 
observed that the transporter showed enantioselectivity for these compounds (Table 13, 
Figure 37).  
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Figure 37. The structure of the enantiomers of propranolol, atenolol, psuedoephedrine, 
Į-methylbenylamine and verapamil used in this study. All compounds have chiral 
centres and they were used to characterize the hydrogen bonding receptor sites to 
demonstrate enantioselectivity of the hOCT1 transporter. 
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In this competitive displacement study, increasing concentrations of a competing ligand 
were added to the mobile phase and the effects on the retention volume of the marker, 
measured at the mid-point of the breakthrough curves, were determined and the Kd 
values calculated using Eqn 1, as had been previously described (Moaddel et al., 2005).  
In this study, both of the enantiomers of propranolol displaced MPP+ when they were 
added to the mobile phase. However, (-)-(S)-propranolol produced a greater 
displacement than (+)-(R)-SURSUDQRORO)RUH[DPSOH WKHDGGLWLRQRIȝ0RI -(R)-
propranolol to the mobile phase reduced the mid-point of the breakthrough curve of 
MPP+ by 3 min (Figure 38), Trace B, while the same concentration of the (S)-
enantiomer reduced the mid-point of the breakthrough curve by 7 min to 13 min, 
(Figure 38) Trace C.   
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Figure 38.  The chromatographic traces from the frontal competitive displacement of 
10 pM [3H]-MPP, where: Trace A  [3H]-033DORQH7UDFH%DIWHUWKHDGGLWLRQRIȝ0
(+)-(R)-SURSUDQRORO WR WKH PRELOH SKDVH 7UDFH & DIWHU WKH DGGLWLRQ RI  ȝ0 -)-(S)-
propranolol to the mobile phase.  The experiments were carried out using a stationary 
phase containing immobilized membranes obtained from the hOCT1-MDCK cell line 
that express a human organic cation transporter. The detection of  [3H]-MPP was 
accomplished using an on-line liquid scintillation detector (IN/US systemȕ-ram model 
3) with a dwell time of 2 s using Laura Lite 3 program). The mobile phase consisted of 
Tris [10 mM, pH 7.4] 1 mM CaCl2, 0.5 mM MgCl2 and the flow rate was 0.2 ml/min.  
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Similar results were observed with atenolol, and pseudoephedrine.  However, the 
DGGLWLRQ RI XS WR  ȝ0 RI 5- or (S)- Į-methylbenzylamine to the mobile phase 
produced no displacement of the marker ligand.  This result indicated that, under the 
H[SHULPHQWDOFRQGLWLRQVXVHGLQWKLVVWXG\Į-methylbenzylamine did not compete with 
MPP+ for binding to the immobilized hOCT1. 
 
The displacement data was analyzed using Eqn. 1 and a Kd value for each compound 
was calculated from the non-linear binding curve, as depicted for (R)-propranolol in 
Figure 39.  
 
 
 
 
 
 
 
 
 
 
Figure 39. Determination of the binding affinity, Kd value, of (+)-(R)-propranolol for 
the immobilized human organic cation transporter calculated using Eqn. 1 and the effect 
of the addition of increasing concentrations of (+)-(R)-propranolol on the 
chromatographic retention of [3H]-N-methyl 4-phenyl pyridinium. 
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As previously demonstrated for the immobilized hOCT1 column (Moaddel et al., 2005) 
and for other immobilized receptor and transporter studies, only a single series of 
displacement studies is required to calculate reproducible Kd values which are 
comparable and consistent with affinities produced using other experimental 
approaches. 
 
A significant enantioselectivity was observed for propranolol where the (S)-enantiomer 
had a lower Kd value, and, therefore higher affinity, and there was an excellent fit to the 
non-linear curve, r2 = 0.999 for each enantiomer (Table 13). 
 
 
Table 13. The binding affinities (Kd) of the compounds used in this study for the 
immobilized human organic cation transporter obtained using frontal displacement 
chromatography with [3H]-MPP+ as the marker ligand. 
Compound 
 
Kd ȝ0 Ratio 
(+)-(R)-Propranolol 
(-)-(S)-Propranolol 
2.85 ± 0.19 
0.95 ± 0.01 
2.98 
(+)-(R)-Atenolol 
(-)-(S)-Atenolol 
0.98 ± 0.42 
0.46 ± 0.25 
2.11 
(+)-(1S;2S)-Pseudoephedrine 
(-)-(1R;2R)-Pseudoephedrine 
1.71 ± 0.67 
1.12 ± 1.08 
1.53 
(+)-(R)-Verapamil 
(-)-(S)-Verapamil 
0.05 
3.46 
86.5 
(+)-(R)-Į-Methylbenzylamine 
(+)-(S)-Į-Methylbenzylamine 
NDa 
NDa 
1.00a 
a
 1'1RGLVSODFHPHQWRIWKHPDUNHUXSWRȝ0FRQFHQWUDWLRQRIWKHGLVSODFHU 
 197 
The same enantioselectivity was observed for atenolol, where (S)-atenolol had a higher 
affinity for the immobilized hOCT1, but the magnitude and the curve fit were 
significantly lower than those observed for propranolol (Table 13).  The 
chromatographically calculated Kd value of (1R;2R)-pseudoephedrine was 53% lower 
than the corresponding value for the (1S;2S)-enantiomer (Table 13).  However, even 
though excellent curve fits were obtained for both enantiomers, the calculated 1.5-fold 
enantioselectivity while representing a reproducible trend, cannot be considered as 
statistically significant.  
 
None of the compounds used in this study have been previously identified as substrates 
or inhibitors of hOCT1.  In order to determine if the data from this study reflected 
actual pharmacological activity, a competitive inhibition study was conducted using 
[14C]-TEA as the substrate and (-)-(S)-propranolol and (+)-(R)-propranolol as the 
competitive inhibitors.  The data demonstrated that propranolol enantioselectively 
inhibited the cellular uptake of [14C]-TEA. (Figure 40)   
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Figure 40. The inhibition of the intercellular uptake of [14C]-tetraethyl ammonium by 
increasing concentrations of (-)-(S)-propranolol {Ŷ`RU  -(R)-propranolol {¨ ` LQ WKH
hOCT1-MDCK cell line. (n = 3) 
 
There was a 2.75-fold difference between the calculated IC50 values of (-)-(S)-
SURSUDQRORO ȝ0 (r2 = 0.9629) and (+)-(R)-SURSUDQRORO ȝ0 (r2 = 0.9786).  
These results were essentially the same as the difference in the chromatographically 
determined affinities (Kd(+)-(R)-propranolol / Kd(-)-(S)-propranolol = 2.98).  This indicated that for 
the compounds used in this study, the chromatographically determined affinities and 
enantioselectivities reflected pharmacologically relevant properties. 
 
Molecular models of propranolol, atenolol and pseudoephedrine were constructed and 
the enantiomers with the lowest Kd values, i.e. the highest affinity, were used to 
construct a preliminary pharmacophore.  The stereogenic centres containing the 
hydroxyl moiety were used to position the molecules relative to the pharmacophore.  
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Under this constraint, the configuration around the centres were identical for (S)-
propranolol, (S)-atenolol and (1R;2R)-pseudoephedrine.  The calculated distances 
between the hydrophobic, ion pair and hydrogen bonding moieties of the compounds 
used in this study are presented in Table 14 (n = 3). 
 
Table 14. The calculated distances between the middle of the aromatic ring (Ar), the 
amine nitrogen atom (N) and the oxygen atom of the hydroxyl group (O) for the 
compounds used in this study (n = 3). 
 
Ligands Distances [Å] 
Ar-N Ar-O N-O 
Į-Methylbenzylamine 3.7 -- -- 
Pseudoephedrine 5.1 3.5 2.7 
N-Methyl-4-phenyl pyridinium 5.7 -- -- 
Atenolol 6.9 5.9 2.9 
Propranolol 6.9 5.9 2.9 
 
 
The resulting pharmacophore contained hydrophobic and ion pair interaction sites and 
the calculated distance between these sites was ~ 5Å.  This distance is consistent with 
the previously described hOCT1 pharmacophore in which the calculated distances 
between three hydrophobic areas and a positive ionizable site ranged from 4.2Å to 5.3Å 
(Bednarczyk et al., 2003).  Although the previous work included chiral compounds in 
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the experimental cohort used to calculate the reported pharmacophore, enantioselective 
interactions were not considered and, consequently, additional binding sites were not 
identified.  In this study, the consideration of the enantioselectivity of the binding led to 
the identification of a third site, a hydrogen bond donor site, located 4.3Å from the 
hydrophobic site and 2.2Å from the ion pair interaction site.   These interactions are 
illustrated by the inclusion of (-)-(S)-propranolol in the proposed pharmacophore. 
(Figure 41) 
 
 
  
Figure 41. Preliminary pharmacophore that describes the enantioselective binding 
interactions observed in this study. 
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Based upon the data obtained in this study, a new pharmacophore is being constructed 
in this laboratory (Dr IW Wainer, National Institute on Aging), using a larger set of 
chiral and achiral compounds and considering enantioselective interactions.  The results 
of this study will be reported elsewhere. 
 
The data from the study suggested that the initial binding to the immobilized hOCT1 
occurs via an ionic interaction between an ammonium moiety on the ligand and an 
anionic site on the extracellular portion of the hOCT1, which is followed by the second 
interaction between a hydrophobic moiety on the ligand and a hydrophobic pocket 
within the lumen of the hOCT1.  Both interactions are necessary for significant binding 
to occur between the ligand and the hOCT1, and position the ligand for the 
enantioselective hydrogen bonding interaction. 
 
It is important to note that the presence of a hydrogen bond acceptor is not necessary for 
a compound to act as a substrate or inhibitor of the hOCT1.  Indeed, the marker ligand 
used in this study, MPP+, does not contain a hydroxyl moiety (Figure 41).  What is key 
to the interaction between a potential ligand and the hOCT1 is the distance between the 
ion pair and hydrophobic moieties.  For MPP+, this distance is 5.7 Å (Table 14), which 
is compatible with the pharmacophore developed in this study as well as the previously 
reported pharmacophore (Bednarczyk et al., 2003). 
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The suggested binding mechanism and the preliminary pharmacophore derived in this 
study, as well as the previously described pharmacophore, provide an explanation for 
WKHODFNRIVLJQLILFDQWELQGLQJRIĮ-methylbenzylamine to the immobilized hOCT1.  It 
can be assumed that an ionic interaction occurs between the ammonium moiety on the 
Į-methylbenzylamine and the anionic site on the hOCT1, which tethers the compound 
to the transporter.  However, the second interaction does not occur because the distance 
between the ammonium moiety and the phenyl ring, 3.7 Å (Table 14), is not long 
enough for the phenyl ring to reach the hydrophobic pocket.  The proposed binding 
mechanism is currently under investigation using liquid chromatographic stationary 
phases containing point-mutation variants of the hOCT1.  The results will be reported 
elsewhere. Also the nature of binding of enantiomers of verapamil shows significant 
enantioselectivity. Although it is believed that verapamil binds to the same site, where 
the nitrile group binds to the hydrogen bonding site, it is likely that is also theders to a 
fourth site, which would be a hydrophobic site resulting in the strong enantioselectivity 
of verapamil. Evidence to support this model for verapamil was generated in further 
work by the Wainer group after this research project was completed.  
 
 
4.7.4 Drug transport on the hOCT1 column 
 
 
Drug uptake studies were also carried out using the hOCT1 cell line and the MDCK cell 
line to evaluate whether any of the substrate/inhibitors which showed binding affinity 
for the hOCT1 transporter on the IAM based columns, were transported by it or not. A 
series of known ligands like propranolol, verapamil, dopamine, MPP, metamphetamine 
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and nicotine were studied and the results indicated that MPP and propranolol were 
transported whereas verapamil, dopamine, nicotine and metamphetamine were not 
transported through the cell membrane (Figure 42). 
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Figure 42. Drug uptake studies on the hOCT1(+) and MDCK cell lines where each cell 
OLQHZDVWUHDWHGZLWKȝPRIWKHIROORZLQJOLJDQGV [3H]-propranolol, [3H]-verapamil, 
[3H]-dopamine, [3H]-MPP, [3H]-metamphetamine and [3H]-nicotine.  The monolayer 
was removed and the drug accumulation was radioametrically assessed by a liquid 
scintillation counter (Beckman Model) (n = 3). 
  
 
This showed that even though a lot of these substrate/inhibitors do bind to the 
transporter they are not transported by it. They can be termed as competitive inhibitors 
of the hOCT1. The results from this data also corroborated previous studies where it 
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had been shown that verapamil is a known inhibitor of the hOCT1 transporter. Thus the 
use of immobilized hOCT1 columns as  a possible screen for target lead optimization is 
a promising tool for Drug Discovery and also in the studying the characteristics of drug-
protein binding which would help in the development of a suitable pharmacophore 
depicting the characteristics of the active site of the protein. 
 
 
4.8 Conclusion 
 
 
Quite clearly the main aim of this part of the programme had been achieved. The data 
from this study indicated that membranes from the hOCT1(+) and MDCK (hOCT1(-)) 
cell lines had been immobilized on IAMs (12 micron, 300 Å). Further the columns were 
fully characterized by conducting displacement chromatographic studies and binding 
affinities were calculated for a series of ligands. Importantly a linear regression analysis 
was carried out between the binding affinities obtained by frontal chromatography on 
the hOCT1 column with those obtained by membrane binding studies reported in the 
literature (Zhang et al., 1998; Bednarczyk et al., 1989) to determine if differences 
represent a qualitative difference or a quantitative difference.  
 
Further, the column demonstrated enantioselectivity showing that both the ionic and 
hydrophobic interactions are necessary for significant binding to occur between the 
ligand and the hOCT1, and position the ligand for the enantioselective hydrogen 
bonding interaction. This data was further confirmed by demonstrating that propranolol 
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enantioselectively inhibited the cellular uptake of [14C]-TEA. Therefore it indicated that 
for the compounds used in this study, the chromatographically determined affinities and 
enantioselectivities also reflected pharmacologically relevant properties. 
 
Molecular models of enantiomers of propranolol, atenolol and pseudoephedrine were 
used construct a preliminary pharmacophore which showed that the configuration 
around the centers were identical for (S)-propranolol, (S)-atenolol and (1R;2R)-
pseudoephedrine.  The resulting pharmacophore contained hydrophobic and ion pair 
interaction sites and the calculated distance between these sites was ~ 5Å which was 
consistent with the previously described hOCT1 pharmacophore in which the calculated 
distances between three hydrophobic areas and a positive ionizable site ranged from 
4.2Å to 5.3Å (Bednarczyk et al., 2003).  Also some new and exciting results led to the 
identification of a third site, a hydrogen bond donor site, located 4.3Å from the 
hydrophobic site and 2.2Å from the ion pair interaction site. Conclusion from these data 
does indicate that immobilized biopolymeric hOCT1 transporter columns provide an 
excellent tool in studying for the drug-protein binding and gives us both qualitative and 
quantitative data which is comparable to other methods. Also further work with more 
ligands will help in the proper characterization of the active sites of this transporter and 
enable in the validation of the pharmacophore for this transporter. 
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5. Conclusion and Suggestion for Future Work 
 
 
Membrane bound receptors and trans-membrane transporters and ion channels are 
difficult to characterize and to utilize in Drug Discovery unless you have a marker 
ligand.  The parallel screening technique demonstrated by the Pgp(+) and Pgp(-) OT 
columns is a new and important approach to this problem.  It will be particularly 
important in characterizing orphan receptors, ion channels and transporters.  To put this 
use into focus, G-protein coupled receptors (GPCRs) are the target for over 50% of the 
marketed drugs.  The human genome contains about 1,000 genes which encode for 
approximately 10,000 GPCRs and only a few 100 GPCRs have been characterized. 
  
The data from this research programme indicated that membranes from a cell line 
expressing a target receptor or transporter could be immobilized on the surface of glass 
capillaries with retention of the target’s binding activity, and that this activity could be 
measured using displacement frontal chromatographic techniques. The results from the 
programme also demonstrated that since cellular membranes were immobilized, instead 
of the purified target, the membranes contributed specific and non-specific off-target 
binding to the observed chromatographic retention. This necessitated the construction of 
a second open tubular capillary column using membranes from a cell line that does not 
express the target receptor or transporter. The target (-) column could then be used as a 
control for the target (+) column. This approach should be applicable for use with any 
membrane bound target where “knock-in” or “knock-out” cell lines are available.  In 
this study, Pgp (+)-OT and Pgp (-)-OT columns were used in 30-min parallel frontal 
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chromatographic experiments to qualitatively rank compounds based upon their relative 
affinities for the immobilized Pgp transporter. The Pgp(+)-OT / Pgp(-)-OT approach 
permitted the ranking of up to 200 compounds per week and, as the columns are active 
for between 3 and 4 weeks, each pair could be used to screen a minimum of 800 
compounds. This capacity would be comfortable enough for the primary role envisaged 
for this technology, i.e. as a secondary screen for profiling predevelopment candidates. 
The chromatographic approach should be a significant advance over the current 
approach to the determination of a Pgp substrate/inhibitor, which involves the use of 
multiple Pgp assays and a complex classification system of transported and non-
transported substrates and inhibitors. A comparative inter-assay assessment is currently 
being conducted with a larger cohort of compounds and will be reported elsewhere 
(Moaddel & Wainer, starting 2005). 
 
 
The success of these experiments would help to generate affinity chromatography 
models for other proteins. There should now be a more effective route into meeting the 
important, exciting, but demanding challenges of elucidating the molecular mechanisms 
of these solute carrier transporters. For example, the ultimate manifestation of this 
technology could be an arrangement of such transporter protein and other columns that 
would allow the study of all the significant drug protein interactions taking place in the 
brain. 
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In order to extract the maximum potential out of these possibilities that arise from this 
research programme there are a number of further studies that would be useful. It is 
vital that these proteins be crystallized, their tertiary structure determined by X-ray 
crystallography and their binding sites characterized by affinity labeling, site-directed 
mutagenisis and biochromatography and QSAR modeling. Also since these transporters 
exhibits marked species variance it is of high importance that all the human transporters 
are identified, cloned, characterized and localized. The expression systems with these 
transporters i.e. immobilized protein based stationary phases, will help in identifying 
new drugs with optimized secretion properties. Also the knowledge regarding the 
structure-activity relationship of these binding sites and their transport mechanism will 
help to design drugs that have modulated transporter activities. 
 
Also this technique with its versatility in determining binding constants of drugs or 
active compounds to pharmaceutical biological targets, offers an interesting opportunity 
in the characterization of the ligand binding sites. The immobilized biopolymers can be 
used in on-line pharmacological studies and as rapid screen for the isolation and 
identification of lead drug candidates from complex biological mixtures. Besides it can 
also be applied to determine apparent equilibrium constants (association constants, 
dissociation constants, binding constants) using very small amount of biopolymer and 
ligand. Also these affinity chromatographic methods are of particular relevance in 
monitoring interactions between exogenous or endogenous compounds in binding to 
different drug receptors. This would lead to the understanding of their pharmacological 
and/or toxicological activities.  
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Therefore in conclusion the use of affinity chromatographic methods are valid for high 
throughput screening of compound libraries, for the development of new drugs and for 
their safe use, the activity of a drug not being fully understood without understanding its 
binding to target proteins. Thus affinity chromatography provides a unique contribution 
and moves the field along from conventional use of purified proteins. 
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